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Abstract:
Background:
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive types of solid 
cancer with 5-year survival rates approaching a dismal 5%. Novel therapeutic targets need to 
be identified thus aiding and assisting the design of treatments which will improve survival 
rates that have not changed in the last 30 years. Of particular interest are homeobox (HOX) 
genes, a set of 39 evolutionarily conserved transcription factors involved in embryonic antero-
posterior patterning. Although expressed in development, HOX genes have been found to be 
re-expressed and indeed dysregulated in several types of cancer including lung, breast, 
ovarian and renal neoplasia. Limited research has been undertaken on the dysregulation of 
HOX genes in PDAC. HOX genes can be antagonised using HXR9, a peptide which 
competitively inhibits the interaction between HOX genes and their co-factor PBX, 
subsequently preventing HOX genes to fulfill their role of transcription factors. 
Cancer-specific tumour-modelling is fundamental to drug testing. There are few animal 
models that recapitulate the unique tumour architecture and molecular signature of PDAC, 
particularly the desmoplastic reaction characteristic of this malignancy. The chorioallantoic 
membrane (CAM) assay, an in ovo model that utilises the immunologically naive properties of 
the developing chick embryo to grow a solid tumour derived from pancreatic cancer cell lines. 
The CAM model is not widely used in pancreatic cancer research and more work is needed to 
evaluate it’s efficacy for tumour remodelling and subsequent drug testing.
 We have found that the CAM model is suitable for drug testing as it recapitulates the 
architecture and molecular signature of PDAC. In order to establish the CAM model as 
appropriate for drug testing in this context, we assessed whether the mitogen-activated 
protein kinases (MAPK) pathway was conserved, due to the high frequency of mutational 
activation of the KRAS gene in this cancer. Global gene expression was also carried out to 
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determine genetic changes between cells grown in vitro and cells in a tumour 
microenvironment in the CAM model. 
Experimental design
We investigated whether there is a signature HOX gene profile unique to this disease. We 
measured HOX gene expression by RT-PCR in four well-described pancreatic cancer cell 
lines. HOX gene expression was also measured in commercially obtained RNA and snap-
frozen pancreatic cancer tissue from surgical resections. The CAM model was set up by 
grafting 4 pancreatic cancer cell lines and tumour architecture and molecular signature was 
evaluated by H&E staining and IHC. Gene expression was assessed by microarray analysis 
to compare global gene expression in cell-lines and CAM tumours and conservation of 
mitogen-activated protein kinases (MAPK) pathway was addressed by western blotting. HOX 
gene expression was measured by RT-PCR in both cell lines and CAM tumours. Finally, the 
efficacy of HRX9 was measured by generating IC50s using MTS and LDH assays. Levels of 
apoptosis were measured in vitro using Annexin-V-PE assay and in vivo by cleaved-caspase 
activation, assessed by IHC.
Results:
We found that HOX gene expression was elevated in tumour samples compared with normal 
tissue and in particular a significantly higher expression of HOXA13 in PDAC samples 
compared with normal pancreas. This was confirmed at the protein level by 
Immunohistochemistry (IHC). We also showed that the CAM model is suitable for drug testing 
as it recapitulates the architecture and molecular signature of PDAC. Results showed that 
MAPK pathway was conserved, due to the high frequency of mutational activation of the 
KRAS gene in this cancer. Cleaved-caspase activation also supports the hypothesis that 
tumour cells are driven into apoptosis upon HXR9 treatment. 
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Conclusions
HOX gene expression is highly dys-regulated in pancreatic cancer and more work is need to 
individually evaluate HOX genes on interest highlighted in this study. HOX gene expression 
can be antagonised by using HXR9. Finally, we have demonstrated the potential for HOX 
gene targeting as a novel therapy for PDAC.
5
Statement of originality 
This is to certify that to the best of my knowledge, the content of this thesis is my own work. 
This thesis has not been submitted for any degree or other purposes. I certify that the 
intellectual content of this thesis is the product of my own work and that all the assistance 
received in preparing this thesis and sources have been acknowledged. 
Sophie Gray
6
Table of contents
List of abbreviations! 10
List of Figures! 17
List of Tables ! 24
Acknowledgements! 26
1. Introduction! 27
1.1.Prevalence of pancreatic cancer! 28
1.2.Function and anatomy of the pancreas! 28
1.3.Causes and risk factors of pancreatic cancer! 29
1.4.Clinical management of pancreatic cancer! 30
1.5.Molecular biology and pathology of PDAC ! 32
1.6.The molecular genetics of PDAC ! 33
1.6.1.The EGFR signalling pathway (RAS)! 34
1.6.2.The Hedgehog signalling pathway! 37
1.6.3.The Notch signalling pathway! 38
1.6.4.TGF-ß signalling pathway (Smad)! 39
1.6.5.p53 mutations! 39
1.7.Tumour-stroma interactions in PDAC! 40
1.8.HOX genes! 41
1.8.1.HOX genes in pancreatic development! 43
1.8.2.HOX gene expression and function in pancreatic cancer! 45
1.9.In vivo modelling of pancreatic cancer! 49
1.10.The CAM assay ! 53
1.11.Hypothesis and aims of study ! 56
2. Materials and methods! 57
2.1.Tissue culture! 58
2.2.Determination of IC50s! 59
2.3.Mechanisms of cell death: Annexin V-PE assay ! 60
7
2.4.RNA extraction from cell lines! 60
2.5.RNA extraction for CAM tumours! 61
2.6.Commercially obtained patient RNA! 62
2.7.RNA extractions from FFPE blocks! 62
2.8.cDNA synthesis ! 63
2.9.Real-time semi quantitative reverse transcriptase polymerase chain reaction 
(RT-PCR)! 64
2.10.CAM model! 66
2.11.Immunohistochemistry ! 68
2.12.Microarray analysis! 69
2.13.Murine flank model! 72
2.14.Western blot! 73
3. HOX gene expression in PDAC! 75
3.1.Introduction! 76
3.2.Hypothesis and objectives! 76
3.3.Results! 77
3.3.1.HOX gene expression in pancreatic cell lines! 77
3.3.2.HOX gene expression in commercially available PDAC and normal pancreatic 
RNA! 81
3.3.3.HOX gene expression in snap-frozen human PDAC ! 87
3.3.4.Clustering analysis of HOX gene expression in pancreatic cancer! 93
3.3.5.HOXA13 immunohistochemistry in human PDAC and normal pancreatic tissue
! 95
3.3.6.PBX expression in pancreatic cell-lines and human tissue! 97
3.4.Discussion! 100
4. Tumour architecture and global gene expression analysis in 
the CAM model! 105
4.1.Introduction! 106
4.2.Hypotheses! 107
4.3.Aims of the study ! 108
4.4.Results! 108
8
4.4.1.Recapitulation on PDAC tumour architecture in CAM tumours! 108
4.4.2.Remodelling PDAC molecular signature in the CAM model! 112
4.4.3.AsPC-1 and BxPC-3 tumours in MFM ! 123
4.4.4.RAS/MAPK pathway in the CAM assay! 127
4.4.5.Microarray analysis in BxPC-3 cell-line versus BxPC-3 derived tumours! 129
4.4.6.Microarray analysis in AsPC-1 cell-line versus AsPC-1 derived tumours! 136
4.4.7.HOX gene expression in pancreatic cancer cell lines versus cell-line derived 
CAM tumours! 146
4.5.Discussion! 165
5. HOX gene antagonism in vitro and in ovo! 168
5.1.Introduction! 169
5.2.Hypothesis! 170
5.3.Aims of study ! 170
5.4.Results! 170
5.4.1.Targeting the HOX-PBX dimer: Pancreatic cancer cell line sensitivity to HXR9
! 170
5.4.2.Mechanisms of cell death caused by HXR9 in vitro measured by Annexin V-PE
! 178
5.4.3.Mechanisms of cell death caused by HXR9 in ovo ! 184
5.5.Discussion! 187
6. Final discussion! 189
Bibliography ! 199
Appendices! 222
9
List	  of	  abbrevia-ons
#/Symbols
! 5.FU !! ! Fluorouracil
! 7AAD!! ! 7-Aminoactinomycin D
! ΣERK!! ! Total Extracellular Signal-Regulated Kinase
A
! akt! ! ! Protein Kinase B
! Annexin-V-PE! Annexin-V-Phycoerythrin
! AMT! ! ! Aminopterin
! AMV! ! ! Avian Myeloblastosis Virus
B
! Bcl-2:!! ! B-Cell Lymphoma 2
! Bcl-XL! ! B-Cell Lymphoma Extra Large
! bFGF!! ! Basic Fibroblast Growth Factor
! BOP! ! ! nitrosobis(2-oxopropyl)amine
! BRCA2 ! ! Breast Cancer 2 Gene
! BRIGHT! ! Better Research Into Gastrointestinal Health And Treatment
C
! CA19-9! ! Carbohydrate Antigen 19-9
! CAM ! ! ! Chorioallantoic Membrane 
! CAV1!! ! Caveolin 1
! CAPZA2! ! F-Actin-Capping Protein Subunit Alpha 2
! CD5! ! ! Cluster Of Differentiation 5
! CD34!! ! Cluster Of Differentiation 34
! CDKN2A! ! Cyclin-Dependent Inhibitor 2A
10
! cFOS!! ! FBJ Murine Osteosarcoma Viral Oncogene 
! CK7! ! ! Cytokeratin 7
! CK19! ! ! Cytokeratin 19
! CK20! ! ! Cytokeratin 20
! CNS! ! ! Central Nervous System
! CT! ! ! Computer assisted Tomography
! CXR9!! ! CXArg9(2D)
D
! D2-40!! ! Podoplanin
! DMBA ! ! 7,12,dimethylbenz-α-anthacene
! DMEM! ! Dulbecco’s Modified Eagle’s Medium
! dNTP!! ! Deoxynucleotide Triphosphate
! DTT! ! ! Dithiotheitol
! DUOX2! ! Dual Oxidase 2
E
! ECM !  ! ! Extracellular Matrix
! EDD! ! ! Embryonic Developmental Day
! EEF1A2! ! Eukaryotic Translation Elongation Factor 1 Alpha 2
! EGF ! ! ! Epithelial Growth Factor
! EGFR ! ! Epithelial Growth Factor Receptor
! EGLN3! ! Egl-9 Family Hypoxia Inducible Factor 3
! erbB ! ! ! Epidermal Growth Factor Receptor 
! ERK! ! ! Extracellular Signal-Regulated Kinase
F
! FACS!! ! Fluorescence-Activated Cell Sorter
! FC:! ! ! Fold Change
11
! FCS! ! ! Foetal Calf Serum
! FFPE!! ! Formalin-Fixed Paraffin-Embedded 
! FGF-1! ! Fibroblast Growth Factor 1
! FGF-2! ! Fibroblast Growth Factor 2
! FISH! ! ! Fluorescence In Situ Hybridisation 
! FTI ! ! ! Farnesyl Transferase Inhibitors
G
! GDP ! ! ! Guanosine Diphosphate
! GEF ! ! ! Guanine Exchange Factor
! GEMM ! ! Genetically Engineered Murine Models
! gli ! ! ! Glioma Associated Oncogene Homologue
! grb2!  ! ! Growth factor bound protein 2
! GTP! ! ! Guanosine Triphosphate
H
! H&E! ! ! Haematoxylin And Eosin
! HCP1!! ! Haem Carrier Protein 1
! HDM2! ! Human Double Minute 2 Homologue 
! HIF-1! ! ! Hypoxia-Inducible Factor 1
! HIF-1α! ! Hypoxia-Inducible Factor 1 Alpha
! HOX !! ! Homeobox
! HOTTIP! ! Long non-coding RNA HOXA Transcript at The Distal Tip
! HRAS ! ! Homology to Harvey Murine Sarcoma (transforming protein 21)
! HXR9!! ! HXArg9(2D)
I
! IC50 ! ! ! Half Maximal Inhibitory Concentration
! IFN-γ!! ! Interferon-Gamma
12
! IGF1! ! ! Insulin-Like Growth Factor 1
! IGF2!  ! ! Insulin-Like Growth Factor 2
! IHC ! ! ! Immunohistochemistry
J
! JNK! ! ! C-Jun N-Terminal Kinase
K
! KRAS!! ! V-Ki-Ras Kirsten Rat Sarcoma Viral Oncogene Homologue
L
! LDH ! ! ! Lactate Dehydrogenase
! LDLs!  ! ! Low Density Lipoproteins
! LDLR! ! ! Low Density Lipoprotein Receptor
! LKB1! ! ! Liver Kinase B1
! lsl! ! ! Lox-Stop-Lox
M
! MAPK! ! Mitogen-Activated Protein Kinases
! MAP3K3! ! Mitogen-Activated Protein Kinase Kinase Kinase 3
! MEIS!! ! Myeloid Ecotropic Viral Integration Site
! MEKK3! ! Mitogen-Activated Protein Kinase Kinase Kinase 3
! MFM! ! ! Murine Flank Model
! miR! ! ! Micro-RNA
! MLH1 ! ! MutL Homologue 1
! M-MLV-RT! ! Moloney Murine Leukaemia Virus Reverse Transcriptase
! MMP-3! ! Metallopeptidase-3
! MRI! ! ! Magnetic resonance imaging 
! MTS! ! ! 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
! sulfophenyl)-2H-tetrazolium)
13
! MTX! ! ! Methotrexate 
N
! NADPH ! ! Nicotinamide Adenine Dinucleotide Triphosphate
! NF-KB ! ! Nuclear Factor Kappa-Light Chain Enhancer Of Activated B-Cells
! Nox! ! ! NADPH Oxidase
! NRAS ! ! Neuroblastoma viral oncogene homologue
O
! ODN !  ! ! Oligodeoxynucleotide
! OligodT! ! Oligo Deoxy-Thymine
! OSCC ! ! Oesophageal Squamous Carcinoma 
P
! P16 ! ! ! Cyclin Dependent Kinase Inhibitors 2A (INK4A)
! P38! ! ! Mitogen-Activated Protein Kinase
! P48! ! ! Pancreas Transcription Factor 1 Subunit Alpha
! P53! ! ! Tumour Suppressor p53
! P205! ! ! Supervillin
! PanIN ! ! Pancreatic Intra-Epithelial Neoplasm
! pax ! ! ! Paired Box
! PBS! ! ! Phosphate-Buffered Saline
! PBX! ! ! Pre-B-Cell Leukaemia Homeobox
! PCFT!! ! Proton-Coupled Folate Transporter
! PCSC!  ! Pancreatic Cancer Stem Cell
! PCSK9! ! Proprotein Convertase Subtilin Kexin Type 9
! PDAC! ! Pancreatic Ductal Adenocarcinoma
! PDGF! ! Platelet-Derived Growth Factor
! PDX! ! ! Pancreatic And Duodenal Homeobox
14
! pERK!! ! Phosphorylated Extracellular Signal-Regulated Kinase
! PET ! ! ! Positron Emission Tomography
! PHD3!! ! Propyl Hydroxyl 3
! PKD! ! ! Proteinase K Digestion
! pMEK!! ! Phosphorylated Mitogen-Activated Protein Kinase Kinase
! PORCN ! ! Porcupine Homologue 
! PP ! ! ! Pancreatic Polypeptide
! PSC! ! ! Pancreatic Stellate Cell
! Ptch1 ! ! Patched 1
! PVDF!! ! Polyvinylidene Fluoride
R
! RA! ! ! Retinoic Acid
! RAF! ! ! Serine/Threonine Protein kinase
! RBC ! ! ! Red Blood Cell
! RER ! ! ! Rough Endoplasmic Reticulum
! RhoA !! ! RAS Homologue Family Member A
! RNAi!  ! ! Ribonucleic acid interference
! ROS! ! ! Reactive Oxygen Species
! RPM !  ! ! Revolution Per Minute
! RPMI!! ! Roswell Park Memorial Institute
!
S 
! S100P ! ! S100 calcium binding protein
! SDF-1! ! Stromal-Derived Factor 1
! SDS ! ! ! Sodium Dodecyl Sulphate
! SEM !! ! Standard Error of the Mean
15
! SH2 ! ! ! Src Homology 2
! SHH ! ! ! Sonic Hedgehog
! siRNA! ! Small Interfering RNA
! SMA! ! ! Smooth Muscle Actin
! SMAD! ! Mothers Against Decapentaplegic 
! SMO ! ! ! Smoothened
! SMURF1! ! SMAD-Ubiquitination  Regulatory Factor 1
! SOS1! ! ! Son of Sevenless
! SPATA2! ! Spermatogenesis-Associated protein 2
T
! TBS ! ! ! Tris-Buffered Saline
! TFF! ! ! Trefoil Family
! TFF3! ! ! Trefoil Factor 3
! TGF-ß! ! Transforming Growth Factor Beta
! TMA! ! ! Tissue Microarray
! TMPRSS3 ! ! Transmembrane Protease Serine 3
! TNF! ! ! Tumour Necrosis Factor
! tPA! ! ! Tissue Plasminogen Activator
! TRAF7! ! TNF Receptor-Associated Factor 7
! tRNA:!! ! Transfer RNA
U
! UTR! ! ! Untranslated region
V
! VEGF!! ! Vascular Endothelial Growth Factor
W
! Wnt! ! ! Wingless
16
List of Figures 
Chapter 1: Introduction
! Figure 1.1: Anatomical structures and cell types of the pancreas.
! Figure 1.2: Genetic changes from normal pancreatic tissue to PDAC with infiltrating 
! immune cells which contribute to the desmoplastic reaction associated with PDAC.
! Figure 1.3: Signalling pathway downstream of mutated KRAS in PDAC cells.
! Figure 1.4: Schematic representation of HOX protein binding to DNA and co-factor! PBX via 
! the hexapeptide sequence found on HOX proteins. HXR9 competitively inhibits HOX protein 
! binding through PBX-binding.
! Figure 1.5: Summary of HOX genes in pancreas development and in pancreatic cancer 
! in the literature.
! Figure 1.6: Schematic representation of the anatomical structures of the developing chick 
! embryo. 
! Figure 1.7: Timeline of the CAM assay
Chapter 2: Materials and Methods
! Figure 2.1: Drug administration methods used for treating CAM tumours with HXR9.
Chapter 3: HOX gene expression in PDAC
! Figure 3.1: Levels of HOX gene expression in the HOXA gene cluster in AsPC-1, 
! BxPC-3, PaCa-3 and PancTu-1 cell lines measured by semi-quantitative RT-PCR.
! Figure 3.2: Levels of HOX gene expression in the HOXB gene cluster in AsPC-1, 
! BxPC-3, PaCa-3 and PancTu-1 cell lines measured by semi-quantitative RT-PCR.
! Figure 3.3: Levels of HOX gene expression in the HOXC gene cluster in AsPC-1, 
! BxPC-3, PaCa-3 and PancTu-1 cell lines measured by semi-quantitative RT-PCR.
17
! Figure 3.4: Levels of HOX gene expression in the HOXD gene cluster in AsPC-1, 
! BxPC-3, PaCa-3 and PancTu-1 cell lines measured by semi-quantitative RT-PCR.
! Figure 3.5: Levels of HOXA expression were measured by semi-quantitative RT-PCR in 
! RNA from neoplastic pancreas and compared with HOXA gene expression in RNA from 
! normal pancreas.
! Figure 3.6: Levels of HOXB expression were measured by semi-quantitative RT-PCR in 
! RNA from neoplastic pancreas and compared with HOXB gene expression in RNA from 
! normal pancreas. 
! Figure 3.7: Levels of HOXC expression were measured by semi-quantitative RT-PCR in 
! RNA from neoplastic pancreas and compared with HOXC gene expression in RNA from 
! normal pancreas. 
! Figure 3.8: Levels of HOXD expression were measured by semi-quantitative RT-PCR in 
! RNA from neoplastic pancreas and compared with HOXD gene expression in RNA from 
! normal pancreas. 
! Figure 3.9: Quality control of RNA extracted from snap-frozen tumours.
! Figure 3.10: Levels of HOXA expression were measured by semi-quantitative RT-PCR in 
! RNA from snap-frozen pancreas of PDAC patients and compared with HOXA gene 
! expression in RNA from normal pancreas. 
! Figure 3.11: Levels of HOXB expression were measured by semi-quantitative RT-PCR in 
! RNA from snap-frozen pancreas of PDAC patients and compared with HOXB gene 
! expression in RNA from normal pancreas. 
! Figure 3.12: Levels of HOXC expression were measured by semi-quantitative RT-PCR in 
! RNA from snap-frozen pancreas of PDAC patients and compared with HOXC gene 
! expression in RNA from normal pancreas. 
! Figure 3.13: Levels of HOXD expression were measured by semi-quantitative RT-PCR in 
! RNA from snap-frozen pancreas of PDAC patients and compared with HOXD gene 
! expression in RNA from normal pancreas. 
18
! Figure 3.14: Clustering analysis of HOX genes in pancreatic cell-lines, normal pancreas 
! and PDAC RNA obtained both commercially and from snap-frozen tumours.
! Figure 3.15: IHC staining of HOXA13 protein on a tissue microarray (TMA) of human cases 
! of PDAC and normal pancreas.
! Figure 3.16: Levels of PBX1-4 expression were measured by semi-quantitative RT-PCR in 
! AsPC-1, BxPC-3, PaCa-3 and Panctu-1 cell lines.
! Figure 3.17: Levels of PBX1-4 expression were measured by semi-quantitative RT-PCR in 
! RNA from neoplastic pancreas and compared with PBX1-4 gene expression in RNA from 
! normal pancreas. 
! Figure 3.18: Levels of PBX1-4 expression were measured by semi-quantitative RT-PCR in 
! RNA from snap-frozen pancreas of PDAC patients and compared with PBX1-4 gene 
! expression in RNA from normal pancreas. 
Chapter 4: Tumour architecture and global gene expression analysis 
in the CAM model 
! Figure 4.1: Macroscopic appearance of AsPC-1, BxPC-3, PaCa-3 and PancTu-1 derived 
! tumours grown on the CAM of a developing chick embryo.
! Figure 4.2: H&E staining of tumours derived from AsPC-1, BxPC-3, PaCa-3 and PancTu-1 
! cell lines grown using the CAM assay.
! Figure 4.3: Panel of immunohistochemistry stains of AsPC-1-derived CAM tumours.
! Figure 4.4: Panel of immunohistochemistry stains of BxPC-3-derived CAM tumours.
! Figure 4.5: Panel of immunohistochemistry stains of PaCa-3-derived CAM tumours.
! Figure 4.6: Panel of immunohistochemistry stains of PancTu-1-derived CAM tumours.
! Figure 4.7: Panel of immunohistochemistry stains of human normal adjacent pancreatic 
! tissue.
! Figure 4.8: Panel of immunohistochemistry stains of Human PDAC
19
! Figure 4.9: H&E staining of AsPC-1 and BxPC-3 derived tumours grown in the MFM.
! Figure 4.10: Panel of immunohistochemistry stains of AsPC-1 derived tumours grown in the 
! MFM.
! Figure 4.11: Panel of immunohistochemistry stains of BxPC-3 derived CAM !tumours 
! Figure 4.12: Western blot analysis of phosphorilated MEK and ERK pathway of AsPC-1 and 
! BxPC-3 cell lines compared with AsPC-1 and BxPC-3 derived CAM tumours and AsPC-1 
! and BxPC-3 tumours grown in the MFM.
! Figure 4.13: Heatmap of differentially expressed probes in AsPC-1 cell line compared with 
! AsPC-1 CAM tumours with a FC>5.
! Figure 4.14: Validation of most differentially expressed genes in AsPC-1 cell-line compared 
! with AsPC-1 CAM tumours by RT-PCR
! Figure 4.15: Summary of most dysregulated pathways in BxPC-3 cells versus BxPC-3 CAM 
! tumours
! Figure 4.16: Apoptosis and survival (fas signalling cascade)
! Figure 4.17: Hedgehog signalling pathway.
! Figure 4.18: Heatmap of differentially expressed probes in BxPC-3 cell line compared with 
! BxPC-3 CAM tumours with FC>5. 
! Figure 4.19: Validation of most differentially expressed genes in AsPC-1 cell-line 
! compared with AsPC-1 CAM tumours by RT-PCR.
! Figure 4.20: Summary of most dysregulated pathways when AsPC-1 cells go from an in 
! vitro to an in ovo tumour environment.
! Figure 4.21: Oxidative phosphorilation. Thermometers numbered represent the change in 
! gene expression when AsPC-1 cells change from being cultured in vitro to growing in the 
! CAM-model.
! Figure 4.22: TGF-beta dependent induction of of EMT via RhoA, PI3K and ILK. !
! Figure 4.23: HOX gene expression levels measured by RT-PCR in AsPC-1 cell-line 
! compared with their cell-line-derived tumours in the HOXA cluster. 
! Figure 4.24: HOX gene expression levels measured by RT-PCR in BxPC-3 cell-line 
! compared with their cell-line-derived tumours in the HOXA cluster. 
20
! Figure 4.25: HOX gene expression levels measured by RT-PCR in PaCa-3 cell-line
! compared with their cell-line-derived tumours in the HOXA cluster.
! Figure 4.26: HOX gene expression levels measured by RT-PCR in PancTu-1 cell-line 
! compared with their cell-line-derived tumours in the HOXA cluster. 
! Figure 4.27: HOX gene expression levels measured by RT-PCR in AsPC-1 cell-line 
! compared with their cell-line-derived tumours in the HOXB cluster. 
! Figure 4.28: HOX gene expression levels measured by RT-PCR in BxPC-3 cell-line 
! compared with their cell-line-derived tumours in the HOXB cluster. 
! Figure 4.29: HOX gene expression levels measured by RT-PCR in PaCa-3 cell-line 
! compared with their cell-line-derived tumours in the HOXB cluster. 
! Figure 4.30: HOX gene expression levels measured by RT-PCR in PancTu-1 cell-line 
! compared with their cell-line-derived tumours in the HOXB cluster. 
! Figure 4.31: HOX gene expression levels measured by RT-PCR in AsPC-1 cell-line 
! compared with their cell-line-derived tumours in the HOXC cluster. 
! Figure 4.32: HOX gene expression levels measured by RT-PCR in BxPC-3 cell-line 
! compared with their cell-line-derived tumours in the HOXC cluster. 
! Figure 4.33: HOX gene expression levels measured by RT-PCR in PaCa-3 cell-line 
! compared with their cell-line-derived tumours in the HOXC cluster.
! Figure 4.34: HOX gene expression levels measured by RT-PCR in PancTu-1 cell-line 
! compared with their cell-line-derived tumours in the HOXC cluster.
! Figure 4.35: HOX gene expression levels measured by RT-PCR in AsPC-1 cell-line 
! compared with their cell-line-derived tumours in the HOXD cluster.
! Figure 4.36: HOX gene expression levels measured by RT-PCR in BxPC-3 cell-line 
! compared with their cell-line-derived tumours in the HOXD cluster.
! Figure 4.37: HOX gene expression levels measured by RT-PCR in PaCa-3 cell-line 
! compared with their cell-line-derived tumours in the HOXD cluster.
21
! Figure 4.38: HOX gene expression levels measured by RT-PCR in PancTu-1 cell-line 
! compared with their cell-line-derived tumours in the HOXD cluster.
Chapter 5: HOX gene antagonism in vitro and in ovo
! Figure 5.1: AsPC-1 cell-line sensitivity to HXR9 shown by MTS assay. 
! Figure 5.2: BxPC-3 cell-line sensitivity to HXR9 shown by MTS assay.
! Figure 5.3: PaCa-3 cell-line sensitivity to HXR9 shown by MTS assay.
! Figure 5.4: PancTu-1 cell-line sensitivity to HXR9 shown by MTS assay.
! Figure 5.5: AsPC-1 cell-line sensitivity to HXR9 shown by LDH assay.
! Figure 5.6: PaCa-3 cell-line sensitivity to HXR9 shown by LDH assay.
! Figure 5.7: PancTu-1 cell-line sensitivity to HXR9 shown by LDH assay.
! Figure 5.8: Summary of IC50 values determined by MTS and LDH assays.
! Figure 5.9: FACS analysis of Annexin-V-PE stained AsPC-1 cells and counter-stained with 
! 7-AAD.
! Figure 5.10: FACS analysis of Annexin-V-PE stained BxPC-3 cells and counter-stained with 
! 7-AAD.
! Figure 5.11: FACS analysis of Annexin-V-PE stained PaCa-3 cells and counter-stained with 
! 7-AAD. 
! Figure 5.12: FACS analysis of Annexin-V-PE stained PancTu-1 cells and counter-stained 
! with 7-AAD.
! Figure 5.13: Cleaved-caspase 3 staining of BxPC-3 CAM tumour and human tonsil 
! sections. Tumours were treated with a topical application or either PBS, CXR9 of HXR9.
Chapter 6: Final Discussion
22
! Figure 6.1: Predicted regulatory gene networks of (available) HOX genes aberrantly expressed 
! in PDAC.
Appendices:
! Appendix 3.1: HOXA13 staining of tissue microarray (TMA) 
! Appendix 5.1: Cleaved-caspase 3 staining on AsPC-1 derived CAM tumour paraffin 
sections. Tumours were treated with intra-tumoral injection of either PBS, CXR9 or HXR9.
! Appendix 5.2: Cleaved-caspase 3 staining on BxPC-3 derived CAM tumour paraffin 
sections. Tumours were treated with intra-tumoral injection of either PBS, CXR9 or HXR9.
! Appendix 5.3: Cleaved-caspase 3 staining on PaCa-3 derived CAM tumour paraffin 
sections. Tumours were treated with intra-tumoral injection of either PBS, CXR9 or HXR9.
! Appendix 5.4: Cleaved-caspase 3 staining on PancTu-1 derived CAM tumour paraffin 
sections. Tumours were treated with intra-tumoral injection of either PBS, CXR9 or HXR9.
23
List of Tables
Chapter 1: Introduction
! Table 1.1: Genetically engineered mouse models of PDAC.
Chapter 2: Materials and methods
! Table 2.1: Seeding rates of AsPC-1, BxPC-3, PaCa-3 and PancTu-1 for 70% confluency.
! Table 2.2: Commercially obtained RNA pathological data.
! Table 2.3: Primer sequences of HOX genes.
! Table 2.4: Primer sequences of genes most differentially expressed in AsPC-1 and BxPC-3 
! cell lines compared with their CAM derived tumours.
! Table 2.5: Primer sequences of PBX1-4 genes
! Table 2.6: Antibodies used in western blotting.
Chapter 3: HOX gene expression in PDAC
! Table 3.1: Summary of results of HOXA13 immunohistochemical staining of human TMA in 
! 59 human PDAC cases versus 20 cases of normal / normal adjacent pancreas.
! Table 3.2: Summary of staining intensities of HOXA13 immunohistochemical staining of 
! human TMA in 59 human PDAC cases versus 20 cases of normal / normal adjacent 
! pancreas.
Chapter 4: Tumour architecture and global gene expression analysis
in the CAM model
! Table 4.1: Summary of immunohistochemical panel of antibodies used to stain AsPC-1, 
! BxPC-3, PaCa-3 and PancTu-1 CAM tumours.
! Table 4.2: Summary of immunohistochemical panel of antibodies used to stain a Human 
! PDAC tumour and surrounding normal tissue.
! Table 4.3: Summary of immunohistochemical panel of antibodies used to stain AsPC-1, 
! BxPC-3 tumours grown in mice.
Chapter 6: Final Discussion 
! Table 6.1: Summary of HOX gene dysregulation in several solid cancers.
Appendices:
24
! Appendix Table 3.1: Summary of RNA extractions and quality controls of snap-frozen 
! tumours used for HOX profiling.
Appendix Table 3.2: Summary of RNA extractions quality control from FFPE blocks.!
Appendix Table 3.3: Specification data of TMA including PDAC, normal and normal 
! adjacent tissue and outcome of HOXA13 immunohistochemistry.
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Chapter I:
1. Introduction
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1.1. Prevalence of pancreatic cancer
Pancreatic cancer has one of the highest cancer-related mortality rates and remains a major 
unsolved clinical problem in the western world. Pancreatic ductal adenocarcinoma (PDAC) is 
the most common type of pancreatic cancer and is biologically distinct from other tumours of 
the pancreas. In 2010, in the UK, 7,921 people died from the disease (PCA, 2011) and a 
projected 45,220 new cases were predicted to occur in the United States in 2013 (Siegel et 
al., 2012) where occurrence is slightly higher in males compared with females (23,530 and 
22,890 new cases respectively) with mortality rates not dissimilar (Siegel et al., 2014). There 
is little variation in the distribution of pancreatic cancer across ethnicities. 53% of patients are 
diagnosed through the occurrence of distant metastases whilst only 8% of cases are 
localised. Only 15% of patients diagnosed with the disease are suitable for surgical resection 
with curative intent. Despite improvements in the understanding of the molecular 
pathogenesis of PDAC, the 5-year survival rate is currently under 5%, a figure that has not 
changed in the last 30 years. These poor survival rates are due, in part, to late diagnosis but 
also to the lack of robust therapeutic targets (Bardeesy and DePinho, 2002).
1.2. Function and anatomy of the pancreas
The pancreas is a complex organ whose functions include synthesising, storing and secreting 
hormones and digestive enzymes. The pancreas consists of an endocrine portion, responsible 
for secreting hormones into the bloodstream and an exocrine portion responsible for secreting 
digestive enzymes. The endocrine pancreas consists of islets of Langerhans made up of α-
cells (responsible for glucagon production), ß-cells (responsible for insulin production), δ-cells 
(that contain somatostatin present in cytoplasmic granules) and pancreatic polypeptide (PP) 
secreting cells (referred to as PP cells) (John P Neoptolemos, 2010a). The exocrine pancreas 
consists of grape like structures containing a dense network of blood and lymphatic vessels 
surrounded by thin connective tissue and located at the termini of the ductal branching system 
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(Bardeesy and DePinho, 2002). The ductal system within the pancreas delivers secretion from 
the acini to the duodenum to which mucus and bicarbonate are added (Figure 1.1) (Bardeesy 
and DePinho, 2002).
  
! Figure 1.1: Anatomical structures and cell types of the Pancreas: a: Gross anatomy and 
! position of the pancreas. b: The exocrine pancreas consisting of ducts and acinar cells 
! responsible for the production of digestive enzymes. c: A single Acinus. d: Pancreatic islets 
! (endocrine pancreas) embedded in the exocrine pancreas. (Bardeesy and DePinho, 2002).
1.3.	  Causes and risk factors of pancreatic cancer
There are few known demographic and environmental risk factors associated with the onset 
of PDAC. Cigarette smoking is the most important risk factor and it is estimated that between 
20 and 30% of pancreatic cancer cases are linked to cigarette smoking (Hezel et al., 2006). 
Incidence of PDAC in the first 4 decades of life is low and advancing age appears to be a risk 
factor (median age = 72 years) (John P Neoptolemos, 2010b). Obesity is also a well 
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established risk factor and an estimated 12% of cases in the UK are thought to be directly 
attributed to it (Wormann and Algul, 2013). Type 2 diabetes mellitus can be classed as both a 
risk factor and/or a potential symptom of pancreatic cancer and patients living with diabetes 
for more than 5 years have a 50% higher risk of pancreatic cancer. Increased risk of PDAC 
has also been associated with hereditary factors; around 10% of PDAC cases are linked to 
genetic predisposition with germ line mutations in genes such as P16 cyclin-dependent kinase 
inhibitor 2A (INK4A) (Also referred to as P16), (breast cancer 2 (BRCA2) and liver kinase 
(LKB1), mutL homologue 1 (MLH1), protease serine 1 (PRSS1)). Thus, age, cigarette 
smoking, obesity, diabetes mellitus and inherited gene mutations are the most documented 
pancreatic cancer risk factors, however, some studies involving alcohol use, dietary factors 
(such as red and processed meats and sugar-sweetened carbonated drinks) have also 
demonstrated a higher risk for pancreatic cancer (Wormann and Algul, 2013). In essence, 
many studies involving dietary factors, alcohol, pancreatitis, occupational / hormonal factors 
and infectious agents associate these factors with an increased risk of pancreatic cancer but 
are often inconclusive and at times subject to publication bias. In a large cohort study 
(n=1,057) Jiao et al. suggest that 50% of pancreatic cancers could be prevented by a healthy 
lifestyle. The interaction between the risk factors of pancreatic cancer and the consequential 
genetic alterations still require more research to better understand the aetiology of the 
disease (Jiao et al., 2009). 
1.4. Clinical management of pancreatic cancer
Clinical decision-making is key to pancreatic cancer management whereby patients must 
undergo staging to classify them into resectable, borderline resectable, locally advanced or 
metastatic disease groups. In patients with (potentially) resectable tumours, elevated pre-
operative levels of carbohydrate antigen 19-9 (CA 19-9) have been shown to lead to poorer 
prognoses compared with patients with lower levels. Whilst surgical resection remains the 
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only curative option, it still results in poor survival rates. Neoadjuvant therapy (before surgery) 
in the form of chemotherapy, radiotherapy or a combination of the two has for long been a 
subject of discussion. The rationale behind such therapies is to limit the risk of microscopic 
distant metastases from remaining untreated during surgical resection and recovery. However, 
clinical trials have failed to determine a significant improvement in survival in patients that do 
receive neoadjuvant therapy (Belli et al., 2013). Its has been shown, however, that adjuvant 
therapy, 4-8 weeks after surgery, significantly improves survival whether using 
chemotherapeutic agents such as gemcitabine or fluorouracil (5-FU) or radiation. Survival 
rates are governed by post-operative recovery, quality of staging before resection and 
complications during the surgery (Tempero et al., 2007). While gemcitabine remains the most 
widely used option since it’s approval in 1996, efforts have been made to use targeted 
therapies such at Erlotinib, an epithelial growth factor (EGFR) inhibitor for pancreatic cancer 
treatment. Erlotinib in combination with Gemcitabine have shown a small increase in survival. 
Other targeted therapies include vascular endothelial growth factors (VEGF) inhibitors, ras-
farnesyltransferase inhibitors and other EGFR inhibitors, although these have not resulted in a 
significant improvement in survival rates (Moore et al., 2007). Other emerging therapies 
include targeting specific pathways, for example, the nuclear factor-kappa B (NFkB) pathway 
which promotes cell growth, disabled apoptosis and promotes angiogenesis, cell invasion and 
metastasis. FUT-175 inhibits constitutive NFkB activation and increases caspase dependent 
apoptosis (Uwagawa et al., 2007) Another attractive therapeutic option is to target micro-
RNAs, (miR) which are small non-coding RNAs around 18 to 24 nucleotides long, thought to 
be implicated in the activation of several cancer pathways. Studies have shown miR-21, 
miR-155,miR-196a, miR-210 and miR-221 to be overexpressed in PDAC which can be 
targeted using antisense oligonucleotides and which have shown to increase tumour 
sensitivity to gemcitabine (Khan et al., 2013) 
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1.5. Molecular biology and pathology of PDAC
Pancreatic neoplasia are classified according to the cell type they affect, being, in most cases 
cells of ductal lineage. Amongst non-ductal neoplasms, the most common are endocrine 
neoplasia, which replicate the islets of Langerhans and which are characterised by uniform 
cells, arranged in nests. Cytologic features include monotonous nuclei that display a “salt and 
pepper” chromatin pattern. Carcinomas of ductal lineage include mucinous non-cystic 
carcinoma, signet-ring carcinoma, adenosquamous carcinoma, undifferentiated (anaplastic) 
carcinoma, and undifferentiated carcinoma with osteoclast-like giant cells. 
Cells of ductal lineage are organised in luminated structures and ductal carcinomas can be 
derived from tubular units (lumen forming), cysts and papillae (projections of the mucosa 
lining the cysts and ducts). The molecular and genetic profiles  of ductal carcinomas are 
different to other tumours of the pancreas  (John P Neoptolemos, 2010b). 
PDAC has been characterised as a step-by-step process that begins with progressive 
accumulation of genetic alterations that occur in a non-random, well-described sequence of 
events. . Such alterations  are graded and named pancreatic intraepithelial neoplasia 
(PanINs) 1, 2, and 3 (Maitra and Hruban, 2008). Initially, genetic alterations accumulate, for 
example, mutations in the tumour suppressor gene p53 (p53) and v-ki-ras kirsten rat sarcoma 
viral oncogene homologue (KRAS) genes that lead to nuclear enlargement in turn leading to 
altered cellular metabolism and accumulation of glycoproteins (mucins) and ultimately loss of 
polarity and increased mitotic activity. PanINs measure around 5 mm and are 
characteristically asymptomatic. PanIN1s are described as “a change from normal ductal 
epithelium made up of cuboidal or low columnar cells to tall columnar cells containing apical 
mucins” (John P Neoptolemos, 2010a). PanIN1s are classified into PanIN1A and PanIN1B 
which are flat and papillary respectively and usually display little architectural atypia while 
PanIN2s are characterised by polynucleated cells with loss of polarity and moderate 
cytological and architectural atypia. PanIN3s are regarded as “carcinomas in situ” and display 
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macronucleoli, loss of polarity with nuclear irregularities and have papillary morphology. 
PanINs are non invasive lesions that do not cross the basement membrane. Early detection of 
these lesions would provide an opportunity for treatment before the onset of invasive PDAC, 
however, imaging techniques are unable to detects PanINs. Research into markers present in 
the pancreatic juice could resolve this (Distler et al., 2014).
1.6. The molecular genetics of PDAC
 The step-by-step transition from normal pancreatic tissue to PDAC involves several genetic 
changes. Amongst these, the most common is the mutational activation of KRAS which can 
be accompanied by abnormalities in sonic hedgehog (SHH), notch and Smad4 genes (Figure 
1.2).
! Figure 1.2: Genetic changes from normal pancreatic tissue to PDAC. Diagram shows 
! infiltrating immune cells which contribute to the desmoplastic reaction associated with PDAC 
! (Wormann and Algul, 2013).
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1.6.1. The EGFR signalling pathway (RAS)
Epithelial growth factor receptor (EGFR) activation initiates a diverse array of cellular 
pathways. The receptor family consists of four single-transmembrane proteins that become 
activated when a single ligand binds to a single receptor monomer epithelial growth factor 
receptor (ErbB1-4 ). In the presence of epithelial growth factor (EGF), EGFRs (or ErbBs) 
dimerise (homo and hetero-dimerisation) and subsequently become phosphorylated at 
multiple tyrosine sites which enables docking of proteins containing src homology 2 (SH2) 
domains such as growth factor bound protein 2 (grb2). Grb2 recruits son of sevenless 1 
(SOS1) which acts as a guanine exchange factor (GEF) for RAS and unloads guanosine 
diphosphate (GDP) and binds guanosine triphosphate (GTP). There are three RAS genes 
encoded by the human genome, HRAS (named from homology to the Harvey murine sarcoma 
virus), NRAS (first isolated from neuroblastoma cells) and KRAS (with homology to the 
Kirsten murine sarcoma virus oncogene). KRAS has two splice variants named KRASA and 
KRASB. There are many different types genetic dysregulations that can affect the EGFR 
pathway, such as mutation in EGFR, EGFR amplification and KRAS mutations (Lee et al., 
2007). ErbB signalling has been shown to be involved in normal growth of both the endocrine 
and exocrine portions of the developing pancreas. ErbB1 has been shown to be 
overexpressed in 30 to 90% of pancreatic cancers (John P Neoptolemos, 2010b) and indeed 
both EGF and EGFR overexpression has been reported as a common feature of pancreatic 
cancer in particular in advanced disease and hence associated with significantly poorer 
clinical outcome (Sarkar et al., 2007). Blocking EGFR signalling is therefore an attractive 
clinical target whose therapeutic arsenal has been slowly growing in the last few years. 
Erlotinib, a small-molecule tyrosine kinase inhibitor was shown to sensitise pancreatic 
tumours to gemcitabine by restoring apoptosis in a randomised trial by the national cancer 
institute of Canada which subsequently lead to its approval in 2005 despite a modest 
improvement in survival (Chang and Saif, 2009). Other efforts to target EGFR signaling 
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include the use of monoclonal antibodies, whose uses have shown clinical benefits in other 
cancers. Cetuximab, a human-mouse chimeric monoclonal antibody, binds to the extra 
cellular portion of EGFR which prevents EGF-binding (Luedke et al., 2012). Cetuximab 
showed promising results in preclinical studies and phase II clinical trials but failed to show 
any improvement in overall survival in a randomised phase II clinical trial in combination with 
gemcitabine (Mahipal et al., 2014).
! Figure 1.3: Signalling pathway downstream of mutated KRAS in PDAC cells and consequences 
! of the mutational activation of RAS. (Pylayeva-Gupta et al., 2011).
 The KRAS gene has been found to be mutated in around 90% of pancreatic cancers making 
it one of the key mediators of pancreatic cancer genesis. RAS activation involves GTP-bound 
RAS migrating to the membrane where it recruits a group of three serine proteases, A-RAF, B-
RAF and C-RAF. 
KRAS mediates a number of cellular functions which include proliferation, differentiation and 
survival. Point mutations in codon 12 of the KRAS gene involve GGT to GAT, GTT and 
sometimes CGT which result in an amino acid substitution from glycine to aspartate, valine or 
arginine (Lee et al., 2007) . KRAS mutations can be detected in around 30% of early PanINs 
and this percentage increases consistently with cancer progression. KRAS mutations result in 
a constitutively activated protein independent of upstream growth factors (Hezel et al., 2006). 
KRAS mutations have been detected in pancreatic juice and peripheral blood, however, these 
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mutations are not specific to PDAC and have been described in patients with chronic 
pancreatitis and other types of pancreatic tumours. KRAS mutations have also been linked to 
other types of cancer and, therefore, their presence in peripheral blood is not specific to 
PDAC (Deramaudt and Rustgi, 2005). Codon 12 mutations were found in 67% formalin-fixed 
paraffin embedded (FFPE) blocks (n=43), however, when cancerous ducts were 
microdissected KRAS mutations were identified in 91% of cases. This study also suggested 
that EGFR and BRAF mutations were predominantly absent in these tumours supporting the 
hypothesis that a single mutation of KRAS is sufficient to induce the MAPK pathway 
(Immervoll et al., 2006). Since KRAS and its downstream effectors are dysregulated in many 
different cancers, targeting KRAS appears to be an attractive therapeutic aim. RAS can be 
directly targeted by either, preventing its expression or, by blocking localisation of RAS protein 
to the plasma membrane, the site at which it is activated. Preventing RAS expression has 
been achieved using antisense oligodeoxynucleotides (ODNs) or RNA interference (RNAi). 
ODNs have been subjected to phase I and II clinical trials in combination with gemcitabine 
and paclitaxel, however, no clinical advantage resulted from them. RNAi has a higher target 
sequence specificity and is yet to be tested in a clinical setting (Takashima and Faller, 2013). 
Approaches to inhibit the activation of RAS (from its GDP to GTP bound state) include the use 
of farnesyl tranferase inhibitors (FTIs) (involved in the post-translational modification of 
proteins) such as lonafarnib and tipifarnib, both of which have progressed to phase III clinical 
trials with little or no success so far (Neuzillet et al., 2013). More success has been achieved 
by targeting RAS effectors rather than RAS itself. Accordingly, so far, four drugs have been 
marketed, temsirolimus and everolimus which are mTOR inhibitors that target the PI3K-AKT-
mTOR pathway and BRAF inhibitors sorfenib and vemurafenib. 
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1.6.2. The Hedgehog signalling pathway
The Hedgehog signalling pathway is essential to the development of most bilatarian 
organisms and central to growth, patterning and morphogenesis in embryonic development. 
The human Hedgehog gene codes for 3 hedgehog ligands, Sonic, Indian and Desert 
Hedgehog (Ingham and Placzek, 2006). Hedgehog ligands activate the 7-transmembrane G-
protein-coupled receptor like protein smoothened (smo) through the interaction with the 
membrane receptor pathced1 (Ptch1). The activation of smo results in the induction and 
nuclear localisation of glioma-associated oncogene homologue (Gli) transcription factors and 
subsequent expression of downstream targets Gli1, Ptch, Bcl-2, myc and Insulin like growth 
factor 2 (Igf2) (Hwang et al., 2012) . Aberrant expression in the Hedgehog signalling pathway 
has been reported to have strong links to cancer, in part, due to genetic mutations in the 
pathway components, described in basal cell carcinoma but also through over-expression of 
the hedgehog ligand (Evangelista et al., 2006) reported in breast, colon, prostate and PDAC 
(Morris et al., 2010). Abnormal expression of Sonic Hedgehog (SHH) has been shown in 
around 75% of human PDACs and its precursors, PanINs. SHH is not expressed in embryonic 
and adult pancreas and is detectable in early PanINs and increases with PanIN progression 
reaching its highest level in metastatic PDAC. Inhibition of the SHH pathway in transgenic 
mice through cyclopamine-induced apoptosis has been shown to block proliferation of 
pancreatic cancer cells; this was also mirrored in vitro. Equally, it was shown that up-
regulation of SHH is required for the maintenance of cancer cells, not only in PDAC but also 
in other gastrointestinal cancers (Rosow et al., 2012). One of the hallmarks of PDAC is the 
strong desmoplastic reaction which results in a dense stroma, composed of cancer 
associated fibroblasts surrounding the tumours. Desmoplasia is thought to drive, in part, 
tumourogenesis through strong tumour-stroma interactions. It is thought that desmoplastic 
reaction is driven by epithelial-produced Sonic and Indian Hedgehog ligands acting on 
surrounding mesenchymal tissue (John P Neoptolemos, 2010b). Bailey et al. showed a 
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significant decrease in desmoplasia in SHH inhibited Capan-2 orthotopic tumours in nude 
mice, strongly supporting the idea that SHH contributes to the desmoplastic reaction that 
drives PDAC (Bailey et al., 2008). 
1.6.3. The Notch signalling pathway
Briefly, the Notch signalling pathway is an evolutionarily conserved pathway, involved in 
embryonic development whose functions include proliferation, apoptosis, maintenance of 
stem cell population and determination of cell fate. The role of notch in cancer is 
contradictory; for example, it was shown to have tumour suppressive functions in skin, 
hepatocellular and small cell lung cancers while it has been found to have oncogenic 
functions in head and neck, colon and prostate cancers (Xia et al., 2012). It’s role in PDAC 
has been a source of debate and it has been questioned whether notch is an oncogene or a 
tumour suppressor.  Notch has been shown to be required for the progression from normal 
cells to PanINs (Avila and Kissil, 2013) and is a purported key player in cancer stem cell self-
renewal (Xia et al., 2012). Several of the key pathway components of the Notch signalling 
pathway have been shown to be over-expressed in PDAC compared with normal pancreatic 
epithelium, indicating that Notch may act an oncogene in PDAC. However, its important to 
state that notch signalling pathway dis-regulation does not establish a causative function for 
notch and indeed some reports have shown no significant up-regulation of Notch in PDAC 
(Avila and Kissil, 2013). Notch expression has been studied in KRAS-induced murine PDACs 
where loss of function of notch has been reported and appeared to correlate with an increase 
in tumourogenesis in this context supporting the hypothesis that notch may act at a tumour 
suppressor in PDAC (Hanlon et al., 2010). Pancreatic cancer stem cells (PCSC) are a sub-
population of cancer cells with the ability to self-renew and differentiate into the other cancer 
cell types which are important for targeted therapy. Notch signalling had been reported to 
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induce epithelial to mesenchymal transition, a characteristic strongly linked to PCSCs and is 
thus a therapeutic target of interest in pancreatic cancer research (Abel and Simeone, 2013).
1.6.4.TGF-ß signalling pathway (Smad)
An important key player in the transforming growth factor-beta (TGF-ß) signalling pathway is 
the mothers against decapentaplegic (Smad) gene. Loss of function of mothers against 
decapentaplegic homologue 4 (Smad4) has been linked to PDAC (Duff and Clarke, 1998). 
The TGF-ß signalling pathway is another important pathway involved in embryonic 
development which controls processes such as cell growth, differentiation and apoptosis. 
Smad4 expression is lost in around 55% of PDAC cases and has been shown to correlate 
with poor survival (Singh et al., 2011).
1.6.5. p53 mutations
The tumour suppressor gene p53, located on chromosome 17, is mutated in around 50-75% 
of pancreatic cancers which results in the loss of function of the gene (Koliopanos et al., 
2008). p53 is central to modulating cellular responses to cytotoxic stresses by causing cell 
cycle arrest and programmed cell death. Loss of function of p53 results not only in 
uncontrolled cell division but also a lack of cell death (Gnoni et al., 2013). Genetic alterations 
in the gene are due to homozygous  deletion, intragenic mutation or promoter methylation. 
This is thought to be attributed to the interaction of cyclin-dependent inhibitor 2A (alternate 
reading frame) (CDKN2A/ARF) with human double minute 2 (MDM2) (Koliopanos et al., 
2008). Interestingly, loss of function of SMAD4 generally leads to inactivation of p53 whereas 
there is no evidence that loss of p53 leads to SMAD4 inactivation. This  suggests  that loss of 
function of SMAD4 occurs later in the onset of the disease than p53 alterations (Yachida and 
Iacobuzio-Donahue, 2013). Loss of function of p53 is purported to be absent in low grade 
tumours such as PanIN-1 and PanIN-2 lesions but present in 12% of PanIN-3 lesions. 
Aberrant expression of p53 has been thought to be a predictor of survival (Gnoni et al., 2013). 
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A meta-analysis which evaluated immunohistochemical prognostic markers in resected PDAC 
revealed no correlation between p53 staining and patient survival (Smith et al., 2011). It is 
thought that p53 genetic alterations are not associated with the initiation of the disease but 
are present relatively early in its s onset (Saif et al., 2007). 
1.7.Tumour-stroma interactions in PDAC
Pancreatic cancer stem cells (PCSC), capable of uncontrolled self-renewal are thought to 
make up only 5% of PDAC tumours (Heinemann et al., 2014). During the onset of PDAC, a 
hallmark of the disease is the appearance of a dense cancer associated stroma, often 
referred to as ‘desmoplastic reaction’. Desmoplasia consists primarily of fibroblasts, 
pancreatic stellate cells (PSCs), extracellular matrix proteins (ECMs) (collagen I, collagen II 
and fibronectin), endothelial cells, immune cells, pericytes and nerve fibres. The desmoplastic 
reaction associated with PDAC is thought to positively correlate with the aggressiveness of 
pancreatic tumours and hence worse clinical outcomes and is also thought to play an 
important part in metastatic spread and drug resistance (Rasheed et al., 2012). 
PSCs feature a prominent rough endoplasmic reticulum (RER), lipid droplets and collagen 
fibrils and have the ability to produce, as well as destroy, extracellular matrix proteins. This is 
thought to be key to maintaining normal pancreatic architecture. Desmoplastic PSCs express 
desmin, glial fibrillary acid protein, vimentin, nestin and neuroectodermal markers such as 
nerve growth factors and neural cell adhesion molecules. When activated, for example, during 
pancreatic injury, PSCs loose their lipid droplets and proliferate, migrate, produce ECMs and 
express α-smooth muscle actin (α-SMA). In normal pancreas, activated PSCs are destroyed 
by apoptosis once the injury has been resolved. However, failure of this process can result in 
permanent irreversible fibrosis (Wilson et al., 2014). In PDAC, PSC activation is a result of 
transforming growth factor ß (TGF-ß), platelet-derived growth factor (PDGF) and vascular 
endothelial growth factor (VEGF) secretion by pancreatic cancer cells which subsequently 
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results in a myofibroblast-like phenotype. PSCs also promote pancreatic cancer cell 
proliferation by secreting stromal-derived factor 1 (SDF-1), epidermal growth factor (EGF), 
insulin-like growth factor-1 (IGF-1) and fibroblast growth factor (FGF). The secretion of anti-
apoptotic proteins such as b-cell lymphoma-2 (Bcl-2) and b-cell lymphoma extra-large (Bcl-xL) 
have also been suggested (Li et al., 2012).
After PSC activation, and subsequent abundance of extra cellular matrix protein deposition, 
stromal growth extends beyond the tumour resulting in increased pressure and subsequent 
reduction in blood supply and oxygen diffusion, which can results in impaired normal function 
of the pancreas. The hypoxic tumour environment leads to induction of genes such as 
hypoxia-inducible factor 1 α (HIF1-α) which promotes cell survival, migration, invasion and 
metastasis. The stroma therefore presents a physical barrier for drug delivery and hence is an 
attractive therapeutic target (Heinemann et al., 2014). Disruption of the Hedgehog signaling 
pathway has been shown to reduce desmoplasia in transgenic mice and to increase tumour 
vasculature and improve drug delivery, however, the effect was only observed to last for 1-2 
weeks. The consensus is that targeting stroma and cancer cells in combination should be a 
goal for future therapies (Apte et al., 2013).
1.8. HOX genes
The development and maintenance of cellular identity is vital in both embryonic and adult 
tissues for normal organ function. Key to this is the establishment of stable transcriptional 
states within the cell, a process in which transcription factors have a key role. One group of 
transcription factors of particular note in this regard are the Homeobox (HOX) genes, a family 
of homeodomain-containing transcription factors that determine cellular and tissue identity by 
regulating specific transcriptional programmes (Abramovich and Humphries, 2005; Iimura and 
Pourquie, 2007; Moens and Selleri, 2006). Mammals have 39 HOX genes split between four 
linked groups on different chromosomes. These are thought to have arisen from a series of 
duplication events. These groups are known as HOXA, HOXB, HOXC and HOXD, and the 
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genes within each group are numbered from the 3’ most member (1) to the 5’ most member 
(13) (Scott, 1993). Thus, for example the 3’ most member of the HOXA group is known as 
HOXA1. Equivalently numbered genes in each group (e.g. HOXB4 and HOXD4) are referred 
to as paralogues and are thought to have arisen from a common ancestral gene as they 
represent the same position within the ancestral HOX cluster. Members of each group often 
share enhancer regions and are co-regulated, giving rise, in part, to coordinated temporal and 
spatial expression patterns in the developing embryo whereby the 3’ most HOX genes are 
expressed earlier and more anteriorly than their more 5’ neighbours (Hoegg and Meyer, 
2005). In this manner the HOX genes give rise to a pattern of overlapping expression 
domains along the anteroposterior axis that is key to defining the identities of cells along it 
(Hoegg and Meyer, 2005).
The HOX transcription factors have a relatively limited specificity for binding to DNA, but this 
is enhanced by the binding of co-factors such as pre-B-cell leukaemia homeobox (PBX) and 
myeloid ecotropic viral integration site (MEIS) that increase DNA binding specificity and also 
modify transcriptional regulation (Knoepfler et al., 1997; Phelan et al., 1994; Piper et al., 
1999). These co-factors, as well as the HOX genes themselves, are highly conserved 
between animal phyla. The HOX genes also show considerable similarities to each other, 
especially paralogues and neighbouring members of the same group (Abramovich and 
Humphries, 2005; Iimura and Pourquie, 2007; Moens and Selleri, 2006).  This has resulted in 
a high degree of functional redundancy, particular with respect to early developmental events 
although later, more organ specific development is generally dependent on a smaller number 
of HOX genes (Di-Poi et al., 2010; Lappin et al., 2006). The expression domains of HOX 
genes that are established during development are generally preserved in the adult (Morgan, 
2006), and there are a number of examples where adult HOX expression is required for the 
continuation of correct cell identity. This is most apparent where cells are turning over quickly, 
for example, in the proliferation and differentiation of blood cells (Abramovich and Humphries, 
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2005) and in the renewal of the endometrium (Lim et al., 1999). The importance of HOX 
genes in these processes indicates a role in the promotion of cell proliferation and survival, in 
addition to maintaining cellular identity, and indeed HOXB4 is crucial for the continued 
proliferation of hematopoietic stem cells (Abramovich and Humphries, 2005). It is, perhaps, 
not surprising then that HOX genes are frequently dysregulated in cancer, where their primary 
function also seems to be in promoting proliferation whilst preventing apoptosis (Daniels et 
al., 2010; Morgan et al., 2007; Morgan et al., 2010; Plowright et al., 2009; Shears et al., 
2008).
1.8.1. HOX genes in pancreatic development 
Although little is known about HOX gene expression patterns in early human development 
perhaps due to the difficult ethical considerations involving human embryo testing (Illig et al., 
2013) more information is available about they way they are expressed in vertebrate. The 
mechanism by which temporal and spacial collinearity occurs is still evasive and mechanisms 
varies between each tissue. Temporal patterns of expression have been reported to be due to 
sequential, post-translational modifications of histones and chromatin decondensation (Sheth 
et al., 2014). The pancreas develops from endodermal cells in the future midgut region of the 
embryo, and is dependent upon a number of inductive interactions between the endoderm 
and other tissues. The best characterised of these events is the development of the dorsal 
pancreatic primordial which is initiated in the endoderm by signalling from the overlying 
notochord through the secreted proteins activin and fibroblast growth factor 2 (FGF-2) .These 
signals are not spatially-restricted to the notochord adjacent to the pre-pancreatic endoderm, 
however, and the responsiveness of endodermal cells is presumably modified by pre-existing 
anteroposterior information in the endoderm. The HOX genes are key determinates of 
anteroposterior identity (Cordes et al., 2004), and the expression patterns of HOX genes in 
the early endoderm suggests that HOXA4, HOXA5 and HOXB4 provide the spatial 
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information needed to restrict the response to signals from the notochord (Kawazoe et al., 
2002). Correspondingly, retinoic acid (RA), which regulates HOX expression through binding 
to nuclear hormone receptors, is also known to have a key role in pancreatic development 
(Tehrani and Lin, 2011). Furthermore, RA is sufficient to drive embryonic stem cell 
differentiation leading to the formation of functional insulin producing cells (Shi, 2010), and 
HOXA4, HOXA5, HOXB4 and HOXA1 (see below) are all activated directly by RA (Langston 
and Gudas, 1994). 
These early patterning events give rise to pancreatic progenitor cells which, in turn, are 
subdivided into exocrine and endocrine progenitors through the presence or absence of Notch 
signalling, respectively. In a number of early developmental processes Notch signalling is 
dependent on HOX transcription factors, together with the PBX co-factor (Cordes et al., 
2004), with the HOX1 paralogues (HOXA1 and HOXD1) mediating key transcriptional 
changes (Cordes et al., 2004; Zakany et al., 2001).  Similarly, HOXA1 expression is activated 
in pancreatic exocrine cells and is required for exocrine development, possibly by modulating 
TGF-β signalling from the foregut mesoderm (Lomberk et al., 2010). 
The endocrine progenitor cells are also defined by the expression of specific transcription 
factors, paired box-6 (Pax-6) for α-cells and γ-cells (secreting glucagon and pancreatic 
polypeptide, respectively), and Pax-4 for β-cells and δ-cells (insulin and somatostatin 
secreting, respectively). Pax transcription factors are known to cross-regulate HOX target 
genes, at least, in part through direct interactions with the latter (Plaza et al., 2008), and also 
through the direct regulation of a number of HOX genes including HOXD4 (Nolte et al., 2006). 
Thus HOX genes play a number of key roles in pancreatic development from the specification 
of early endodermal progenitor cells through to the determination of specific cellular subtypes 
within the maturing pancreas. 
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1.8.2. HOX gene expression and function in pancreatic cancer
The dysregulation of HOX genes in cancer is now well established, though generally rather 
less is known about their function (Shah and Sukumar, 2010). For a number of malignancies, 
including melanoma (Morgan et al., 2007), myeloma (Daniels et al., 2010), and ovarian 
(Morgan et al., 2010), renal (Shears et al., 2008) ,lung (Plowright et al., 2009) and, indeed, 
pancreatic cancer (Aulisa et al., 2009), it has been shown that the HOX genes of paralogue 
groups 1 to 9 can promote cell survival by blocking apoptosis. In this respect many of these 
27 HOX genes have a redundant, or at least a highly overlapping, function (Morgan et al., 
2007). Targeting the anti-apoptotic function of this group of genes has been achieved by 
antagonising the interaction between HOX proteins and the PBX co-factor. This approach 
exploits a highly conserved hexapeptide motif on PBX that is required for HOX binding 
(Knoepfler et al., 1997). The motif forms part of peptides such as HXR9 that act as 
competitive antagonists of HOX/PBX dimer formation that can induce apoptosis both in vitro 
and in vivo, at least in part through the greatly elevated expression of FBJ murine 
osteosarcoma viral oncogene (cFOS) (Morgan et al., 2007). Disrupting HOX / PBX dimer 
formation in the pancreatic cancer derived cell line T3M4 also blocks cell proliferation (Aulisa 
et al., 2009) and reduces the expression of a number of cancer-related target genes by at 
least one order of magnitude. These include TMPRSS3, which codes for transmembrane 
serine protease involved in tumour invasion and metastasis (frequently over-expressed in 
pancreatic cancer (Wallrapp et al., 2000)), and the S100 calcium binding protein P (S100P) 
which is involved in regulating the cell cycle and cell proliferation (Arumugam et al., 2005). 
Interestingly HOXB2 and HOXA10 are also down-regulated when HOX / PBX dimer formation 
is blocked, indicating a possible auto-regulatory pathway for these genes (Aulisa et al., 2009). 
45
	  HOX protein PBX
Transcription of targets
ON
HOX protein
-NH3-
-COOH-
-NH3- -COOH-
HXR9
CXR9
OFF
Downregulation of targets
Functional Hexapeptide sequence (HXR9)
Non-functional Hexapeptide sequence (CXR9) (1 amino-acid different to HXR9)
Alpha Helix component of Homedomain
Poly-Arginine Tail
A
B
! Figure 1.4: Schematic representation of HOX protein binding DNA and co-factor PBX via 
! the hexapeptide sequence found on HOX proteins (A). HXR9 (containing hexapeptide 
! sequence) competitively inhibits HOX protein binding through PBX-binding (B).
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Other functions of HOX genes in pancreatic cancer may be more specific to particular 
members of the HOX family. Although, currently, there is only very limited data on HOX 
expression in normal pancreatic tissue of both the developing and adult pancreas, it would 
seem that, generally, these genes (HOXA1 (Lomberk et al., 2010), HOXA4 (Kawazoe et al., 
2002), HOXA5 (Kawazoe et al., 2002) and HOXB4 (Kawazoe et al., 2002)) are not up-
regulated in pancreatic cancer. Instead, other HOX genes are expressed, some of which have 
known oncogenic functions. Most notable amongst these is HOXB7 which has been shown to 
mediate epithelial to mesenchymal transition in breast cancer cells through the induction of 
basic fibroblast growth factor (bFGF) (Wu et al., 2006), and to promote proliferation in oral 
cancer (De Souza Setubal Destro et al., 2010) and progression and metastasis in lung cancer 
(Chen et al., 2008). HOXB7 is also overexpressed in pancreatic cancer, both in primary 
pancreatic adenocarcinoma and in the pancreatic adenocarcinoma cell lines AsPC-1, BxPC-3, 
MiaPACA and PANC1 (Nguyen et al., 2009). Two neighbouring genes of the HOXB cluster, 
HOXB5 and HOXB6, are also overexpressed in pancreatic cell lines as well as resected 
infiltrating pancreatic cancer tissue. Although the significance of this finding is unknown it is 
noteworthy that forced overexpression of HOXB6 in murine bone marrow is sufficient to 
immortalise a population of myelomonocytic precursor cells, leading to acute myeloid 
leukaemia (Fischbach et al., 2005) . Also upregulated in pancreatic cancer is HOXB2 (Segara 
et al., 2005), which has been found to be present in 38% of pancreatic tumours. HOXB2 has 
been shown to have prognostic value, as its expression is associated with non-resectable 
tumours, and when present in resected tumours it is associated with poor survival rates. This 
finding may relate to the apparent ability of HOXB2 to promote metastasis in lung cancer, 
where its expression is also associated with a poor prognosis (Inamura et al., 2008). HOXB2 
additionally promotes proliferation, as it is bound by the tumour suppressor protein supervillin 
(p205) that is known to delay G2/M progression in dividing cells (Asefa et al., 2006).
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Other HOX genes are strongly downregulated in pancreatic cancer. These include HOXD13, 
which is involved in the determination of the terminal digestive and urogenital tracts. HOXD13 
expression is lower in tumour tissue compared with normal pancreatic parenchyma (Cantile et 
al., 2009), and the absence of HOXD13 expression in tumours is associated with a 
significantly poorer prognosis, the 12-month survival rate for patients with HOXD13(-negative) 
tumours being 17.2% as compared with 79.8% for patients with HOXD13+(positive) tumours. 
These findings imply that HOXD13 functions as a suppressor of metastasis, a characteristic 
shared by two further HOX genes, HOXB1 and HOXB3 (Weiss et al., 2009). Specific 
knockdown of either of these genes is sufficient to reduce the migration of pancreatic cancer 
cells in vitro and invasion and metastasis of pancreatic cancer cells in vivo, using zebrafish 
embryo xenotransplantation models. The same study also showed that HOXB1 and HOXB3 
are suppressed by the microRNA (miR) miR-10a, the expression of which is significantly 
higher in metastatic pancreatic cancer (Weiss et al., 2009).
HOX gene dysregulation is also associated with pre-malignant PanINs. HOXB2 was found to 
be expressed in 15% of early PanIN lesions (Segara et al., 2005), and as described above, is 
also associated with the fully malignant state. It is, therefore, possible that expression of 
HOXB2 in PanIN lesions may predict the development of cancer, but this is yet to be shown 
conclusively. Also upregulated in PanIN is HOXA5 (Prasad et al., 2005), which is of interest 
because other studies have suggested that its function is closer to being a tumour suppressor 
rather than an oncogene as it activates the transcription of a number of key tumour 
suppressors, including p53 (Raman et al., 2000). The regulatory mechanisms of HOX genes 
are complex and numerous. Chromatin-mediated regulation of HOX genes and co and post-
translational processes that affect mRNA integrity and quality have been shown to play a role 
in HOX gene regulation. MiRNAs, small non-coding sections of RNA that bind to 3‘ 
untranslated regions (UTRs) repress HOX expression by mRNA degradation. Notably,in 
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vertebrates, miR-196, miR-10 and miR-615 have been shown to repress HOX genes (Mallo 
and Alonso, 2013). 
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1 2* 3 4 5 6 7* 8 9 10 11 12 13
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B
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No HOX gene at this position in the cluster
Possible function in pancreatic development
Possible suppressor of metastasis
Expression increased in pancreatic cancer
Expression decreased in pancreatic cancer
* High expression associated with poor prognosis
Paralogue
group
! Figure 1.5: Summary of the role of HOX genes in pancreas development and in pancreatic 
! cancer in the literature (updated from (Gray et al., 2011). 
1.9. In vivo modelling of pancreatic cancer
The first in vivo models of pancreatic cancer, developed in the 1970s, were generated by 
administration of nitrosamines to Syrian hamsters. This relatively simple model produced 
tumours in the pancreas, lung, kidney and gallbladder and showed significant similarities to 
human disease, both histologically and clinically, but the tumours did, however, lack acinar 
cells. Mutagenesis induced pancreatic cancer in the Syrian hamster by injections of N-
nitrosobis(2-oxopropyl)amine (BOP) induces pancreatic tumours that are similar to human 
disease within 3 to 12 months. A disadvantage of this model however is that specific genes 
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expression and gene dysregulation cannot be controlled (Murtaugh, 2014).Chemically 
induced pancreatic cancer was also developed in rats and mice by treatment with 7,12-
dimethylbenz-α-anthacene (DMBA) but lacked cells of ductal lineage in rats and required 
surgical implantation of DMBA in the head of the pancreas in mice. 
Pancreatic xenografts in immunocompromised mice have been widely used in pancreatic 
cancer research. Subcutaneous flank murine models, where tumour cells are implanted in the 
back of the mouse between the dermis and underlying muscle, present some advantages as 
they are time and cost effective and provide visual confirmation of tumour growth. Many 
chemotherapeutic agents such as gemcitabine have been tested in the MFM, however, some 
studies have shown this model not to be predictive of human disease (Herreros-Villanueva et 
al., 2012). Direct grafting of human resected tumours can also be achieved in this model. This 
enables drug testing resulting in tailored therapy, however, due to the small percentage of 
operable cases, this method is less common in pancreatic cancer research (Saluja and 
Dudeja, 2013). Orthotopic models, where an incision is made just off the midline of a 6-8 
week immunocompromised mouse allows for cells to be directly injected into the pancreas. 
Although expensive, labour intensive and technically challenging, this method has been 
shown to be more clinically relevant as it allows tumour/host interactions at the relevant 
location. Importantly, orthotopic models have shown evidence of tumour metastasis.
 Disadvantages are that mice require a long recovery time and tumours are neither visible nor 
palpable, and hence monitoring can only be carried out by weighing (Herreros-Villanueva et 
al., 2012; Saluja and Dudeja, 2013). Both subcutaneous and orthotopic methods fail to 
recapitulate tumour architecture and microenvironment (Takahashi M et al., 2011).Early 
attempts on genetically engineered murine models (GEMMs) targeted oncogenes in the 
acinar component of the pancreas due to the numerous available promoters capable of 
acinar-specific expression.
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Many GEMMs have since been developed, focussing, in the early days, solely on KRAS 
mutations. This was not sufficient to induce progression to metastatic disease. In 2001, the 
first mutant KRAS model known as KRAS LSL-G12D was constructed with a STOP cassette 
flanked by two Lox-P sites (Lox-Stop-Lox or LSL) inserted upstream of exon 1 of KRAS. 
KRAS LSL-G12D also contains a guanine to alanine point mutation in codon 12 that yields a 
glycine to aspartic acid substitution which alters the intrinsic GTPase activity of KRAS 
resulting in its GTP-bound active state (Westphalen and Olive, 2012). KRASLSL-G12D  mice are 
heterozygous and oncogenic KRAS is expressed via cre-mediated recombination which 
results in removal of the LSL cassette, thus activating the KRAS pathway (Karreth and 
Tuveson, 2009). During development, pancreatic transcription factors PDX and Pancreas 
transcription factor 1 subunit α (p48) are expressed in progenitor cells. In 2003, Tuveson et 
al., crossed the KRASLSL-G12D mouse with PDX1-cre and p48-cre mice thereby restricting RAS 
overexpression to the pancreas alone. While this was a breakthrough model (also referred to 
as the KC model), it also had some disadvantages. Notably, while PanINS were initiated 
straight after birth, the onset of PDAC in these mice did not occur before 12 months and 
because PDX1 is expressed in the developing foregut extra-pancreatic tumours developed. 
Since then there have been numerous models (Table 1.1) which combine gain-of-function and 
loss-of-function alleles which have helped with the understanding of key effectors involved in 
the development of PDAC. (Table 1.1).GEMMs have been shown to not only recapitulate the 
tumour biology of PDAC including PanINs but are also useful for identifying genetic mutations 
associated with PDAC (Mazur and Siveke, 2012). Live scanning using magnetic resonance 
imaging (MRI), computer-assited tomography (CT) and positron emission tomography (PET) 
scanners can be used to visualise of tumours in subcutaneous and orthotopic and GEM 
models without sacrificing of the animal. MRI scanners offer better soft tissue contrast 
compared with CT and PET scans and are routinely used as a non-invasive method to 
monitor tumour progression in these models (Grimm et al., 2003).
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1.10. The CAM assay
The chick embryo was for long a source of fascination amongst the early Egyptians (c.1400 
BC) and during Greek antiquity (Wellner, 2010). It’s use as a cancer research tool began in 
1911 when Rous and Murphy successfully transplanted Rous 45 chicken sarcoma onto the 
CAM of a developing chick embryo, a model that was further developed in the 1970s by 
Knighton et al. (Cimpean et al., 2008). The CAM (or chorioallantois) is the extra-embryonic 
membrane that mediates nutrient and gas exchange before hatching of the embryo and 
whose main function is to serve as the respiratory organ during the 21-day incubation period 
of the chick embryo (outlined in Figure 1.6). The CAM together with the yolk-sac membrane 
and the amnion are the three extra-embryonic membranes that protect and nourish the 
embryo in the early stages of development. The CAM appears between embryonic 
developmental day (EDD) 4 and 5 and is the product of the fusion of the mesodermal layers 
of the allantois and chorion. The CAM is highly vascularised and supports veins, arteries and 
a dense capillary plexus (Vargas et al., 2007).
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! Figure 1.6: Schematic representation of the anatomy of the developing chick embryo. The CAM 
! represented in red, is highly vascularised and serves as the respiratory organ of the embryo 
! before hatching on EDD 21. 
The CAM model has been extensively used in the study of angiogenesis. Angiogenesis is 
central to wound healing and successful implantation of medical devices but an imbalance in 
this process can lead to a number of pathologies such as rheumatoid arthritis, inflammation 
and indeed, cancer. The CAM model has been used as a platform for testing angiogenic, 
angiostatic and anti-angiogenic molecules whereby gelatin sponges treated with blood vessel 
stimulators or inhibitors are implanted on the CAM. In particular, treatment of the sponge with 
the angiogenic cytokine FGF-2 and angiostatic molecule TNP-470 results in a dense network 
of capillaries with the former and limited blood vessel formation with the latter (Ribatti et al., 
2001). The CAM model has also been widely used in the study of tumour angiogenesis. Solid 
tumours can be implanted on the CAM on EDD10 (Figure 1.7) due to the immunologically 
immature properties of the developing chick embryo. On EDD10 the chick embryo lacks both 
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B and T lymphocytes (that control antibody and cell mediated immunity respectively) which 
appear on EDD11 and 12 at which time mononuclear phagocytes and reticulum cells also 
develop making the chick immunocompetent by EDD18 (Ribatti, 2008; Vargas et al., 2007).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
 (EDD)
 Inner shell membrane removal  Challenge with cancer cell line  Tumour grown in the CAM
!
! Figure 1.7: Timeline of the CAM assay. Eggs are set EDD1 and incubated at 37°C (60% 
! humidity). Eggs were opened on EDD4 and challenged with cancer derived cell-lines on EDD10. 
The CAM model has been used to grow cell-line derived tumours in many types of cancer 
including glioma, ovarian, bowel and prostate cancers (Richardson and Singh, 2003).  The 
value of this model in such a context is attributed to it’s simplicity, high reproducibility, cost 
effectiveness and its ability to recapitulate the cellular structures of human tumours. Several 
human xenografts have been implanted on the CAM which include renal cell and urothelial 
carcinomas, testicular tumours and also renal, colon and ovarian adenocarcinomas (Morgan 
et al., 2012).
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1.11. Hypothesis and aims of study
Based on previously published work we hypothesised that PDAC could be characterised by a 
unique, PDAC-specific HOX gene profile. We also hypothesised that this profile could be 
recapitulated using the CAM model which could be used as vehicle for HOX gene antagonism 
as a potential novel targeted treatment strategy.
The aims of this work were: 
 i) to investigate the pattern of HOX gene expression in PDAC derived cell lines and in normal 
human pancreas and human PDAC. This would validate published findings and add to the 
limited research base available on HOX dysregulation in PDAC.
ii) to establish a simple, robust and cost effective animal model which mimics dysregulation 
and architecture of human PDAC due to the high percentage of patients with inoperable 
disease and hence the limited availability of pancreatic cancer tissue.
 iii) to treat PDAC by interfering with the interaction between HOX proteins and their cofactor 
PBX in human cell-lines (and consequently to impair their ability to act as transcriptional 
regulators), and measure whether cell death could be achieved and determine mechanisms of 
cell death. 
iv) to establish that the CAM model would allow evaluation of targeted drug therapy aimed 
primarily at disrupting HOX/PBX.
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Chapter II: 
2.Materials and methods
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2.1. Tissue culture
Cell lines AsPC-1 (Chen, Horoszewicz et al. 1982), BxPC-3 (Loor et al., 1982) and PancTu-1 
(Vonbulow et al., 1982) were cultured in Roswell Park Memorial Institute (RPMI-1640) 
medium supplemented with 10% Fetal Calf Serum (FCS), 1% penicillin/streptomycin (SIGMA-
ALDRICH) and 1% Glutamax (SIGMA-ALDRICH). PaCa-3 (Lohr et al., 1994) cells were 
cultured in (Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FCS, 1% 
penicillin/streptomycin (SIGMA-ALDRICH) and 1% Glutamax (SIGMA-ALDRICH). Cells 
passaged 1:4 twice a week using 9ml 1X trypsin solution (SIGMA-ALDRICH) and incubated at 
37°C with 5% CO2. Cells were cryopreserved in complete growth medium, supplemented with 
5% DMSO using 1x106 cells/cryovial. Each cryovial was added to a Mr Frosty freezing 
container containing 2-propanol (SIGMA-ALDRICH) and stored at -80°C for 24 hours before 
storing in liquid nitrogen. Cells were resurrected by fast-thawing cryovials in 37°C water bath 
for 1 minute before adding cells to warm, fresh, complete medium and passaged as described 
above. AsPC-1 and BxPC-3 cells were purchased from LGC standards. PaCa-3 and 
PancTu-1 cells were available at Surrey and had previously been used at St George’s 
University and were chosen to keep consumable costs down and will be authenticated for 
publications. AsPC-1 and BxPC-3 were chosen because they were derived from metastatic 
ascites and primary tumour respectively.  Synthesis of HXR9 and CXR9 peptides
HXR9 is an 18 amino acid peptide, containing a hexapeptide sequence and includes a 
polyarginine (R9) sequence (containing 9 arginine residues) which facilitates peptide delivery 
to the cell (Jiang et al., 2004; Morgan et al., 2007). CXR9 was designed in the same way but 
with a single amino acid difference (W to A (tryptophan to alanine)) rendering it inactive. For 
increased stability, the amino acids located at the NH2 and COOH terminals of both HXR9 and 
CXR9 were synthesised as D-isomers (Morgan et al., 2007). Both peptides were synthesised 
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using conventional column based chemistry and purified to at least 80% (Biosynthesis Inc, 
USA). The sequences of the peptides are as follows:
! ! HXR9: WYPWMKKHHRRRRRRRRR (2700.06 Da)
! ! CXR9: WYPAMKKHHRRRRRRRRR (2604.14 Da)
2.2. Determination of IC50s
Seeding plates were set up to determine the best seeding rate to achieve 70% confluency 
(Morgan et al., 2007) (due to differential cell growth rates) after overnight incubation. Lactate 
dehydrogenase (LDH) was measured using a Cytotoxicity Detection Kit (Roche) and MTS 
assay was performed using CellTiter96® Aqueous One Solution proliferation assay 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-!(4-sulfophenyl)-2H-tetrazolium)(MTS) 
(Promega) (Morgan et al., 2007). Both MTS and LDH assay were performed to determine the 
IC50 of the cell lines. MTS assay measures mitochondrial respiration i.e. detects the number 
of live cells after a 2-hour treatment whereas the LDH assay measures lactate 
dehydrogenase released after cell lysis, hence measuring the number of dead cells after the 
same treatment.
Cell line Seeding rate
AsPC-1 2x106 cells/ml
BxPC-3 4x106 cells/ml
PaCa-3 2x106 cells/ml
PancTu-1 2.5x105 cells/ml
! Table	  2.1: Seeding rates in AsPC-1, BxPC-3, PaCa-3, PancTu-1 cell lines to achieve 70% 
! confluency after 16 hours. 
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2.3. Mechanisms of cell death: Annexin V-PE assay
Cells were seeded in a 24-well plate and grown overnight until 70% confluent and harvested 
by adding trypsin to each flask, resuspended in an equal volume of media and centrifuged for 
3 minutes at 1,200 revolutions per minute (RPM) .  Cells were either untreated or treated with 
either CXR9 (1x IC50) or HXR9 (1x IC50) or CXR9 (2x IC50) or HXR9 (2x IC50). Media were 
supplemented with antibiotics and Glutamax (as above), 2% FCS and incubated for 2 hours at 
37⁰C. Cells were harvested and apoptosis was measured using Annexin-V-Phycoerythrin 
(AnnexinV-PE) apoptosis detection kit (BD pharmingen) via Fluorescence-Activated Cell 
Sorter (FACS) analysis. Cells were stained with Annexin-V, used to measure levels of 
phosphatidylserine detectable in the early stages of apoptosis, and counterstained with the 
dye 7-Aminoactinomycin D (7AAD) which can only enter cells whose membrane integrity has 
been compromised.
2.4.RNA extraction from cell lines
Cells were grown in 6-well plates and left to grow until 80-90% confluent. In order to harvest 
cells, plates were washed in sterile 1xPBS and treated with 1 ml/well trypsin (SIGMA-
ALDRICH) for 10 minutes. The cell-containing trypsin was recovered from each well and 
added to 1 ml cell media. Cells were centrifuged and cell-pellets were lysed in 600µl RLT 
buffer (QIAGEN) with 1% ß-mercaptoethanol. RNA was extracted following RNeasy® Plus 
Mini kit (QIAGEN) protocol by adding lysed cells to a QIAshredder spin column and 
centrifuged at maximum speed for 2 minutes. Homogenised lysate was then passed through a 
gDNA Eliminator spin column and centrifuged for 30 seconds at 10,000 RPM. 600µl of 70% 
ethanol was added to the flow-through and mixed by pipetting. 700µl of the sample were 
added to RNeasy spin column (QIAGEN) and centrifuged at 10,000 RPM for 15 seconds. The 
flow-through was discarded and an additional 700µl of the sample was added to the column. 
This was repeated until all of the sample was passed through. 700µl buffer RW1 was added to 
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the column and centrifuged at 10,000 RPM for 15 seconds. Then, 500µl buffer RPE was 
added to the spin column and centrifuged for 15 seconds at 10,000 RPM. An additional 500µl 
was passed through the column by centrifuging for 2 minutes at 10,000 RPM. In order to dry 
the column, the RNeasy column was centrifuged at full speed for 1 minute. RNase-free H2O 
was passed through the column and total RNA was eluted in 30µl RNAse free H2O and stored 
at -80⁰C. (Morgan et al., 2007)
2.5. RNA extraction for CAM tumours
CAM tumours were removed from RNAlater (SIGMA-ALDRICH) and placed into an M tube 
(Miltenyi Biotech) containing 600µl RLT buffer (QIAGEN) with 1% ß-mercaptoethanol. RNA.
01.01 standard programme was used on gentleMACS™ dissociator (Miltenyi biotech). M 
tubes were centrifuged at 1,500 RPM for 3 minutes.  Supernatant was transferred to an 
Eppendorf tube and spun in a microcentrifuge at maximum speed (24,000 RPM) for 2 
minutes, a step that was repeated twice. Supernatant was transferred to gDNA column 
(QIAGEN) and spun for 30 seconds at 10,000 RPM.  One volume (approx 350µl) of 70% 
Ethanol was added to the collection tube and mixed by pipetting. 700µl of RLT buffer-Ethanol 
mixture was loaded onto an RNeasy spin column (QIAGEN) and centrifuged for 30 seconds at 
10,000 RPM. This step was repeated until all the mixture had passed through the RNeasy 
column. 700µl buffer RW1 (QIAGEN) were added to the column and centrifuged for 30 
seconds at 10,000 RPM. 500µl buffer RPE were added to the spin column and centrifuged for 
30 seconds at 10,000 RPM. Next, an additional 500µl buffer RPE were added to the column 
and centrifuged for 2 minutes at 10,000 RPM. The RNeasy column was then transferred to a 
new Eppendorf tube and centrifuged for 1 minute at 10,000 RPM to ensure the dryness of the 
column. The RNeasy column was then transferred to a new Eppendorf tube and 30µl RNase-
free water was loaded onto the column and incubated at room temperature for 1 minute, 
before centrifuging for 1 minute at 10,000 RPM. RNA purity was quantified using a Nanodrop 
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ND-100 UV-VIS spectrophotometer and samples with 260/280 and 260/230 ratios above 2.2 
and below 1.8 were discarded.
2.6.Commercially obtained patient RNA
In order to measure HOX gene expression in PDAC patients, RNA was purchased from 
Origene and gene expression was measured by semi-quantitative RT-PCR.
Cat # Age Gender Tissue of 
(Origin/
Finding)
Appearance Sample 
pathology
Patient diagnosis Tumor Grade TNM
CR56
0156
75 Male Pancreas / 
Pancreas
Tumour Adenocarcinoma 
of pancreas, 
ductal
Adenocarcinoma 
of pancreas, 
ductal
AJCC G2: 
Moderately 
differentiated
pT3pN1pMX
CR56
0779
79 Female Pancreas / 
Pancreas
Tumour Adenocarcinoma 
of pancreas, 
ductal
Adenocarcinoma 
of pancreas, 
ductal
AJCC G3: 
Poorly 
differentiated
pT2pN0pMX
CR56
0781
79 Female Pancreas / 
Pancreas
Tumour Adenocarcinoma 
of pancreas, 
ductal
Adenocarcinoma 
of pancreas, 
ductal
AJCC G3: 
Poorly 
differentiated
pT2pN0pMX
CR55
9938
67 Female Pancreas / 
Pancreas
Normal Within normal 
limits
Adenocarcinoma 
of bile duct
n/a n/a
CR56
0209
71 Male Pancreas / 
Pancreas
Normal Within normal 
limits
Gastrointestinal 
stromal tumor of 
stomach
n/a n/a
CR56
0569
53 Male Pancreas / 
Pancreas
Normal Within normal 
limits
Adenocarcinoma 
of pancreas, 
ductal
n/a n/a
	   Table 2.2: Pathological data of the commercially obtained RNA. 
2.7.RNA extractions from FFPE blocks
Haematoxylin and eosin sections of the FFPE blocks were viewed under the microscope by 
an NHS pathologist in order to identify areas of tumour.  FFPE punch biopsies were taken 
with a 5 mm diameter circular blade and subsequently snap-frozen in liquid nitrogen before 
grinding into powder using a pestle and mortar. RNA was extracted using the RNeasy FFPE 
kit (QIAGEN). The powdered sample was then added to 160µl deparaffinisation solution 
(QIAGEN) and incubated at 56 ⁰C for 3 minutes and left to cool. 150µl buffer PKD were added 
to the sample and mixed by vortexing for 10 seconds and centrifuged for 1 minute at 10,000 
RPM. 10µl proteinase K were added to the lower, clear phase of the samples and mixed by 
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pipetting. Samples were then incubated at 56 ⁰C for 15 minutes followed by 15 minutes at 80 
⁰C. The lower clear phase was then transferred to a new micro centrifuge tube in order to be 
incubated on ice for 3 minutes and then centrifuged for 15 minutes at 13,500 RPM. 10 µl 
DNAse 1 and 16µl DNase booster were added to the supernatant of the centrifuged samples 
and incubated at room temperature for 15 minutes. 320µl buffer RBC were added and mixed 
before adding 720µl absolute ethanol. 700µl were added to an RNeasy MinElute column and 
centrifuged for 15 seconds at 10,000 RPM and the flow-though was discarded. This step was 
repeated until all of the sample had passed through the column. Then, 500µl buffer RPE were 
added to the column and centrifuged for 15 seconds at 10,000 rpm. For each sample, the 
flow-through was discarded and a subsequent 500µl buffer RPE were added to each column 
before centrifuging for 2 minutes at 10,000 RPM. Columns were placed in a new centrifuge 
tube and centrifuged again at full speed for 5 minutes. The lids were left open to ensure 
dryness of the columns. 20µl RNAse-free H2O were added to each column and incubated on 
the bench top for 5 minutes before centrifuging for 1 minute at 10,000 RPM. RNA 
concentration and sample purity were then measured using a Nanodrop ND-100 UV-VIS 
spectrophotometer.
2.8. cDNA synthesis
cDNA was prepared using 500 ng purified RNA and following the cloned avian myeloblastosis 
virus (AMV) first strand cDNA synthesis kit protocol (Invitrogen). Each preparation was made 
up of 4µl of 5x cDNA synthesis buffer, 1µl Oligo DT, 1µl RNase out, 1µl AMV reverse 
transcriptase, 1µl DTT and 2µl dNTPs. Each preparation was heated to 50⁰C for 30 minutes 
followed by a 5 minutes incubation at 80 ⁰C (Morgan et al., 2007).
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2.9.Real-time semi quantitative reverse transcriptase polymerase 
chain reaction (RT-PCR)
Each well of a 96-well plate contained 2ng cDNA, 5µl forward and reverse mixed primers (2 
µM), 12.5µl 2x SYBR® Green Jumpstart™Taq Ready Mix™ (SIGMA-ALDRICH), 0.25µl of 
100x reference dye for quantitative PCR (SIGMA-ALDRICH) and 5.25µl PCR-grade H2O. 
Plates were pulse spun to eliminate air bubbles and and placed in a thermocycler and 
subjected to the following programme: heat to 95⁰C for 10 minutes; followed by 40 cycles of 
30 seconds at 95⁰C, 60 seconds at 60⁰C and 30 seconds at 72⁰C.  CT values were normalised 
using the house keeping gene β-actin. This protocol was selected based on previously 
published data (Morgan et al., 2007). During the project, the PCR machine and protocol were 
updated. Both protocols were run side-by-side to ensure results were not compromised. 
Brilliant III Ultra-Fast SYBR® Green qPCR kit (Agilent technologies) was used. Each 
preparation contained 10µl 2x SYBR Green qPCR master mix, 2.5µl (2µM) forward primer 
(tables 2.3 and 2.4), 2.5µl (2µM) reverse primer (tables 2.3 and 2.4), 0.3µl diluted reference 
dye, 2.7µl PCR-grade H2O and 2ng cDNA. Plates were briefly centrifuged to remove bubbles 
and added to the Agilent Mx3005p thermocycler. Samples were initially heated for 3 minutes 
to 95 ⁰C and subjected to 40 cycles of 5 seconds at 95 ⁰C followed by 20 seconds at 60⁰C. 
Finally samples were heated to 95⁰C for 1 minute followed by 30 seconds at 55⁰C and 30 
seconds at 95⁰C.
Primer Forward sequence Reverse sequence
HOXA1 CTGGCCCTGGCTACGTATAA TCCAACTTTCCCTGTTTTGG
HOXA2 TTCAGCAAAATGCCCTCTCT TAGGCCAGCTCCACAGTTCT
HOXA3 ACCTGTGATAGTGGGCTTGG ATACAGCCATTCCAGCAACC
HOXA4 CCCTGGATGAAGAAGATCCA AATTGGAGGATCGCATCTTG
HOXA5 CCGGAGAATGAAGTGGAAAA ACGAGAACAGGGCTTCTTCA
HOXA6 AAAGCACTCCATGACGAAGG TCCTTCTCCAGCTCCAGTGT
HOXA7 TGGTGTAAATCTGGGGGTGT TCTGATAAAGGGGGCTGTTG
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Primer Forward sequence Reverse sequence
HOXA9 AATAACCCAGCAGCCAACTG ATTTTCATCCTGCGGTTCTG
HOXA10 ACACTGGAGCTGGAGAAGGA GATCCGGTTTTCTCGATTCA
HOXA11 CGCTGCCCCTATACCAAGTA GTCAAGGGCAAAATCTGCAT
HOXA13 GGATATCAGCCACGACGAAT ATTATCTGGGCAAAGCAACG
HOXB1 TTCAGCAGAACTCCGGCTAT CCTCCGTCTCCTTCTGATTG
HOXB2 CTCCCAAAATCGCTCCATTA GAAAGGAGGAGGAGGAGGAA
HOXB3 TATGGCCTCAACCACCTTTC AAGCCTGGGTACCACCTTCT
HOXB4 TCTTGGAGCTGGAGAAGGAA GTTGGGCAACTTGTGGTCTT
HOXB5 AAGGCCTGGTCTGGGAGTAT GCATCCACTCGCTCACTACA
HOXB6 ATTTCCTTCTGGCCCTCACT GGAAGGTGGAGTTCACGAAA
HOXB7 CAGCCTCAAGTTCGGTTTTC CGGAGAGGTTCTGCTCAAAG
HOXB8 GTAGGCTTCAGCTGGGACTG GGGAGCCTTTGCTTAAATCC
HOXB9 TAATCAAAGACCCGGCTACG CTACGGTCCCTGGTGAGGTA
HOXB13 CTTGGATGGAGCCAAGGATA CCGCCTCCAAAGTAACCATA
HOXC4 CGCTCGAGGACAGCCTATAC GCTCTGGGAGTGGTCTTCAG
HOXC5 CAGTTACACGCGCTACCAGA AGAGAGGAAAGGCGAAAAGG
HOXC6 AAGAGGAAAAGCGGGAAGAG GGTCCACGTTTGACTCCCTA
HOXC8 CTCAGGCTACCAGCAGAACC TTGGCGGAGGATTTACAGTC
HOXC9 AGACGCTGGAACTGGAGAAG AGGCTGGGTAGGGTTTAGGA
HOXC10 CGCCTGGAGATTAGCAAGAC GGTCCCTTGGAAGGAGAGTC
HOXC11 CGGAACAGCTACTCCTCCTG CAGGACGCTGTTCTTGTTGA
HOXC12 CAAGCCCTATTCGAAGTTGC GCTTGCTCCCTCAACAGAAG
HOXC13 GTGGAAATCCAAGGAGGACA TTGTTGAGGGACCCACTCTC
HOXD1 TTCAGCACCAAGCAACTGAC TAGTGGGGGTTGTTCCAGAG
HOXD3 CAGCCTCCTGGTCTGAACTC ATCCAGGGGAAGATCTGCTT
HOXD4 TCAAATGTGCCATAGCAAGC TCCATAGGGCCCTCCTACTT
HOXD8 TCAAATGTTTCCGTGGATGA GCTCTTGGGCTTCCTTTTTC
HOXD9 TCCCCCATGTTTCTGAAAAG GGGCTCCTCTAAGCCTCACT
HOXD10 GCTCCTTCACCACCAACATT AAATATCCAGGGACGGGAAC
HOXD11 GGGGCTACGCTCCCTACTAC GCTGCCTCGTAGAACTGGTC
HOXD12 CGCTTCCCCCTATCTCCTAC CTTCGGGCGCATAGAACTTA
HOXD13 GGGGATGTGGCTCTAAATCA AACCTGGACCACATCAGGAG
! Table	  2.3: Primer sequences of HOX genes.
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Primer Forward sequence Reverse sequence
DUOX2 GGTCAACCTCATCCTGTCCA AGCTCCTTCTCGCTCATCTC
HCP1 GCCCAGGACATCTTAACCCT ATCTCAGCTACCCAGGCATC
EEF1A TCTGGAAGTTCGAGACCACC AGTCCATTTTGTTCACGCCC
TRAF7 ACAATTACGAGACCCACCTG GCTGAGCTTGCTTGGTTTT
CAPZ2A GGCGACTTGGGAAATGGAAA CACAGTGCAGACTCCATTCG
PCSK9 AGGGGAGGACATCATTGGTG TCAGTCTCTGCCTCAACTCG
SMURF1 TCTTCAATCAACCCCGACCA AAGGTGTGGTCCAGTACAGG
EGLN3 CTTCCTCCTGTCCCTCATCG CAGGATCCCACCATGTAGCT
CAV1 GCTTCACCACCTTCACTGTG AGACGGTGTGGACGTAGATG
TFF3 ATGAAGCGAGTCCTGAGCTG ATCCTGGAGTCAAAGCAGCA
PORCN CCTACCTGAAGCATGCAAGC TGGTGACGGATAGGAAGACG
! Table	  2.4: Primer sequences of genes most differentially expressed in AsPC-1 and BxPC-3 cell 
! lines compared with their derived CAM tumours.
Primer Forward sequence Reverse sequence
PBX1 CAAGCTAACTCGCCCTCAAC GCTGCGAGTCCATCACTGTA
PBX2 CAGATGCAGCTGAAGCAGAG CACTTCTTGGCAAGCTCCTC
PBX3 CGGAAAAGGCGTAACTTCAG  GCAGCATAGAGGTTGGCTTC
PBX4 GGATGAAGCCTGCTCTGTTC AGCTTGGCCCTGTAGTCAGA
Table	  2.5: Primer sequences of PBX1-4 genes
2.10. CAM model 
 Fertilised chicken eggs were obtained from Henry Stewart & Co.Ltd, a specialised, pathogen-
free facility. Eggs were kept at 16⁰C upon arrival and subsequently incubated at 37⁰C with 
60% humidity commencing on EDD1 (http://www.medeggs.com/). Eggs were opened on 
EDD4 under sterile conditions; the inner shell membrane was removed using sterile forceps. 
Open eggs were covered with a small petri dish. Although opening of the eggs was performed 
under sterile conditions, eggs were prone to infections. For each experiment 50 eggs were 
opened in order to have suffiecient biological repeats for the experimental design.  On EDD7, 
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cells grown in vitro (AsPC-1, BxPC-3, PaCa-3 and Panc-Tu1 cell-lines) were harvested using 
1x trypsin solution washed in Hank’s salt solution (Sigma-Aldrich) 3 times and resuspended in 
Matrigel™. A medium sized blood vessel on the CAM was bruised using a sterile cotton swab 
by gentle rubbing the surface. Each egg was seeded with 4x106 cells. Tumours were treated 
on EDD17 either by intratumoural injection of HXR9/CXR9 (n=4 for each treatment) diluted 
according to the IC50 of the cell line in a final volume of 25µl or by topical application of HXR9/
CXR9 diluted in Matrigel™ (1:1) with Hank’s salt solution (Figure 2.1). Tumours were 
photographed and embryos were sacrificed on EED19. Tumours were excised and stored in 
10% buffered formalin (Sigma-Aldrich) for section cutting, and Allprotect Tissue reagent 
(QIAGEN) for RNA extraction (Dumartin, Quemener et al. 2010). Tumours were dehydrated 
and wax-embedded using the following reagents for the following times: 70% ethanol (1 hour), 
90% ethanol (1hour) 100%ethanol I (1hour), 100%ethanol II (2 hours), 100% ethanol I 
( 2hours), toluene I (1 hour), toluene II (1.5 hours), toluene II (1.5 hours), paraffin-wax I (2 
hours), paraffin-wax 2 (3 hours). Tumours were blocked in paraffin-wax by pouring molten wax 
into metal moulds embedding the tumour. Blocks were cut into 4µm sections and stained at 
the Royal Surrey County Hospital using a routine in-house automated H&E staining procedure 
using the protocol described below (Immunohistochemistry 2.11).
67
EGGGGGGGGG#EGGGGGGGGG#
HXR9#
EGGGGGGGGG#
HXR9#
Intratumoural administration of HXR9 Topical application of HXR9 held in place by 
(diluted) Matrigel™ 
! Figure	  2.1: Drug administration methods used for treating CAM tumours with HXR9.
2.11. Immunohistochemistry
Slides were deparaffinised in 3 washes of Xylene (Sigma-Aldrich) for 3 minutes followed by a 
20 minute wash in 0.3% H2O2 in methanol (Sigma-Aldrich) then boiled for 20 minutes in 
boiling citrate buffer (pH=6) and left to cool for 1.5 hours. Slides were then washed in distilled 
H2O for 3 minutes followed by 2 washes in 1xPBS for 3 minutes and incubated in a moist 
chamber for 15 minutes with horse serum (Vectastain Elite ABC kit RTU, Vector) and blocked 
for 15 minutes with avidin (Vectastain Avidin/Biotin blocking kit, Vector) followed by a quick 
wash (5 seconds) in 1xPBS and by a 15-minute incubation with biotin. Then slides were 
incubated for a minimum of 3 hours with a primary antibody (cleaved-caspase 3 (cell 
signalling cs9664) (dilution 1:150) or HOXA13 (ABCAM ab26084) (dilution 1:400), using 
normal human tonsil and normal human kidney as positive controls respectively. Slides were 
washed for 3 minutes in PBS, 3 times, and incubated for 30 minutes with secondary 
biotinilated antibody (Vectastain Elite ABC kit RTU, Vector) then washed 3 times in 1xPBS for 
3 minutes and incubated with ABC reagent (Vectastain Elite ABC kit RTU, Vector). Slides 
were washed in PBS, 3 times, for 3 minutes and incubated with DAB substrate (DAB 
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peroxidase substrate kit, Vector) (formulated following the manufacturer’s instructions: 5ml 
H2O, 2 drops of buffer solution, 4 drops DAB concentrate and 2 drops hydrogen peroxide) for 
4 minutes. Sections were washed in distilled H2O for 5 minutes and counterstained with 
Haematoxylin (Vector) and washed under a running tap for 5 minutes. Following this, sections 
were dehydrated in different concentrations of ethanol (50% followed by 70% and 2 washes in 
100%) and washed in 3 washes of 100% xylene. Sections were left to dry and cover slips 
were mounted using VectaMount Permanent Mounting Medium (Vector). HOXA13 was used 
to stain normal human kidney, normal pancreas and PDAC mega blocks to assess HOXA13 
specificity. Tumour cells in PDAC sections resembled the satining of normal human kidney 
cells. Pancreatic cancer tissue microarray (TMA) containing 30 cases of PDAC, 5 cases of 
normal-adjacent and 5 cases of normal pancreas (US BIOMAX PA803) were stained with anti-
HOXA13 using this protocol.  Sections were scored for staining intensity by an expert 
consultant pathologist at the Royal Surrey county Hospital 0 = Absent, 1 = Weak, 2 = 
Moderate and 3= strong). The proportion of stained cells was difficult to asses due to the fact 
some of the cores only contained a few tumour cells surrounded by dense stroma. Other HOX 
antibodies were tested. Anti-HOXB7, anti-HOXB6 and anti-HOX13 were also used, however 
due to limited specificity and high background staining, these antibodies were not taken 
further to TMA staining.
2.12.Microarray analysis
RNA was extracted from cell-lines and CAM tumours as previously described (section 2.5: 
RNA extraction from CAM tumours). Samples were prepared following the One-colour 
microarray-based gene expression analysis protocol (quick amp labelling) (Agilent). One-
colour spike-mix was prepared by serial dilutions (first dilution 1:20 (e.g. 5µl stock spike-mix in 
100µl dilution buffer), then second dilution 1:25 and finally third dilution 1:5) and incubated at 
37 °C for 5 minutes. The template and T7 promoter-mix was made by mixing 10 µg RNA 
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(diluted in 5.3 µl nuclease free H2O) with 5µl the third dilution spike-mix as prepared 
previously and 1.2µl T7-promoter primer. The primer and template where denatured by 
incubating at 65 °C for 10 minutes followed by a 5-minute incubation on ice. Following this, 
the cDNA master mix was prepared by adding 4µl 5X first strand buffer (which had been 
previously heated at 80 °C for 4 mins) to 2µl 0.1 M DTT, 1µl 10 mM dNTP mix, 1µl Moloney 
Murine Leukemia Reverse Transcriptase  (MMLV-RT) and 0.5µl RNaseOUT in each 
preparation. 8.5µl cDNA master mix were added to each sample and incubated at 40 °C for 2 
hours followed by 15 minutes at 65 °C. Samples were transferred to ice and incubated for 5 
minutes. Next, the transcription master-mix was prepared by mixing 15.3µl Nuclease-free H2O 
to 20µl 4x transcription buffer, 6µl 0.1 M DTT, 8µl Nucleoside Triphosphate (NTP) mix, 6.4µl 
50% Polyethylene Glycol (PEG) (which had been pre-warmed  at 40 °C for 1 min), 0.5µl 
RNaseOUT, 0.6µl inorganic pyrophosphatase, 0.8µl T7 RNA polymerase and 2.4µl Cyanine 3- 
Cytosine Triphosphate (CTP). 60µl of this transcription master-mix were added to each 
sample, mixed by pipetting and incubated at 40 °C for 2 hours.
 In order to purify the labelled/amplified RNA Qiagen’s RNeasy mini spin columns were used. 
20µl nuclease-free H2O were added to the cRNA samples. Then, 350µl RLT buffer were 
added and mixed followed by 250µl absolute ethanol. The sample was spun through the 
column 700µl at a time by discarding the flow-through after each 30 second spin (at 4 °C, 
13,000 RPM). 500µl RPE buffer where then added to the column and centrifuged for 30 
seconds at 13,000 RPM at 4 °C. After discarding the flow-through this step was repeated 
once more and centrifuged for 60 seconds at 13,000 RPM. In order to ensure dryness of the 
column, samples were centrifuged for 30 seconds (at 13,000 RPM) at 4 °C. In order to elute 
the purified cRNA, 30µl nuclease-free H2O were added to the column and incubated for 1 
minute and centrifuged at 13,000 RPM at 4 °C.
The purified cRNA was then quantified using the nanodrop ND-100 UV-VIS 
spectrophotometer. The cyanine 3 dye (Cy3) concentration (pmol/µl), RNA absorbance ratio 
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(260 nm/ 280 nm) and the cRNA concentration (ng/µl) were recorded. The yield and specific 
activity of each reaction were calculated as follows :
Yield:
concentration of cRNA (ng/µl) x 30µl (elution volume) / 1000 = Yield of cRNA (µg)
Specific activity:
(concentration of Cy3) / (concentration of cRNA) x 1000 = Specific activity (pmol Cy3 per µg 
cRNA)
Only samples with a yield > 1.65µg and a specific activity > 9.0 pmol Cy3 perµg cRNA were 
taken though to the hybridisation step. 
In order to prepare the fragmentation mix, a solution of 10x blocking agent was prepared by 
adding 500µl nuclease-free H2O to the lyophilised 10x blocking agent and heating for 5 
minutes at 37°C. Following this, 1.65µg of each cyanine 3-labelled linearly amplified cRNA 
sample were added to a nuclease-free microfuge tube with 11µl 10x blocking agent, nuclease-
free H2O to bring to a volume of 52.8µl and finally, 2.2µl 25x fragmentation buffer. Samples 
were incubated for 30 mins at 60 °C in order to fragment the RNA. After this incubation each 
sample (55µl) from the fragmentation mix was added to 55µl 2x GEx Hybridisation buffer HI-
RPM, mixed by pipetting and centrifuged at 13,000 RPM for 1 minute. Samples were placed 
on ice and loaded on a SureHyb gasket slide and 8 single colour Agilent “Whole Human 
Genome 4x44” microarrays were used (a total of 2 slides) array was placed and clamped with 
the top “active side” down. The clamps were hand tightened and slides were gently tapped to 
ensure mobility of the bubbles.The assembled slide chamber was placed in a rotisserie in a 
hybridisation oven which was set to 65°C and to rotate at 10 RPM. Finally the arrays were 
hybridised at 65 °C for 17 hours. 
Microarrays where removed from the oven and the clamps were removed. In order to wash 
the arrays, 0.005% Triton X-102 was added to the gene expression wash buffers 1 and 2, to 
reduce the possibility of artifacts. The array gasket sandwich was transferred to a dish 
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containing gene-expression wash-buffer 1. The array was separated from the gasket while 
submerged in gene-expression wash-buffer 1. The array was then placed in a slide rack in a 
second dish containing gene-expression wash-buffer 1 and stirred using a magnetic stir bar 
and plate for 4 minutes at room temperature. The slide rack was then transferred to a third 
dish containing gene-expression wash-buffer 2 (which had been pre-warmed overnight at 
37°C) and stirred for 1 minute. The array was slowly removed from the third dish to avoid 
droplet formation. The array was then scanned on Agilent G4900DA SureScan Microarray 
Scanner. Microarray data was kindly analysed by Dr. Carla S. Moller-Levet, PhD, a 
bioinformatics experimental officer at the University of Surrey. The minimum replicates 
needed had been calculated using the programme GPower3. Sample similarity was evaluated 
via hierarchical clustering and PCA, using R functions “pvclust” and “prcomp” 
respectively.Differential expression between two groups (cell-lines and tumours) was 
calculated using the ttest from the stats library. P-values were corrected for multiple testing 
using function “p.adjust” from the stats library. A cut off of 0.05 Benjamin and Hochberg 
corrected p-value was chosen to classify probes as differentially expressed. GeneGo was 
used to perform enrichment analysis and interactome analysis of the list of significantly 
expressed probes with an absolute fold change larger than 3. 
  
2.13.Murine flank model
The murine flank model has been extensively used in pancreatic cancer research and was 
therefore selected due its wide use, ease and cost effectiveness to directly compare tumour 
architecture with that of CAM tumours. Female BALB/c nude mice CAnN.Cg-Foxn1nu/Crl 
were sourced from Charles River Laboratories and housed under specific pathogen free 
conditions in accordance with the requirements of University Ethics Committee. Procedures 
were conducted under the supervision of Dr Guy Simpson at the university of Surrey. AsPC-1 
and BxPC-3 cells were grown as previously described (section 2.1), harvested by 
72
trypsinisation and washed 3 times in Hank’s salt solution (Sigma-aldritch). AsPC-1 cells were 
resuspended in Hank’s salt solution and 4x106 cells were injected subcutaneously into the 
flank of each 6-8 week old BALB/c nude mouse. BxPC-3 cells were resuspended in 
Matrigel™ and 3x106 cells per animal were injected as described above. Tumours were 
measured every 3 days, until theu were judged large enough (around 1cm diameter), after 
which the mice were sacrificed, tumours removed and processed using the same protocol as 
for CAM tumours.   
2.14. Western blot
Western blot protocol was kindly carried out by Dr. Victoria Roulstone at the Institute of 
Cancer Research (Institute of Cancer Research (London)). Frozen cell pellets and tumours 
were thawed and 200μl of lysis buffer were added to Eppendorf tubes. RIPA lysis buffer 
contained 0.15 mol/L NaCl, 1% sodium deoxycholate, 1% Triton, 0.1% SDS, 0.01 % Tris 
buffer (pH=7.4) and cOmplete® protease inhibitor cocktail (Roche). The cells were placed on 
ice for 15 minutes and centrifuged for 15 minutes at 15,000 rpm. The supernatant was then 
transferred to a new tube. Samples were loaded on to 10% acrylamide NuPage Novex® Bis-
Tris gel with loading buffer composed of 15μl of sample, 12μl 2x Laemmli (sigma-aldrich) and 
3μl ß-Mercaptoethanol (sigma-aldrich) after having been heated for 5 minutes at 95 °C and 
centrifuged briefly. MOPS (NuPage (Novex®)). The gel was run for 30 minutes at 100 volts 
followed by 60 minutes at 150 volts at room temperature. The Polyvinylidene fluoride (PVDF) 
membrane was labelled and soaked in methanol and transfer cassette-pads and filter-paper 
were soaked in transfer buffer. After removal from the tank, the gel was briefly rinsed in 
transfer buffer and the transfer sandwich was made up containing the pads, filter paper, 
membrane, gel, filter paper and pad (from positive to negative electrode) and transfer buffer 
was added to the transfer tanks. The transfer was run in the cold room for 1.5 hours at 70 
volts followed by 3 hours at 50 volts.  The membrane was then rinsed in TBS-Tween was 
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made up of 0.1% Tween, 10x Tris-buffered Saline (TBS) in ultrafiltrated H2O. The membrane 
was then covered with 5% milk in TBS-Tween and blocked for 60 minutes at room 
temperature. The primary antibody was added and incubated overnight at 4°C (Table 2.5). 
This was followed by 4 washing steps, each 5 minutes, in TBS-Tween, on a rocker. The 
secondary antibody was then added and incubated for 60 minutes at room temperature. This 
was again, followed by 4 washing steps, each 5 minutes in TBS-Tween, on a rocker. A 
substrate composed of 5ml stable peroxidase and 5ml luminol enhancer (SuperSignal West 
Pico Chemiluminescent substrate Pierce) was poured onto the blot and incubated at room 
temperature for 5 minutes on a rocker. The blot was then drained and wrapped in cling film 
and attached to a film cassette. The signal was added and exposed to film for 1-10 minutes. 
Finally in order to strip the membrane, it was incubated in 10ml Pierce Restore Western 
Stripping solution for 15 minutes at room temperature. 
Antibodies Provider
Phospho-p44/p42 MAPK (Erk1/2) (1:1000) Cell signalling (#9101) 
MAPK (Erk1/2) (1:1000) Cell signalling (#9102) 
Phospho-MEK1/2 (1:1000) Cell signalling (#9154) 
Anti β-actin (1:5000) ABCAM (ab6276)
Table	  2.6: Antibodies used for Western blotting.
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Chapter III:
3. HOX gene expression in PDAC
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3.1.Introduction
A substantial body of evidence supports the hypothesis that “Oncology recapitulates 
ontology”. Normal development relies on an intricate balance of cell differentiation and 
proliferation both safeguarded, in part, by HOX genes. The fine balance between these two 
processes is lost with the onset of neoplasia (Lappin et al., 2006). Previous work has shown 
that HOX genes appear to be re-expressed in the adult and have been implicated in several 
types of solid tumours including those of the lung, ovary, breast and pancreas (Gray et al., 
2011; Morgan, 2006; Morgan et al., 2012; Morgan et al., 2007; Plowright et al., 2009). As 
previously discussed, little is currently known about the levels of HOX gene expression in 
normal adult pancreatic tissue and hence the dysregulation that may occur at the inception 
and establishment of neoplasia. 
So far, HOXA1, HOXA4,HOXA5, HOXB4 and HOXD1 have been shown to be involved in 
pancreatic development. HOXB1 and HOXB3 are suspected to be suppressors of metastasis 
and HOXB2, HOXB5, HOXB6 and HOXB7 have been shown to be up-regulated in pancreatic 
cancer with HOXB2 and HOXB7 showing potential as predictive prognostic factors. 
Most studies involving HOX genes focus on a single gene of interest, in this study the aim 
was to assesses the whole panel of 39 HOX genes and their potential role in pancreatic 
cancer and more specifically in PDAC.  
3.2.Hypothesis and objectives
Based on the body of evidence in the literature, we hypothesised that there is a unique HOX 
gene profile specific to PDAC, the aim of this work was therefore  to determine a signature 
HOX gene expression pattern in pancreatic cancer-derived cell lines and PDAC tissue. As a 
preliminary, we measured and compared HOX gene expression in 4 pancreatic cancer cell-
lines. Due to the limited availability of human PDAC samples we sourced RNA commercially 
from both normal pancreatic tissue and pancreatic cancer patients. We also proposed to 
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extract RNA from FFPE blocks and extract and analyse RNA from snap-frozen PDAC patient 
tumours. We also evaluated the expression of HOX gene cofactors PBX1-4. Finally, we aimed 
to validate genes found to be dysregulated at the protein level by IHC. 
3.3.Results 
3.3.1. HOX gene expression in pancreatic cell lines
HOX gene expression was measured in AsPC-1, BxPC-3, PaCa-3 and PancTu1 cell lines 
using semi-quantitative PCR. Results were normalised using the house-keeping gene ß-actin.
 HOXA expression results are shown in Figure 3.1. AsPC-1 cells show elevated levels of 
expression for HOXA9, HOXA10 and HOXA13 compared with other HOXA genes. In BxPC-3 
cells, HOXA9 and HOXA10 are more highly expressed than the other HOX genes in cluster A. 
In PaCa-3 cells, HOXA9 and HOXA10 have a higher expression than other HOX genes in 
cluster A. Finally, levels of HOXA expression in PancTu-1 cells were much higher in 
comparison with the other cells lines showing elevated expression of HOXA1-3, HOXA5-6, 
HOXA9 and HOXA13.
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HOXA gene expression in cell lines
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! Figure 3.1: Levels of HOX gene expression in the HOXA gene cluster in AsPC-1, BxPC-3, 
! PaCa-3 and PancTu-1 cell lines by semi-quantitative RT-PCR. Ct values were normalised using 
! the housekeeping gene ß-actin. Error bars were calculated using standard error of the mean 
! (SEM). Genes represented in green have been previously described as having a role in 
! pancreas development.Y axis was Log10 scaled. Experiment was performed on 3 biological 
! repeats (n=3) using 3 technical repeats of each.
Gene expression in the HOXB cluster is summarised in Figure 3.2. HOXB5, HOXB9 and 
HOXB13 were the most highly expressed genes in the HOXB cluster in AsPC-1 cells. In 
BxPC-3 cells, HOXB9 and HOXB5 were the most highly expressed. The most highly 
expressed genes in PaCa-3 cells were HOXB4, HOXB5, HOXB9 and HOXB13, however, 
expression levels were generally low. HOX gene expression in PancTu-1 cells was 
considerably higher than in the other three cell lines. HOXB5, HOXB6, HOXB7, HOXB9 and 
HOXB13 can be highlighted as highly expressed compared with other genes in the cluster.
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! Figure	  3.2: Levels of HOX gene expression in the HOXB gene cluster in AsPC-1, BxPC-3, PaCa-3 
! and PancTu-1 cell lines by semi-quantitative RT-PCR. Ct values were normalised using the 
! housekeeping gene ß-actin. Error bars were calculated using standard error of the mean (SEM). 
! Genes represented in green have been previously described as having a role in pancreas 
! development, genes represented in yellow, a role in metastasis suppression and genes 
! represented in red described as overexpressed in PDAC. Y axis was Log10 scaled. Experiment 
! was performed on 3 biological repeats (n=3) using 3 technical repeats of each.
Levels of HOXC expression are summarised in Figure 3.3. HOXC genes are generally 
expressed only at a very low level compared with HOX gene clusters A and B. HOXC9 is 
expressed in AsPC-1, BxPC-3 and PancTu-1 cells at low levels. HOXC8 is expressed in both 
BxPC-3 and PancTu-1, and HOXC13 is strongly expressed in PancTu-1 cells.
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HOXC gene expression in cell lines
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! Figure	  3.3: Levels of HOX gene expression in the HOXC gene cluster in AsPC-1, BxPC-3, PaCa-3 
! and PancTu-1 cell lines by semi-quantitative RT-PCR. Ct values were normalised using the 
! housekeeping gene ß-actin. Error bars were calculated using standard error of the mean (SEM). 
! Y axis was Log10 scaled. Experiment was performed on 3 biological repeats (n=3) using 3 
! technical repeats of each.
Levels of HOXD expression are displayed in Figure 3.4. In BxPC-3 and PaCa-3 cell lines 
there are very low levels of HOX gene expression. AsPC-1 shows very low expression in the 
HOXD12 gene. PancTu-1 has the highest HOXD expression compared with the 3 other cell 
lines, however, compared with the other HOX clusters, HOXD genes appear to be expressed 
at much lower levels.
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! Figure 3.4: Levels of HOX gene expression in the HOXD gene cluster in AsPC-1, BxPC-3, 
! PaCa-3 and PancTu-1 cell lines by semi-quantitative RT-PCR. Ct values were normalised using 
! the housekeeping gene ß-actin. Error bars were calculated using standard error of the mean 
! (SEM). Genes represented in green have been previously described as having a role in 
! pancreas development and genes represented in blue as being down-regulated in PDAC. Y axis 
! was Log10 scaled. Experiment was performed on 3 biological repeats (n=3) using 3 
! technical repeats of each.
3.3.2. HOX gene expression in commercially available PDAC and 
normal pancreatic RNA
Previously published data has questioned the genetic integrity of cell lines as a result of 
continuous culturing, sometimes spanning over half a century (John P Neoptolemos, 2010a). 
Whilst gene expression patterns in cell-lines strongly resemble their primary predecessors 
and provide important clues about gene expression and therefore justify their use as a 
suitable setting for preliminary studies, it is paramount to measure gene expression in fresh, 
human primary tumours in order to draw conclusions about gene dysregulation. Due to the 
relatively rare nature of PDAC resections, primary tumours were problematic to obtain and 
were therefore, perforce, sourced commercially. 
HOX gene expression was measured in RNA obtained from pancreata of pancreatic cancer 
patients and pancreata resected within normal limits. 
Results summarising HOXA gene expression in normal versus pancreatic cancer are 
displayed in Figure 3.5. Generally, HOXA gene expression was found to be higher in RNA 
from pancreatic cancer patients compared with RNA from normal pancreata. Statistical 
analysis showed a significant difference in HOXA1, HOXA2, HOXA3, HOXA5, HOXA6, 
HOXA10 and HOXA9 (p≤0.05). HOXA1, HOXA4 and HOXA5 have been shown to play a role 
in pancreas development. Levels of HOXA13 expression were found to be significantly higher 
(p≤0.01) in PDAC samples compared with RNA from normal pancreas. HOXA13 had been 
previously linked to neither pancreatic development nor PDAC. It was also noted that there 
was little or no expression in normal pancreatic RNA. 
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HOXA expression in commercially available RNA
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! Figure 3.5: Levels of HOXA expression were measured by semi-quantitative RT-PCR in RNA 
! from neoplastic pancreas and compared with HOXA gene expression in RNA from normal 
! pancreas. Ct values were normalised using the housekeeping gene ß-actin. Error bars were 
! calculated using standard error of the mean (SEM). P-values were calculated using a t-test 
! (p≤0.05*, p≤0.01**, p≤0.001*** ). Genes represented in green have been previously described 
! as having a role in pancreas development. Y axis was Log10 scaled. Experiment was performed 
! on 3 biological repeats (n=3) in both normal and PDAC samples using 3 technical repeats of 
! each.
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HOXB gene expression was also found to be considerably higher in pancreatic cancer 
patient-tissue compared with normal pancreatic tissue. Gene expression in, HOXB4, HOXB6, 
HOXB7 was elevated in cancer tissue compared with normal tissue (p≤0.05) and even more 
significantly so in HOXB3, HOXB7 (both p≤0.01). 
HOXB expression in commercially available RNA
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! Figure 3.6: Levels of HOXB expression were measured by semi-quantitative RT-PCR in RNA 
! from neoplastic pancreas and compared with HOXB gene expression in RNA from normal 
! pancreas (within normal limits). Ct values were normalised using the housekeeping gene 
! ß-actin Error bars were calculated using standard error of the mean (SEM). P-values were 
! calculated using a t-test (p≤0.05*, p≤0.01**, p≤0.001*** ). Genes represented in green have 
! been previously described as having a role in pancreas development, genes represented in 
! yellow, a role in metastasis suppression and those in red described as over-expressed in PDAC. 
! Y axis was Log10 scaled. Experiment was performed on 3 biological repeats (n=3) in both normal 
! and PDAC samples using 3 technical repeats of each.
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HOXC gene expression was also found to be higher in cancer-patient tissue compared with 
normal pancreatic tissue (Figure 3.7). In particular, HOXC4 and HOXC13 were found to be 
significantly higher in cancer versus normal (p≤0.05). HOXC9 gene expression levels were 
significantly higher in PDAC RNA compared with normal RNA (p≤0.01). There has been little 
research linking HOXC gene expression with pancreatic development, function or disease.  
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HOXC expression in commercially available RNA
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! Figure 3.7: Levels of HOXC expression were measured by semi-quantitative RT-PCR in RNA 
! from neoplastic pancreas and compared with HOXC gene expression in RNA from normal 
! pancreas (within normal limits). Ct values were normalised using the housekeeping gene ß-actin 
! Error bars were calculated using standard error of the mean (SEM). P-values were calculated 
! using a t-test (p≤0.05*, p≤0.01**, p≤0.001*** ). Y axis was Log10 scaled. Experiment was 
! performed on 3 biological repeats (n=3) in both normal and PDAC samples using 3 technical 
! repeats of each.
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Levels of HOXD expression are summarised in Figure 3.8. HOXD gene expression was found 
to be higher in HOXD1-11 and HOXD13 (HOXD10: p<0.05). However, HOXD12 expression 
was found to be higher in normal tissue compared with Pancreatic cancer tissue (No 
statistical significance was observed). 
1 3 4 8 9 10 11 12 13HOXD
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! Figure 3.8: Levels of HOXD expression were measured by semi-quantitative RT-PCR in RNA 
! from neoplastic pancreas and compared with HOX D gene expression in RNA from normal 
! pancreas (within normal limits). Ct values were normalised using the housekeeping gene ß-actin. 
! Error bars were calculated using standard error of the mean (SEM). P-values were calculated 
! using a t-test (p≤0.05*, p≤0.01**, p≤0.001*** ). Genes represented in green have been 
! previously described as having a role in pancreas development and genes represented in blue 
! previously described as being down-regulated in PDAC. Y axis was Log10 scaled. Experiment 
! was performed on 3 biological repeats (n=3) in both normal and PDAC samples using 3 
! technical repeats of each.
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3.3.3.HOX gene expression in snap-frozen human PDAC     
In order to measure and compare HOX gene expression in human tissue, it was originally 
hoped that total RNA could be extracted from FFPE blocks. Due to the low number of 
resectable cases of PDAC, it was hoped that successful RNA extraction from FFPE would 
become an invaluable resource of RNA due to the abundance of PDAC FFPE blocks in 
national biobanks. Several FFPE-RNA extraction kits were tested and protocols optimised. 
RNA purity was assessed by testing samples on the Nanodrop 100 UV-VIS 
spectrophotometer and RNA integrity was estimated by gel electrophoresis. Although the 
literature quoted that an RNA integrity number (RIN) score of around 2.0 was acceptable in 
FFPE-RNA extraction, the RNA run in-house showed a high level of RNA degradation 
revealed by a large smear and no visible 18s and 28s ribosomal bands. In addition, semi-
quantitative RT-PCR of the house-keeping gene ß-actin was performed with limited success 
even when using primers that amplified shorter amplicons (data not shown). 
In view of this set-back and in order to identify HOX gene dysregulation in human cancer, 
snap-frozen tumour samples were obtained (kindly made available) for RNA extraction at the 
Bart Cancer Institute (Queen Mary University of London). PDAC cases were assessed with a 
full pathological report. RNA was extracted and RNA purity was quantified using Nanodrop 
ND-100 UV-VIS spectrophotometer and RNA integrity was measured using Agilent 2100 
bioanalyser (Figure 3.9). In total, 7 human PDAC samples passed the quality control and 
were used for subsequent analysis. 
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! Figure 3.9: Quality control of RNA extracted from snap-frozen tumours. RNA was run on a 2% 
! agarose Egel to determine RNA integrity (A) and RNA integrity number (RIN scores were 
! obtained from running samples on agilent 2100 bioanalyser. RNA with RIN<7 was discarded 
! (B).
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Results from the semi-quantitative RT-PCR of snap-frozen tumours showed different values 
from those obtained from the commercially available samples, however, the general HOX-
gene pattern showed remarkable similarities in both sets of samples. HOX genes showed 
higher expression in the commercially available samples compared with the snap-frozen 
samples. 
Statistical analysis also showed that HOX gene expression was higher in snap-frozen tumour 
sample RNA compared with the RNA from normal pancreata obtained commercially. In 
particular, HOXA5 (p<0.05), HOXA9 (p<0.001), HOXA10 (p<0.001) and HOXA13 (p<0.001) 
expression was significantly higher in PDAC RNA compared with normal RNA. 
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HOXA expression in snap-frozen PDAC versus normal (commercial)
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! Figure 3.10: Levels of HOXA expression were measured by semi-quantitative RT-PCR in RNA 
! from snap-frozen PDAC patients and compared with HOXA gene expression in RNA from normal 
! pancreas (within normal limits) (obtained commercially). Ct values were normalised using the 
! housekeeping gene ß-actin. Error bars were calculated using standard error of the mean (SEM). 
! P-values were calculated using a t-test (p≤0.05*, p≤0.01**, p≤0.001*** ). Genes represented in 
! green have been previously described as having a role in pancreas development. Y axis was 
! Log10 scaled. Experiment was performed on 3 biological repeats (n=3) in normal pancreas RNA 
! and 7 biological repeats (n=7) in snap-frozen PDACs using 3 technical repeats of each.
Expression of HOXB genes were all higher in tumour tissue compared with normal tissue and 
statistical analysis showed that HOXB2 (p<0.05), HOXB3 (p<0.0001), HOXB4 (p<0.0001), 
HOXB5 (p<0.0001), HOXB6 (p<0.001), HOXB7 (p<0.0001), HOXB9 (p<0.05) were all 
significantly more highly expressed in PDAC than in normal.  
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HOXB expression in snap-frozen PDAC versus normal (commercial)
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! Figure 3.11: Levels of HOXB expression were measured by semi-quantitative RT-PCR in RNA 
! from snap-frozen PDAC patients and compared with HOXB gene expression in RNA from normal 
! pancreas (within normal limits) (obtained commercially). Ct values were normalised using the 
! housekeeping gene ß-actin. Error bars were calculated using standard error of the mean (SEM). 
! P-values were calculated using a t-test (p≤0.05*, p≤0.01**, p≤0.001*** ). Genes represented in 
! green have been previously described as having a role in pancreas development, genes 
! represented in yellow a role in metastasis suppression and genes represented in red described 
! as over expressed in PDAC. Y axis was Log10 scaled. Experiment was performed on 3 biological 
! repeats (n=3) in normal pancreas RNA and 7 biological repeats (n=7) in snap-frozen PDACs 
! using 3 technical repeats of each.
 In the HOXC cluster, a smaller number of genes were differentially expressed in tumour 
tissue compared with normal tissue. HOXC4 (p<0.05) and HOXC6 (p<0.001)(expression was 
higher in tumour compared with normal. HOXC10 (p<0.001) and HOXC13 (p<0.001) were 
significantly more highly expressed in normal tissue compared with neoplastic tissue.
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HOXC expression in snap-frozen PDAC versus normal (commercial)
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! Figure 3.12: Levels of HOXC expression were measured by semi-quantitative RT-PCR in RNA 
! from snap-frozen PDAC patients and compared with HOXC gene expression in RNA from normal 
! pancreas (within normal limits) (obtained commercially). Ct values were normalised using the 
! housekeeping gene ß-actin. Error bars were calculated using standard error of the mean (SEM). 
! P-values were calculated using a t-test (p≤0.05*, p≤0.01**, p≤0.001*** ). Y axis was Log10 
! scaled. Experiment was performed on 3 biological repeats (n=3) in normal pancreas RNA and 7 
! biological repeats (n=7) in snap-frozen PDACs using 3 technical repeats of each.
Gene expression in the HOXD cluster was significantly higher in normal RNA compared with 
snap-frozen tumour RNA, in particular HOXD1 (p<0.001), HOXD3 (p<0.05), HOXD4 
(p<0.001), HOXD9 (p<0.0001), HOXD10 (p<0.0001), HOXD11 (p<0.0001) and HOXD13 
(p<0.0001).
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HOXD expression in snap-frozen PDAC versus normal (commercial)
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! Figure 3.13: Levels of HOXD expression were measured by semi-quantitative RT-PCR in RNA 
! from snap-frozen PDAC patients and compared with HOXD gene expression in RNA from normal 
! pancreas (within normal limits) (obtained commercially). Ct values were normalised using the 
! housekeeping gene ß-actin. Error bars were calculated using standard error of the mean (SEM). 
! P-values were calculated using a t-test (p≤0.05*, p≤0.01**, p≤0.001***, p≤0.0001**** ). Genes 
! represented in green have been previously described as having a role in pancreas development 
! and genes represented in blue as being down-regulated in PDAC. Y axis was Log10 scaled. 
! Experiment was performed on 3 biological repeats (n=3) in normal pancreas RNA and 7 
! biological repeats (n=7) in snap-frozen PDACs using 3 technical repeats of each.
3.3.4. Clustering analysis of HOX gene expression in pancreatic 
cancer  
HOX genes were clustered into most similarly expressed clusters using a hierarchical 
clustering analysis. Cluster.3.0 and java tree view were used to generate a dendrogram 
(Figure 3.15) of HOX gene expression in pancreatic cell lines, normal pancreas RNA 
(obtained commercially) and PDAC RNA obtained both commercially and from snap-frozen 
tumours using the mean of the data discussed above. Broadly speaking, figure 3.15 shows 
that HOXA and HOXB clusters are most similarly expressed and the same applies for HOXC 
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and HOXD cluster although there are exceptions. For example, HOXA1 and HOXC13 have 
been clustered together. Figure 3.15 also highlights the differences between normal pancreas 
RNA and PDAC RNA obtained both commercially and from snap-frozen tumours. This 
dendrograms also enables us to compare PDAC RNA from 2 sources side by side.
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! Figure 3.14: Clustering analysis of HOX genes in pancreatic cell-lines, normal pancreas and 
! PDAC RNA obtained both commercially and from snap-frozen tumours.
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3.3.5. HOXA13 immunohistochemistry in human PDAC and normal 
pancreatic tissue
Semi-quantitative RT-PCR results showed that HOXA13 expression was significantly higher in 
tumour tissue compared with normal pancreas. In order to confirm these findings, a tissue 
microarray (TMA) was sourced commercially in order to assess levels of HOXA13 protein in 
human PDAC cores compared with normal-adjacent and normal pancreatic cores. The 
rationale behind selecting HOXA13 as a candidate gene in PDAC was that it is expressed in 
all 4 cancer-derived cell lines and that there was no evidence that HOXA13 was a pancreatic 
developmental gene. Hence, we hypothesised that expression levels in normal tissue would 
be low. Also, statistical significance was achieved when comparing commercially obtained 
RNA and snap-frozen samples with normal pancreas RNA. Based on the gene expression 
data, several other genes were considered under the same rationale. For example, we 
selected HOXA9, HOXB6, HOXB7, HOXB8 and HOXD13 as candidate genes. However, HOX 
antibodies were difficult to work with due to limited specificity and tight time lines did not 
permit us to take this further within this project. There was also a limited amount of previously 
published worked in the literature to aid this task. We hope to continue this work in the future. 
Recently, HOXA13 overexpression in gastric cancer tissue compared with normal gastric 
mucosa has been demonstrated by immunohistochemistry and shown to have a clinical 
significance (Han et al., 2013). HOXA13 staining was optimised on human kidney (positive 
control) in order to determine the best antibody dilution. The human TMA was stained, 
staining intensity was assessed and final scoring was done with help from an expert 
consultant pathologist at the Royal Surrey County Hospital. Results showed that all (100%) of 
the 20 normal-adjacent and normal cores stained negative for HOXA13 while 45.76% (32 out 
of 59) of neoplastic cores stained positive for the protein (Table 3.1). 37.29% (22 out of 59) of 
PDAC cores were scored at 1+ positive and 8.47% (5 out of of 59) of cores were scores at 2+ 
positive staining (Table 3.2). Positivity and staining intensity showed no correlation with 
tumour grade and the commercially obtained TMA offered no data on patient survival. 
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! Figure 3.15: Immunohistochemical staining of HOXA13 protein on a tissue microarray (TMA) of 
! human cases of PDAC (A, B and C) and normal pancreas (D). A: scored 2+ positive. B: scored 
! 1+ positive. C: scored negative. D: Scored Negative. (x40 magnification scale bars represent a 
! length of 100 µm).
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Tissue type Positive Negative
PDAC (n=59) 45.76% 54.79%
Normal Pancreas (n=20) 0% 100%
! Table 3.1: Summary of results of HOXA13 immunohistochemical staining of human tissue 
! microarray (TMA) in 59 human PDAC cases versus 20 cases of normal and normal adjacent 
! pancreas.
HOXA13 staining PDAC (n=59)
Negative 54.79%
1+ positive 37.29%
2+ positive 8.47%
! Table 3.2: Summary of different HOXA13 staining intensities on a tissue microarray (TMA) 
! containing 59 cores of human PDAC.
3.3.6. PBX expression in pancreatic cell-lines and human tissue
HOX proteins have limited affinity with DNA, however this affinity is greatly increased by 
cofactors such as PBX. PBX proteins have previously been reported to be required for HOX 
function. In humans there are 4 PBX genes (compared with one ortholog in drosophila 
(named extradenticle)) PBX1-4. Like HOX proteins, PBX contain a homeodomain, which is 
classed as a ‘three amino acid loop extention’ (TALE) and PBX binds to the DNA sequence 
TGAT through the TALE homeodomain (Ladam and Sagerstrom, 2014) . The PBX and HOX 
homeodomain as well as the HOX YPWM motif are the minimum requirements for effective 
DNA binding. Binding occurs between PBX and all HOX paralogs except HOX11-13. Our 
previous data showed elevated expression of certain HOX genes and we aimed to investigate 
the PBX expression in these samples (Sprules et al., 2003).
PBX expression was measured in RNA extracted from pancreatic cell lines. Results showed 
PBX1 and PBX2 were more highly expressed compared with PBX3 and PBX4 with PBX4 
displaying the lowest gene expression of the 4 PBX genes. 
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! Figure 3.16: Levels of PBX1-4 expression were measured by semi-quantitative RT-PCR in RNA 
! from pancreatic cancer derived cell lines. Ct values were normalised using the !housekeeping 
! gene ß-actin. Error bars were calculated using standard error of the mean (SEM). Experiment 
! was performed on 3 biological repeats in each cell lines (n=3) using 3 technical repeats of each. 
PBX expression was also compared between RNA from normal pancreas and RNA from 
PDAC patient (both obtained commercially). Results are summarised in figure 3.17. Results 
showed a significantly lower expression in PDAC RNA compared with normal pancreas RNA 
in PBX1, PBX2, PBX3. There was a slightly higher expression in PDAC RNA compared with 
normal pancreas in PBX4 although statistical significance was not achieved.
98
PBX gene expression in snap frozen PDAC versus normal (commercial)
Gene
RQ
 (n
or
m
ali
se
d t
o β
-a
cti
n)
PB
X1
PB
X2
PB
X3 PB
X4
0
200
400
600
Normal pancreas
PDAC ***
***
***
! Figure 3.17: Levels PBX1-4 were measured by semi-quantitative RT-PCR in RNA from 
! neoplastic pancreas and compared with PBX1-4 expression in RNA from normal pancreas 
! (within normal limits). Ct values were normalised using the housekeeping gene ß-actin. Error bars 
! were calculated using standard error of the mean (SEM). P-values were calculated using a t-test 
! (p≤0.001*** ). Experiment !was performed on 3 biological repeats (n=3) in both normal and 
! PDAC RNA using 3 technical repeats of each.
PBX expression was also compared between RNA from normal pancreas and RNA (obtained 
commercially) from PDAC patient (extracted from snap-frozen tumours). Results showed a 
significantly lower expression in snap-frozen PDAC RNA compared with normal pancreas 
RNA in PBX1, PBX2, PBX3. PBX4 was slightly more highly expressed in snap-frozen PDAC 
compared with normal RNA, although statistical significance was not achieved. Results are 
summarised in figure 3.18.
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PBX gene expression in snap-frozen PDAC versus normal (commercial)
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! Figure 3.18: Levels PBX1-4 were measured by semi-quantitative RT-PCR in RNA from !          
! snap-frozen PDAC patients and compared with PBX1-4 expression in RNA from normal 
! pancreas (within normal limits). Ct values were normalised using the housekeeping gene ß-actin. 
! Error bars were calculated using standard error of the mean (SEM). P-values were calculated 
! using a t-test (p≤0.0001**** ). Experiment was performed on 3 biological repeats (n=3) in both 
! normal and PDAC RNA using 3 technical repeats of each.
3.4.Discussion
Pancreatic cancer cell lines provide some evidence concerning general HOX gene expression 
patterns. Broadly speaking, HOX expression in cell lines appears to be highest in clusters A 
and B with little gene expression in clusters C and D, consistent with previously published 
data.
HOXB2 expression was almost absent in all 4 cell lines and commercially sourced RNA, 
however, HOXB2 expression level was higher in the snap-frozen cases of PDAC compared 
with normal pancreatic RNA (p<0.05). HOXB2 has previously been identified as an important 
effector in the retinoic acid (RA) signalling pathway and had been shown to be over-
expressed both at RNA and protein level in PDAC patients (Segara et al., 2005). HOXB2 has 
also been found to have prognostic value where patients with low HOXB2 expression show 
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considerably longer survival after pancreatectomy compared with high expressors, showing 
its promising potential as a biomarker of advanced disease (Biankin et al., 2008). This could 
provide some insight into why not all cases in this study show high levels of expression.
HOXB7 expression in this study appears to be elevated in PancTu-1 cells compared with 
other cell lines and expression is higher in snap-frozen cases of PDAC compared with normal 
RNA (P<0.001). These results were not observed in the commercial cases of PDAC. In recent 
years, HOXB7 has been shown to be over-expressed in PDAC and also to promote invasion 
and metastasis. It has also been shown to have a prognostic significance to PDAC patients. 
Previously, HOXB7 has been shown to be overexpressed in 43 cases of snap-frozen PDAC 
compared with 7 normal samples (a 4-fold increase) and confirmed by immunohistochemistry 
on a PDAC-TMA. (Nguyen et al., 2009; Nguyen Kovochich et al., 2013). Chile et al. also 
measured HOXB7 expression in 29 cases of PDAC and 2 cell lines but achieved statistical 
significance only when comparing cell line expression with normal tissue (stored at 4⁰C in 
RNAlater®) (Chile et al., 2013). In this study, HOXB7 expression was not assessed at the 
protein level because expression level by qPCR although statistically significant, remained 
low. HOXB7 does, however, remain of interest and will be tested further. 
Another gene of interest, previously highlighted in the literature, is HOXD13. Levels of 
HOXD13 expression were significantly lower in snap-frozen tumour RNA compared with 
normal RNA. Previous studies have reported similar findings, in fact, the absence of HOXD13 
has previously been found to result in poorer patient outcome (Cantile et al., 2009). It has 
been suggested that HOXD13, HOXB1 and HOXB3 all have a ‘suppressor of metastasis’ 
function. Our data supports this theory with relation to HOXD13 (in RNA extracted from snap-
frozen samples) but not for HOXB1 and HOXB3 genes. Interestingly, other HOX genes in the 
HOXD cluster were significantly higher in normal RNA compared with snap-frozen RNA. We 
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should therefore question whether other HOXD genes may also have tumour suppressor 
functions. Although our current data shows underexpression of HOXD13, these result are 
preliminary and will have to be validated at the protein in future work.
It must be noted that transcripts from the HOXC and HOXD clusters display low levels of gene 
expression compared with the HOXA and HOXB clusters. This is also made clearer in figure 
3.15. Referring back to the famous saying that ‘Oncology recapitulates ontology’ the argument 
can be made that HOXB overexpression in tumours is significant, perhaps due genes such as 
HOXB4 being involved in the development of the pancreas. The same idea applies to the 
HOXA cluster where several HOXA genes are involved in this process most notably, HOXA1, 
HOXA4 and HOXA5. There are no pancreatic developmental genes within the HOXC cluster, 
further supporting this idea. However, this argument does not stand for the HOXD cluster 
where HOXD1 has been shown to have a role in pancreas development while HOXD13 has 
been report to be downregulated in PDAC.
It must also be noted that HOX gene expression in snap-frozen PDAC, although higher than 
in normal tissue, was lower that in commercially obtained PDAC RNA. There a 3 biological 
repeats (and 3 technical repeats) within commercial RNA compared with 7 biological repeats 
(and 3 technical repeats). This difference in gene expression could simple be down to a low 
number of biological repeat available commercially. The argument for combining all the PDAC 
RNAs could therefore be made. In this study, results have shown that HOXA13 is expressed 
in PDAC and no expression was detected in normal pancreas and Immunohistochemical 
staining confirmed these findings. This appears to be the first report linking HOXA13 to 
PDAC. HOXA13 has been shown to be overexpressed in gastric cancer tissue compared with 
normal gastric mucosa and patients with a high level of HOXA13 expression had lower 
disease-free and overall survival (Han et al., 2013). Other reports have associated high 
HOXA13 expression with oesophageal squamous cell carcinoma (OSCC) measured by qPCR 
(with no HOXA13 expression in normal tissue) (Chen et al., 2005) and by 
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immunohistochemistry (Gu et al., 2009). Also, knockdown of HOXA13 was shown to decrease 
tumour size in nude mice and Kaplan-Meier survival curves showed significantly longer 
survival in low HOXA13 expressors compared with OSCC patients exhibiting high HOXA13 
expression (Gu et al., 2009). Interestingly, a proteomics study which evaluated the 
downstream targets of HOXA13 in an OSCC cell-line showed that knockdown of HOXA13 
resulted in a decrease in Annexin A2 protein. Annexin A2 is a receptor for tissue plasminogen 
activator (tPA) which is required for activation of the ERK1/2 signalling pathway (Shen and 
Chen, 2011). Previously, tPA and Annexin A2 have been found to be over-expressed in PDAC. 
Ortiz-Zapater et al. suggest that both Annexin A2 and EFGR are involved in the transduction 
of tPA in pancreatic tumours. (Ortiz-Zapater et al., 2007).
Little is known about HOXA13’s specific function in normal pancreas although HOXA13 is a 
know marker of gut primordial posteriorisation during development. A recent study has found 
that HOXA13 may be regulated in part by the long non-coding RNA lncRNA HOXA transcript 
at the distal tip (HOTTIP) where overexpression of HOTTIP results in overexpression of 
HOXA13 in PDAC clinical samples and which also demonstrated that HOTTIP and 
consequently HOXA13 promoted cell proliferation, invasion and chemoristance (Li et al., 
2015).
As previously outlined in Chapter I, PDAC is characterised by a desmoplastic reaction where 
PSCs become activated and are responsible, in part, for the appearance of a dense stroma. 
Stroma and tumour cells differ on a cytological, architectural and molecular level (Waghray et 
al., 2013). Grützmann et al investigated differential gene expression in micro-dissected PDAC 
tumour cells when compared with normal ductal cells. Results showed a significantly higher 
expression of HOXC6 in micro-dissected PDAC tumour cells compared with micro-dissected 
normal ductal cells with a fold change (FC) of +3.55 (Grutzmann et al., 2004). During this 
work, RNA was extracted from the tumour mass composed of both stroma and tumour cells. 
This leads to the hypothesis that tumour and stroma have different HOX gene profiles. We 
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intend to investigate this further by profiling the HOX gene expression in micro-dissected 
tumours and stroma from patient tumours. This may also explain why some results from this 
study appear to conflict with data in the literature.   
As previously outlined, PBX enables increased DNA- binding affinity upon dimerisation with 
HOX genes (HOX genes 1-10). Surprisingly, PBX expression results showed lower 
expression in PDAC compared with normal RNA while HOX genes expression is generally 
higher in PDAC RNA compared with normal pancreas. In order to investigate this further it 
would be interesting to asses the level of HOX-PBX dimers formed in PDAC samples 
compared with normal pancreas at the protein level. 
This is the first study to evaluate gene expression of all 39 HOX genes in PDAC. Our results 
are consistent with those from previous studies involving HOX genes in PDAC but also reveal 
some contradictions with previously published data. This report is the first to show HOXA13 
overexpression in PDAC and we aim to pursue these findings by comparing HOXA13 
expression with patient survival rates by measuring protein levels on a PDAC-TMA with 
patient outcomes and we also aim to investigate the observed underexpression of HOXD13 in 
this cancer. The HOXD cluster remains an area of interest which we recommend for further 
investigation. Ideally, this might lead to a multivariate analysis study where several HOX 
genes can be considered simultaneously. 
In conclusion, it appears that HOX genes play a key role in PDAC, although more work is 
needed at the protein level to individually validate these. From this work we have identified 
overexpression of HOXA13 at the protein level and we wish to take this further in knockdown 
studies to investigate it’s role on chemoresistance and survival.
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Chapter	  IV:	  
4. Tumour architecture and global gene 
expression analysis in the CAM model
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4.1.Introduction
 The chicken embryo is a well-described animal model, dating back to Aristotle’s work and 
widely used throughout the last century, predominantly in angiogenesis studies (Vargas et al., 
2007). During development, the chorioallantois, one of three extra-embryonic membranes 
grows from around 6 cm2 on EDD6 to 65 cm2 by EDD14. Its primary function is to receive O2 
and eliminate CO2 through the pores of the shell. Chick embryos are naturally 
immunodeficient until EDD18, providing a window of opportunity for cancer-cell grafting before 
their dual immunity system comprising of T and B cells has appeared (Ribatti, 2014).The CAM 
assay has been shown to be suitable for the study of angiogenesis, metastasis and, more 
recently, an appropriate model for recapitulating the biology of several solid cancers 
(Dumartin et al., 2010; Richardson and Singh, 2003). As previously outlined in Chapter 1, 
there is a lack of robust, cost effective in vivo models of PDAC that recapitulate its tumour 
architecture and molecular phenotypes.  As well as being simple and inexpensive, the CAM 
model has already shown promising results in the study of migration and invasion of 
pancreatic cancer (Dumartin et al., 2010). Currently, the murine flank model (MFM) is often 
used as a moderately low cost option for remodelling PDAC and had been extensively used in 
this context. The MFM therefore seems a suitable benchmark to compare with the CAM 
model and justify it’s use in PDAC research. As well as the characterisation of tumour 
structure and cell-surface markers, changes in gene expression between cells grown in 
culture and cells grown in vivo remain of interest. For example, point mutations in codon 12 of 
the KRAS gene have been described in 95% of PDAC cases. To validate the use of the CAM 
model for targeted therapy, it is paramount to determine the mutational status of KRAS before 
(in vitro) and after (in vivo) cell challenge and therefore assess whether the status of the 
KRAS pathway is conserved and thus could be interfered with experimentally. Differential 
gene expression studies have been conducted in the CAM model. However, these assessed 
differential gene expression in a time-dependent manner during development in the 
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chorioallantois itself (Javerzat et al., 2009), but have not compared gene expression in 
cancer-derived cell lines and cell line derived tumours, grown on the CAM. 
 AsPC-1 and BxPC-3 are well characterised PDAC-derived cell lines with known molecular 
properties. AsPC-1 cells carry the mutations in KRAS, p16, SMAD4, p53 and are thought to 
have a mesenchymal phenotype based on molecular markers determined by gene expression 
profiling; AsPC-1 cells are resistant to gemcitabine. BxPC-3 cells are KRAS and p16 wild type 
with mutations in both SMAD4 and p53 genes. BxPC-3 are thought to have an epithelial 
phenotype and have been shown to be sensitive to gemcitabine (John P Neoptolemos, 
2010a).
To date there is no published evidence of a direct comparison between the MFM and the CAM 
model. Lai et al. used both MFM and CAM models, in colon and prostate cancer to determine 
the mechanisms by which plumbagin, a naturally occurring, biologically active plant 
compound inhibits tumour growth and angiogenesis. Although both in vivo models were used, 
they showed evidence of downregulation of the RAS/MAPK pathway in the mouse model only 
(Lai et al., 2012). 
4.2.Hypotheses
Based on the current lack of swift, cost effective in vivo models of PDAC and previously 
published data we hypothesised that PDAC could be accurately remodeled using the CAM 
assay including tumour architecture, molecular signature and key cancer pathways. 
We therefore investigated the accuracy of the CAM in remodelling PDAC architecture and 
molecular phenotypes. Previous work involving the CAM model has not investigated whether 
cancer pathways were conserved. In the context of PDAC, where 90% of cases are RAS 
mutants we explored RAS effector protein levels along the MAPK pathway. Also, as a 
response to the lack of data available on differential gene expression in tumours grown using 
107
the CAM model, we explored changes in gene expression in cell lines compared with CAM-
tumours to establish the suitability of the CAM model for targeted cancer therapy.
4.3.Aims of the study
• To recapitulate PDAC tumour architecture and molecular signature in the CAM model 
including desmoplasia and compare it with human disease.
• To compare the architecture in the CAM model to the conventional murine flank model 
(MFM). 
• To evaluate conservation of KRAS pathway at the protein level, using western blotting.
• To compare gene expression in cell lines and their tumour derivatives, using microarray 
analysis in AsPC-1 and BxPC-3 cell lines. 
• To determine whether the HOX gene profile of pancreatic cancer cell lines is conserved 
when cell-line derived tumours are grown on the CAM.
4.4.Results
4.4.1. Recapitulation on PDAC tumour architecture in CAM tumours
AsPC-1, BxPC-3, PaCa-3 and PancTu-1 cell lines were added to the avian CAM on EDD10. 
Figure 4.1 shows tumours derived from all 4 cell lines. All tumours were reproducibly grown 
and showed good vascularisation. AsPC-1 and PancTu-1 tumours were somewhat smaller in 
size than BxPC-3 and PaCa-3 tumours with no other differences in their macroscopic 
appearance. 
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A B
C D
! Figure 4.1: Macroscopic appearance of tumours grown on the CAM. A: Tumour derived from 
! AsPC-1 cells, B: Tumour derived from BxPC-3 cells, C: tumour derived from PaCa-3 cells and D: 
! tumour derived from PancTu-1 cells. 
Histopathological examination suggested that BxPC-3 tumours strongly resemble 
adenocarcinoma of the pancreas including gland-like structures, and the presence of dense 
stroma, characteristic of PDAC. The presence of blood vessels (light blue arrows) can be 
noted on the H & E sections (Figure 4.2) with strong Eosin staining as well as glandular 
structures (green arrows). The Desmoplastic reaction associated with PDAC is apparent in 
BxPC-3 tumours, as indicated by the dense stroma present throughout the section (Blue 
arrows).
PaCa-3 tumours have significant differences in their histology and resemble undifferentiated 
human PDAC. H&E sections show a poorly differentiated adenocarcinoma with multinucleated 
cells (yellow arrow). Eosin staining shows the presence of blood vessels (red arrow) and 
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eosinophilic structures. PancTu-1 CAM tumours also resemble human PDAC with 
desmoplasia present throughout the section. 
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AsPC%1 AsPC%1
BxPC%3 BxPC%3
PaCa%%3 PaCa%%3
PancTu%1 PancTu%1
! Figure 4.2: H&E staining of tumours derived from AsPC-1, BxPC-3, PaCa-3 and PancTu-1 
! cell-lines grown on the CAM of a developing chick embryo (Left panel x10 magnification. Right 
! panel x40 magnification). 
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4.4.2.Remodelling PDAC molecular signature in the CAM model
CAM-PDAC sections were stained using a panel of antibodies routinely used by the NHS 
pathology laboratory on patient biopsies to screen for PDAC. A resected case of human 
PDAC was also stained using the same panel in order to directly compare CAM tumours with 
human PDAC. (Figure 4.3, Figure 4.4, Figure 4.5 and Figure 4.6 display staining results for 
AsPC-1, BxPC-3, PaCa-3 and PancTu-1 CAM derived tumours respectively.)
BxPC-3 and PaCa-3 stained negative for vimentin while AsPC-1 stained positive and 
PancTu-1 tumours displayed focal staining. Vimentin is found in normal mesenchymal tissue 
and is considered to be a marker of mesenchymal differentiation.  It has previously been 
reported that PDAC tumours lack vimentin expression while other reports, however, have 
shown little, but some, vimentin expression in 30 cases of primary PDAC. More recently, 
vimentin-expressing cancers have been shown to have poorer prognostic outcomes than 
vimentin negative cases (Handra-Luca et al., 2011). In the case of human pancreas 
(displayed in Figure 4.7 (normal adjacent) and Figure 4.8 (tumour)), both normal adjacent and 
tumour sections stain positive for vimentin. 
Sections stained positive for smooth muscle actin (SMA) in stroma surrounding the tumour 
derived from AsPC-1, BxPC-3, PaCa-3 and PancTu-1 cell lines. SMA is produced by PSCs 
when activated from a quiescent to myofibroblastic state. These cells are responsible for the 
production of desmoplasia in pancreatic cancer. In normal human pancreas (Figure 4.7) SMA 
positivity is found around normal pancreatic lobules whereas in PDAC (Figure 4.8), positive 
staining is observed in cancer-associated stroma.
AsPC-1, BxPC-3 and PaCa-3 tumour stroma stained negative for desmin while PancTu-1 
tumours show localised staining in the blood vessels. Desmin is a muscle-specific protein 
found in cardiac, skeletal and smooth muscle and not typically associated with PDAC (Paulin 
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and Li, 2004). Desmin is a marker for pericytes, contractile cells found in the lining of blood 
vessels (Dumartin et al., 2010). In the human case displayed in Figures 4.7 and 4.8, both 
normal and tumour sections stained negative for Desmin.
Cytokeratin phenotyping is often used to determine cancers from unknown primary sites (Tot, 
2002). Cytokeratin 7 (CK7), a filament protein found in normal simple epithelial lining of the 
gastrointestinal tract and found at high concentration in carcinomas of the pancreas, was also 
detectable by IHC in BxPC-3, AsPC-1 and PancTu-1 tumours. Both human normal adjacent 
and human tumour sections were positive for CK7 (Figures 4.7/4.8).
Cytokeratin 19 (CK19) positivity was observed in all 4 cell line-derived tumours. CK19 is 
normally expressed in the lining of gastroenteropancreatic and hepatobillary tracts and most 
adenocarcinomas of the gastrointestinal tract (GIT) and pancreas are positive for this protein. 
CK19 has been shown to have prognostic values in neuroendocrine tumours especially in 
insulin-negative tumours. Unsurprisingly, the human case showed positive CK19 staining in 
both normal adjacent and tumour sections (Figures 4.7/4.8).
All 4 cell line-derived tumours stained negative for cytokeratin 20 (CK20). CK20 has 
previously been noted as positive in 44% (n=148) of reported cases of PDAC. In contrast, 
95% (n=78) of PDACs have been reported as positive for CK7 (98% in primaries and 87% in 
metastatic). Accordingly, 48% (n=22) of PDAC tumours were reported to be CK20+/CK7+ and 
41% (n=19) CK20-/CK7+ (Tot, 2002). Negative staining was observed in the human case in 
both normal adjacent and tumour sections with occasional, isolated cell positivity (Figures 
4.7/4.8).
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Tumours derived from all cell lines also tested positive for Cluster of Differentiation 5 (CD5), 
normally expressed in lymphocyte T cells and associated with lymphoma and leukaemia. 
Similarly, both normal-adjacent and tumour sections from human resected case stained 
positive for CD5 (Figures 4.7/4.8).
AsPC-1, BxPC-3, PaCa-3 and PancTu-1 tumours were all CD34 negative. CD34 is a marker 
for haematopoietic cells and is often used for assessment of intratumoural microvessel 
density. CD34 expressing PDACs have been associated with poor patient outcome, but not 
been shown to predict length of patient survival (Fujioka et al., 2001). Human normal adjacent 
tissue was primarily negative for CD34 with positive staining in the normal vascular 
framework. Human PDAC was also mainly negative, however, some scattered blood vessels 
stained positive in between tumour cells.
All cell-line derived tumours were negative for D2-40, normally found in lymphatic endothelium 
and associated with breast cancer, Kaposi’s sarcoma and a subset of angiosarcomas (Kahn 
et al., 2002). D2-40 staining was negative in normal-adjacent tissue and showed some 
positivity in normal stromal lymphatics and human PDAC showed similar staining (Figures 
4.7/4.8).
Collagen type IV is up-regulated in cancer associated stroma and is the main component of 
the basement membrane (Ohlund et al., 2013). All 4 types of CAM tumours stained negative 
for Collagen type IV. Positive staining was observed in normal pancreatic lobules in normal-
adjacent tissue and was positive in stromal cells around pancreatic glands in human PDAC 
sections (Figures 4.7/4.8).
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CAM-grown tumours show remarkable similarities to human pancreatic tissue and in 
particular to ductal adenocarcinoma shown by keratin profiling and stromal response markers. 
Also, the glandular structures and tumour architecture are also present in CAM tumours thus 
making the CAM model an effective tool for PDAC tumour remodeling.
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Vimen&n SMA
Desmin CK7
CK20 CK19
CD5 CD34
D240 Collagen:IV
! Figure 4.3: Panel of IHC stains of AsPC-1 derived CAM tumours (x10 magnification). This 
! panel is routinely used by NHS pathologists on human biopsies to diagnose PDAC. 
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Vimen&n SMA
Desmin CK7
CK20 CK19
CD5 CD34
D240 Collagen:IV
! Figure 4.4: Panel of IHC stains of BxPC-3 derived CAM tumours (x10 magnification). This 
! panel is routinely used by NHS pathologists on human biopsies to diagnose PDAC.
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Vimen&n SMA
Desmin CK7
CK20 CK19
CD5 CD34
D240 Collagen:IV
! Figure 4.5: Panel of IHC stains of PaCa-3 derived CAM tumours (x10 magnification). This 
! panel is routinely used by NHS pathologists on human biopsies to diagnose PDAC.
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Vimen&n SMA
Desmin CK7
CK20 CK19
CD5 CD34
D240 Collagen:IV
! Figure 4.6: Panel of IHC stains of PancTu-1 derived CAM tumours (x10 magnification). This 
! panel is routinely used by NHS pathologists on human biopsies to diagnose PDAC.
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IHC AsPC-1 (CAM) BxPC-3 (CAM) PaCa-3 (CAM) PancTu-1 (CAM)
Vimentin + - - + focal
SMA + in stroma + in stroma + in stroma + in stroma
Desmin - - - + in blood vessels
CK7 + focal + in stroma - -
CK20 - - - -
CK19 + + + + 
CD5 + + very focal + +
CD34 - - - -
D2-40 - - - -
Collagen IV - - - -
! Table 4.1: Summary of IHC panel of antibodies used to stain AsPC-1, BxPC-3, PaCa-3 and 
! PancTu-1 CAM tumour. +: positive staining. -: Negative staining.
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Vimen&n SMA
Desmin CK7
CK20 CK19
CD5 CD34
D240 Collagen:IV
! Figure 4.7: Panel of IHC stains of human normal-adjacent tissue used by NHS pathologists to 
! diagnose PDAC.
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Vimen&n SMA
CK7
CK20 CK19
CD5 CD34
Desmin
D240 Collagen:IV
! Figure 4.8: Panel of IHC stains of human tumour tissue used by NHS pathologists to diagnose 
! PDAC.
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IHC Human Normal (adjacent) Human Tumour
Vimentin + +
SMA + around normal pancreatic lobules + in the stromal cells around single 
infiltrative glands and cells
Desmin - -
CK7 + +
CK20 -/occasional cell + -/occasional cell +
CK19 + +
CD5 + +
CD34 -/ + in the normal vascular framework -/ + in scattered blood vessels in 
between tumour cells
D2-40 -/+ in normal stromal lymphatics -/+ in scattered lymphatics
Collagen IV + around normal pancreatic  lobules + in the stromal cells around single 
infiltrative glands and cells
! Table 4.2: Summary of IHC panel of antibodies used to stain a human PDAC tumour and 
! surrounding normal-adjacent tissue. +: positive staining. -: Negative staining.
4.4.3.  AsPC-1 and BxPC-3 tumours in MFM
AsPC-1 and BxPC-3 cells were also transferred to the flank of BALB/c nude mice, grown for 
4-6 weeks and tumours were resected shortly after sacrifice. They were then embedded in 
paraffin blocks and sent to the Royal Surrey County Hospital pathology department for routine 
ICH staining (as previously shown for CAM and human tumours). AsPC-1 derived mouse 
tumours strongly resembled a poorly differentiated adenocarcinoma and bore some 
similarities to human melanoma (H&E staining in Figure 5.19). AsPC-1-Mouse tumours 
stained positive for the keratins, CK7, CK19 (patchy) and CK20 (patchy). Positive staining 
was also observed in vimentin stained sections, however, tumours appeared prominently 
negative for CD5 (some focal staining) and desmin. The stromal component of the tumours 
showed positivity in SMA, Collagen IV, CD34 and D2-40 stained sections (Figure 5.20) 
(Staining results summarised in Table 5.3)
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BxPC-3-mouse tumours exhibited more similarities with BxPC-3-CAM tumours than tumours 
derived from AsPC-1 cells in both models. Strong membranous and cytoplasmic staining was 
observed in both CK7 and CK19 stained sections. There appears to be a lot of background 
staining in these sections. Negative staining was observed in CK20 and desmin stained 
sections with the latter displaying minimal stromal staining and diffusion staining in the 
surrounding skeletal muscle from the mouse flank. Stromal positivity was observed on SMA 
stained sections as well as in Collagen IV and CD34 stained sections although collagen IV 
and CD34  stains were difficult to interpret due to the extensive background staining (Figure 
5.21) (Staining results summarised in table 5.3).
These reports have enabled a direct comparison between the CAM and traditional MFM. In 
the context of this disease, it appears that there is a lot more interaction between tumour and 
surrounding tissue (shown by diffusion staining) in the mouse model which could lead to over-
interpretation. The mouse model showed strong staining with keratins, however, the stromal 
response was difficult to interpret due to background diffusion positivity. In addition, the CAM 
model displayed glandular structures, closely mimicking human PDAC and generally the 
tumour architecture was more extensive in this model. 
BxPC%3AsPC%1
! Figure 4.9: H&E staining of tumours derived from AsPC-1 and BxPC-3 cell-lines grown in a 
! nude mouse (x40 magnification).
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Vimen&n SMA
Desmin CK7
CK20 CK19
CD5 CD34
D240 Collagen:IV
! Figure 4.10: Panel of IHC stains of AsPC-1 derived mouse tumours (x20 magnification). This 
! panel is routinely used by NHS pathologists on human biopsies to diagnose PDAC.
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Desmin
Vimen(n SMA
CK7
CK20 CK19
CD5 CD34
D240 Collagen:IV
! Figure 4.11: Panel of IHC stains of BxPC-3 derived mouse tumours (x20 magnification). This 
! panel is routinely used by NHS pathologists on human biopsies to diagnose PDAC.
126
IHC AsPC-1 (mouse) BxPC-3 (mouse)
Vimentin + + in stroma
SMA + in stroma + in stroma
Desmin - -
CK7 + +
CK20 + very focal -
CK19 + very focal +
CD5 + very focal Not interpretable
CD34 + in stroma + in stroma (difficult to interpret)
D2-40 + in stroma -
Collagen IV + in stroma + in stroma (difficult to interpret)
! Table 4.3: Summary of IHC panel of antibodies used to stain in mouse tumours. +: positive 
! staining. -: Negative staining.
4.4.4.RAS/MAPK pathway in the CAM assay 
AsPC-1 and BxPC-3 cells were added to the CAM of a developing chick embryo. Protein 
levels of downstream effectors of RAS were measured by western blot in order to assess 
maintenance of the RAS/MAPK pathway when cells were transferred from culture in vitro, to 
growing in a solid tumour in vivo. In order to consider the CAM model as a suitable in vivo 
model, levels of protein present therein were also compared with those in a conventional 
MFM (MFM has been extensively used throughout the literature in the context of pancreatic 
cancer) (Figure 4.12).
Results showed similar amounts of β-actin suggesting equal amounts of protein were added 
to the sodium dodecyl sulphate (SDS) gel. Phosphorylated-mitogen activated protein kinase 
kinase (pMEK), phosphorylated-extracelullar signal regulated kinase (pERK) were detected in 
all cases. Levels of pMEK and pERK were higher in both AsPC-1 and BxPC-3 cell lines 
compared with their respective derived CAM tumours. Levels of pMEK were lower in AsPC-1 
mouse tumours compared with AsPC-1 CAM tumours whereas levels of pMEK were higher in 
BxPC-3 mouse tumours compared with BxPC-3 CAM tumours. Protein levels of pERK were 
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higher in AsPC-1 murine tumours compared with CAM-tumour and lower in mouse tumours 
compared with AsPC-1 cell line. The amount of total ERK (ΣERK) was found to be lower in 
AsPC-1 mouse tumours compared with both AsPC-1 CAM tumours and AsPC-1 cell lines. In 
BxPC-3 tumours, pMEK levels were higher in mouse tumours compared with both BxPC-3 
CAM tumours and BxPC-3 cells. In contrast, levels of pERK were comparable in both mouse 
and CAM tumours. Finally, ΣERK was higher in both BxPC-3 CAM tumours and BxPC-3 cells 
(with similar levels to one another) compared with BxPC-3 mouse tumours.
 Surprisingly, BxPC-3 cells are RAS wild type whilst AsPC-1 are RAS mutant (John P 
Neoptolemos, 2010a). These results show that protein levels of the downstream effectors of 
RAS are more consistent in the CAM model and therefore suggest that CAM tumours are 
more representative of the cell line from which they were derived when compared with the 
MFM. 
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! Figure 4.12: Western blot analysis of phosphorilated MEK and ERK pathway of AsPC-1 and 
! BxPC-3 cell lines compared with AsPC-1 and BxPC-3 derived CAM tumours and AsPC-1 and 
! BxPC-3 tumours grown in the mouse. Results were normalised using ß-actin.
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4.4.5.Microarray analysis in BxPC-3 cell-line versus BxPC-3 derived 
tumours
To compare gene expression in BxPC-3 cell line versus BxPC-3-CAM tumours, microarray 
analysis was carried out using two samples of cell line RNA and 3 samples of CAM tumours 
(each sample contained a pool of RNA from 2 different CAM tumours). T tests were used to 
compare gene expression levels between the two groups. A summary of the most differentially 
expressed genes are displayed in the heatmap in Figure 4.13 and candidate targets were 
summarised and validated by RT-PCR in Figure 4.14.
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! Figure 4.13: Heatmap of differentially expressed genes in BxPC-3 cell line compared with 
! BxPC-3 derived CAM tumours with a fold change (FC) >5. C1 and C2 represent BxPC-3 cell line.  
! (RNA from 4 independent extractions from different passages. T1-T3 represent BxPC-3 CAM 
! tumours (RNA was extracted from 6 CAM tumours and pooled into pairs).
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Amongst the most differentially expressed genes was Egl-9 Family Hypoxia Inducible Factor 3 
(EGLN3) (Figure 4.13) also referred to as of Propyl Hydroxyl-3 (PHD3) in the literature. 
EGLN3 or PHD3 was up-regulated in the CAM tumours compared with the BxPC-3 cells from 
which they were derived. PHD3 mediates oxygen-dependant degradation of Hypoxia 
Inducible Factor 1 (HIF-1) which, under normoxic cellular conditions is subject to rapid 
degradation (2013). PHD3 has been found to be upregulated in human pancreatic cancer 
shown by qPCR, and IHC reports have shown strong immuno-staining in ductal cancer with 
cytoplasmic localisation. Tumour hypoxia has been shown to be consistent with increased 
therapeutic resistance, invasion and metastasis and poor survival rates. However, Su et al. 
reported that PHD3 up-regulation resulted in reduction in tumour size by abrogation of 
angiogenesis leading to induction of apoptosis shown by cleaved-caspase-3 activation. The 
specific function of PHD3 is thus poorly understood but remains an area of interest in 
pancreatic cancer research due to its high expression in tumour tissue (Su et al., 2010). 
The Caveolin-1 (CAV1) gene was also found to be down-regulated in CAM tumours compared 
with their BxPC-3 predecessors grown in vitro. CAV1 codes for membrane proteins that are 
required for the formation of small plasma membrane invaginations, caveolae, involved in 
cellular trafficking processes and numerous intracellular signalling pathways. CAV1 has been 
previously described as having the characteristics of a tumour suppressor gene, for instance, 
CAV1 knockout mice have displayed lung hyperplasia and also a predisposition to mammary 
and skin hyperplasia. However, evidence to the contrary has also been reported in the 
literature where it has been shown to promote metastasis and multi-drug resistance. CAV1 
has also been strongly linked to the RAS/RAF/ERK pathway which is of particular interest in 
pancreatic cancer. Indeed, CAV1 expression has been shown to correlate with a reduction in 
activity of the pathway and equally, down-regulation of CAV1 by small interfering RNA 
(siRNA ) leads to MAPK/ERK activation (Quest et al., 2013). More specifically, Han et al. have 
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reported that knockdown of CAV1 in BxPC-3 cells promoted cell invasion (Han and Zhu, 
2010).  In human cancer, however, CAV1 positive patients has been shown to have a 
significantly poorer prognosis than CAV1 negative patients (n=79). Positive expression also 
correlated with tumour diameter and histopathological grade. Although CAV1 appears to have 
strong implications in pancreatic tumourogenesis, its specific mechanisms are still poorly 
understood (Suzuoki et al., 2002).
Gene expression of Trefoil Factor 3 (TFF3) was found to be significantly higher in BxPC-3-
CAM tumours compared with BxPC-3 cells grown in vitro (Figure 4.13). These findings were 
validated by RT-PCR (Figure 4.14). Trefoil family (TFF)-domain peptides are commonly found 
in goblet cells of the gastrointestinal tract and have been found to be up-regulated in areas of 
cellular damage such as ulcers thereby promoting wound healing by preventing apoptosis 
(Matsunaga et al., 2009; Wright et al., 1997). These properties have equipped TTF3 peptides 
with an oncogenic potential associated with cell migration, cell proliferation and angiogenesis. 
TFF3 has been reported to be up-regulated in gastric cancer and a strong case has been 
made for its use as a potential biomarker (Huang et al., 2014). Meng et al. described a 
significantly higher expression in cancer patients with 51.1% of cases staining positive for 
TFF3 (n=90) and Kaplan-Meier survival analysis showed a significantly longer survival (in the 
first 3 years after diagnosis) in patients whose IHC reports showed no TFF3 expression 
(Meng et al., 2013). Up-regulation of TFF3 has been described in endometrial (Mhawech-
Fauceglia et al., 2013), breast (Kannan et al., 2010) and colon cancer (Yio et al., 2005) 
although some reports have suggested that under-expression of TFF3 plays a key role in 
colonic carcinogenesis (John et al., 2007). Little, if anything, is known about the involvement 
of TFF3 in pancreatic cancer. A report has shown TFF3 expression in pancreatic islets and 
provided some evidence that TFF3 may act though the EGFR and akt signalling pathways 
(Fueger et al., 2008). Whilst TFF3 seems an attractive candidate as a biomarker for certain 
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gastrointestinal cancers, no evidence has placed TFF3 in the context of pancreatic cancer 
and more specifically PDAC. 
The Porcupine Homologue gene (PORCN) was found to be down-regulated in BxPC-3-CAM 
tumours compared with BxPC-3 cells grown in vitro (validation of gene expression Figure 
4.14). PORCN encodes endoplasmic reticulum proteins responsible and essential for the 
processing of Wnt proteins. PORCN is a key developmental gene and embryonic knockout is 
lethal (Covey et al., 2012). The Wnt pathway has been shown to be dysregulated in a number 
of cancers. Targeting the Wnt pathway, therefore, seems like an attractive therapeutic goal 
and indeed inhibition of the Wnt pathway has been achieved by antagonising PORCN in 
breast cancer cell lines and transgenic mice, resulting in tumour regression (Proffitt et al., 
2013). PORCN inhibitors have also been tested in head and neck cancers with similar results 
(Liu et al., 2013).
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Gene expression in BxPC-3 CAM tumours versus BxPC-3 cell line 
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! Figure 4.14: Validation of microarray results. Gene expression levels measured by RT-PCR of 
! most differential expression in BxPC-3 cell-line compared with BxPC-3 CAM tumours. Results 
! were normalised using β-actin. Error bar calculated using SEM and statistical significance using 
! t-test (p≤0.05*, p≤0.01**, p≤0.001***, p≤0.0001**** ). Y axis was Log10 scaled. Experiment was 
! performed on 3 biological repeats (n=3) in both BxPC-3 cells and BxPC-3-CAM tumours using 3 
! technical repeats of each.
GeneGo was used to analyse the most dis-regulated pathways. Results of most dysregulated 
pathways are summarised in Figure 4.15. Results showed that apoptosis and survival is the 
most dys-regulated pathway, followed by hedgehog signalling.
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! Figure 4.15: Summary of most dysregulated pathways in BxPC-3 cells versus BxPC-3 CAM 
! tumours. Yellow bars represent the comparison between BxPC-3 cells and BxPC-3-CAM 
! tumours. (Red and blue bars summarise a different experiment not included in this work.)
In the apoptosis and survival pathway summarised in figure 4.16, results show that MAK3K5 is 
downregulated when BxPC-3 cells change form an in vitro environment to growing in a CAM-
tumour. Results also show a down-regulation of Fas associated death domain (FADD). 
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! Figure 4.16: Apoptosis and survival (fas signalling cascade). Thermometers numbered ‘1’ 
! represent the change in gene expression when BxPC-3 cells change from being cultured in vitro 
! to growing in the CAM-model. Blue thermometers represent gene down-regulation.
In the Hedgehog signalling pathway summarised in figure 4.17, results show that Gli-3 and 
Gli-3R are downregulated when BxPC-3 cells change form an in vitro environment to growing 
in a CAM-tumour.
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! Figure 4.17: Hedgehog signalling pathway. Thermometers numbered ‘1’ represent the change 
! in gene expression when BxPC-3 cells change from being cultured in vitro to growing in the 
! CAM-model. Blue thermometers represent gene down-regulation.
4.4.6.Microarray analysis in AsPC-1 cell-line versus AsPC-1 derived 
tumours
Microarray analysis was also performed in AsPC-1 cells to compare gene expression in cells 
maintained in culture with expression in tumours resected from the CAM. T tests were used to 
compare gene expression levels between the two groups. A total of 2,668 genes were 
identified as having a significant change in expression (P<0.05) in tumours compared with 
cell-lines. Figure 4.15 shows the heatmap of the most differentially expressed genes with a 
fold change greater than 5 and their associated gene symbol if available. Differential gene 
expression was validated by qPCR, results are summarised in Figure 4.16.
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! Figure 4.18: Heatmap of differentially expressed probes in AsPC-1 cell line compared with 
! AsPC-1 CAM tumours with a fold change (FC)>5. C1-C4 represent AsPC-1 cell line (RNA from 4 
! independent extractions from different passages. T1-T4 represent AsPC-1 CAM tumours (RNA 
! was extracted from 8 CAM tumours and pooled into pairs).
Results showed that Haem Carrier Protein 1 (HCP1) was up-regulated in AsPC-1-CAM 
tumours compared with AsPC-1 cell line.  HCP1 codes for a transmembrane protein 
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responsible for the transport of haem and is normally expressed in the small intestine and 
found in the duodenum and jejunum.  Recently, HCP1 has been identified as the primary 
transporter of dietary folates and is therefore also referred to as Proton-Coupled Folate 
Transporter (PCFT) (Laftah et al., 2009) and has been shown to be highly expressed in solid 
tumours. HCP1 functions optimally at a pH of 5.5 which is conducive to reduction in the 
slightly acidic microenvironment of solid tumours (Desmoulin et al., 2012).
Historically, the antifolate drug Aminopterin (AMT) was the first substance to induce remission 
in children with acute lymphoblastic leukaemia. Since then, other antifolates such as 
Methotrexate (MTX) have proven clinically successful in several malignancies including 
breast, bladder and lung cancer, brain medulloblastoma, chronic myeloid leukaemia and 
primary CNS lymphoma. Currently it is the ‘gold standard’ treatment for rheumatoid arthritis 
(Abolmaali et al., 2013; Desmoulin et al., 2012). There are currently no reports that link over-
expression of PCFT with PDAC. In the CAM model, the developing embryo is contained within 
a self-sufficient system that contains all the essential nutrients required for embryonic growth 
until hatching (including folates) (Sherwood et al., 1993). This leads to the belief that up-
regulation of HCP1/PCFT may be caused by the environmental change from a folate-poor, to 
a folate-rich, environment upon transfer of cancer cells from an in vitro culture medium to an 
in vivo microenvironment. 
Tumour Necrosis Factor (TNF) Receptor-Associated Factor 7 (TRAF7) was found to be down-
regulated in AsPC-1 CAM tumours compared with their cellular predecessors grown in vitro. 
TRAF7 codes for an E3 ubiquitin ligase (responsible for ubiquitination), and is one of 7 in the 
TRAF protein family of proteins. The general function of TRAF proteins is to assemble 
cytoplasmic signal transducers with regulatory molecules downstream of receptors. The 
specific cellular functions of TRAF7 are still poorly understood. However, there is evidence 
that TRAF7 interacts with a number of downstream targets, sometimes resulting in 
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contradictory effects. TRAF7 has been shown to interact with MEKK3 (MAP3K3) a key 
effector of the TNF-dependent Nuclear Factor Kappa-Light-Chain-Enhancer of activated B 
cells (NF-KB) pathway responsible for regulating immune responses to infection. Co-
expression of TRAF7 and MEKK3 leads to activation of JNK and p38 MAP Kinases (Zotti et 
al., 2012).  In keeping with this, over-expression of TRAF7 has been shown to lead to cell 
death and promote apoptotic pathways (Xu et al., 2004; Zotti et al., 2012). A recent study has 
shown that TRAF7 is down-regulated in breast cancer which leads to cytosolic accumulation 
of p53 and correlates with poor prognosis (Wang et al., 2013). 
SMAD-ubiquitination regulatory factor 1 (SMURF1) (also an E3 ubiquitin ligase) was found to 
be down-regulated in AsPC-1 CAM tumours compared with the AsPC-1 cells they were 
derived from (Results were validated by qPCR, Figure 4.16). As well as SMAD ubiquitination, 
SMURF1 induces degradation of RAS Homologue family member A (RhoA) which plays a role 
in cell motility. Kwon et al. showed that SMURF1 is induced by EGF and that EGFR and 
ERK1 and ERK2 play a role in its up-regulation in breast cancer. Over-expression of SMURF1 
leads to down-regulation of RhoA which blocks cell migration and invasion (Kwon et al., 
2013). SMURF1 has been found to be amplified in pancreatic cancer by fluorescence in situ 
hybridisation (FISH) (but only in 4.2% (4 out of 95 case of primary disease)). Interestingly, 
knock-down of SMURF1 in AsPC-1 cells has no effect on cell growth, however, it does reduce 
cell invasion and anchorage-independent growth (Kwei et al., 2011). Amplification as well as 
over-expression have also been reported in 6 and 4 cases respectively (n=43) but were not 
shown to have any significant bearing on patient survival (Loukopoulos et al., 2007). In this 
study, the reason behind SMURF1 down-regulation in CAM tumours compared with cell lines 
is currently unknown, however, SMURF1 seems to be a gene of interest in PDAC research. 
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Dual oxidase 2 (DUOX2) was found to be down-regulated in AsPC-1-CAM tumours compared 
with AsPC-1 cells. DUOX2 is part of the Nicotinamide Adenine Dinucleotide Phosphate-
Oxidase (NADPH) oxidase (Nox) gene family and is responsible for the biosynthesis of thyroid 
hormone and generating reactive oxygen species (ROS) (which include H2O2) playing a 
pivotal role in immunity in the respiratory system epithelium and gastrointestinal tract. 
DUOX2 has been found to be up-regulated in several cancers including lung, prostate, breast, 
colon and pancreatic cancer cell lines (Wu et al., 2013).
Interferon-γ (IFN-γ) is a cytokine involved in immunity which inhibits tumour cell growth and 
has been shown to induce expression of DUOX2. This, in turn, leads to a significant increase 
in the intracellular ROS and extracellular H2O2 which is dependent on the p38-MAPK 
pathway, however, the cellular consequences are still being investigated (Wu et al., 2011). 
Microarray analysis showed that proprotein convertase subtilisin kexin type 9 (PCSK9) was 
down-regulated in AsPC-1-CAM tumours compared with AsPC-1 cells grown in vitro. PCSK9 
is normally expressed in the liver (with a low level of expression detectable in the small 
intestine and kidney) and is key player in cholesterol homeostasis and has been linked to 
hypercholesterolemia, a genetic disorder also caused by mutations in low-density lipoprotein 
receptor (LDLR) (Ly et al., 2014). PCSK9 has been shown to down-regulate LDLR expression 
and low levels of low density lipoproteins (LDLs) have been associated with an increased risk 
of cancer (Benn et al., 2011). There is currently no evidence that links PCSK9 dysregulation in 
PDAC.
F-actin-capping protein subunit alpha-2 (CAPZA2) was found to be down-regulated in 
AsPC-1-CAM tumours compared with AsPC-1 cell lines. CAPZA2 binds to the growing ends 
of actin filaments (which are also referred to as barbed ends), facilitated by calcium ions. 
CAPZA2 gene amplification has been reported in several types of cancer including human 
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renal cell carcinoma and glioblastoma and may be involved in cell motility. It’s use as a 
potential biomarker in breast cancer has been identified by increased levels of CAPZA2 
protein level identified by IHC (Ou et al., 2008). There is currently no evidence of CAPZA2 
being linked to PDAC. 
Eukaryotic translation elongation factor 1 alpha 2 (EEF1A2) gene was found to be up-
regulated in AsPC-1-CAM tumours compared with the AsPC-1 cell-line. EEF1A2 is a 
housekeeping gene responsible for the delivery of aminoacyl tRNAs to ribosomes and is 
normally expressed in the heart, brain and skeletal muscle. A strong case has been made for 
its involvement in the development of ovarian, lung, breast and hepatocellular tumours but 
also, more pertinently, in pancreatic cancer.  Over-expression of EEF1A2 was observed in 
PDAC cell lines by Xu et al. who also showed, by siRNA knockdown, that EEF1A2 plays a 
role in invasion, migration and metastasis (Xu et al., 2013). EEF1A2 was also shown to be 
over-expressed in primary pancreatic cancer by IHC and western blotting with little or no 
expression in either chronic pancreatitis or normal pancreatic tissue. Over-expression of 
EEF1A2 was found to promote cell growth, survival and invasion in vivo (Cao et al., 2009).
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! Figure 4.19: Validation of microarray results. Gene expression levels measured by RT-PCR of 
! most differentially expressed genes in AsPC-1 cell-line compared with AsPC-1 CAM tumours. 
! Results were normalised using β-actin. Error bar calculated using SEM and statistical 
! significance using t-test (p≤0.05*, p≤0.01**, p≤0.001*** ). Y axis was Log10 scaled. Experiment 
! was performed on 3 biological repeats (n=3) in both AsPC-1 cells and AsPC-1-CAM tumours 
! using 3 technical repeats of each.
GeneGo was used to analyse the most disregulated pathways. Results of most dysregulated 
pathways are summarised in Figure 4.20. Results showed that the oxidative phosphorilation 
pathway was the most dysregulated pathway followed by TGF-beta dependent induction of of 
EMT via RhoA, PI3K and ILK. 
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! Figure 4.20: Summary of most dysregulated pathways when AsPC-1 cells go from an in vitro to 
! an in ovo tumour environment. Yellow bars represent the comparison between AsPC-1 cells and 
! AsPC-1-CAM tumours. 
In the oxidative phosphoriation pathway, NADH-ubiquinone oxidoreductase was down 
regulated in AsPC-1 tumour compared with AsPC-1 cells grown in vitro. Respiratory complex III 
and ATP synthase were also downregulated in tumours whereas Cytochrome c oxidase was 
upregulated in BxPC-3 tumours compared with BxPC-3 cells. 
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   Figure 4.21: Oxidative phosphorilation. Thermometers numbered represent the change in gene 
! expression when AsPC-1 cells change from being cultured in vitro to growing in the CAM-model. 
! Blue thermometers represent gene down-regulation and red thermometers represent 
! upregulation of gene expression.
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Beta-catenin and SLUG were found to be down regulated in AsPC-1 tumours compared with 
AsPC-1 cells whereas tropomyosin-1 was found to be upregulated in AsPC-1 CAM tumours 
compared with AsPC-1 cells.
! Figure 4.22: TGF-beta dependent induction of of EMT via RhoA, PI3K and ILK. 
! Thermometers numbered represent the change in gene expression when AsPC-1 cells change 
! from being cultured in vitro to growing in the CAM-model. Blue thermometers represent gene 
! down-regulation and red thermometers represent upregulation of gene expression.
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4.4.7.HOX gene expression in pancreatic cancer cell lines versus 
cell-line derived CAM tumours
In order to establish whether HOX gene expression is maintained when cells grown in vitro 
are transferred to an in vivo environment on the CAM, quantitative RT-PCR was performed to 
compare HOX gene expression in pancreatic cancer cell lines with cell line derived CAM-
tumours in order to evaluate changes in HOX gene expression. Generally, HOX gene 
expression was found to be lower in the CAM tumours compared with the cell-lines they were 
derived from with the exception of PaCa-3 cells where, predominantly HOX gene expression 
was higher in PaCa-3 tumours compared with PaCa-3 cell line.
Results for HOX gene expression in cell lines versus CAM tumours in the HOXA cluster are 
summarised in Figures 4.17-4.20. Results show that HOXA gene expression has a similar 
general pattern cell lines compared with their respective derived tumours. However, some 
significant differences can be observed. HOXA1 expression was higher in both BxPC-3 
(p≤0.05) and PaCa-3 cell lines compared with their derived CAM tumours (Figures 4.18 and 
4.19 respectively). HOXA4 expression was significantly higher in AsPC-1 (p≤0.05) (Figure 
4.17) and BxPC-3 (p≤0.01) (Figure 4.18) CAM-tumours compared with their cell-lines while 
HOXA6 expression was higher in AsPC-1 (p≤0.01) (Figure 4.17), BxPC-3 (p≤0.01) (Figure 
4.18) and PancTu-1(p≤0.06) (Figure 4.20) cell lines compared with CAM tumours and 
appeared to have been lost completely in AsPC-1 (Figure 4.17) and BxPC-3 (Figure 4.18) cell 
lines.
HOXA10 expression was higher AsPC-1 (Figure 4.17) and PaCa-3 (Figure 4.19) cells 
compared with CAM-tumours.
There were significant changes in HOXA13 expression. HOXA13 expression was higher in 
AsPC-1 (p≤0.01) (Figure 4.17) and PancTu-1 (p≤0.05) (Figure 4.20) cell-lines compared with 
CAM tumours, however, the contrary was observed in PaCa-3 cells (p≤0.05) (Figure 4.19). 
Both HOXA2 (p≤0.05) and HOXA5 (p≤0.05) genes were upregulated in PaCa-3 CAM-tumours 
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compared with PaCa-3 cells (Figure 4.19) and down regulated in PancTu-1 tumours 
compared with PancTu-1 cells (Figure 4.20).
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! Figure 4.23: HOX gene expression levels measured by RT-PCR in AsPC-1 cell-line 
! compared with AsPC-1 derived tumours in the HOXA cluster. Results were normalised using 
! β-actin. Error bar calculated using SEM and statistical significance using T-test (p≤0.05*, 
! p≤0.01**, p≤0.001*** ). Genes represented in green have previously been reported to have a 
! role in pancreas development. Y axis was Log10 scaled. Experiment was performed on 3 
! biological repeats (n=3) using 3 technical repeats of each.
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HOXA expression in BxPC-3 cells versus CAM tumours
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! Figure 4.24: HOX gene expression levels measured by RT-PCR in BxPC-3 cell-line compared 
! with BxPC-3 derived tumours in the HOXA cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (p≤0.05*, p≤0.01**, 
! p≤0.001*** ). Genes represented in green have previously been reported to have a role in 
! pancreas development. Y axis was Log10 scaled.Experiment was performed on 3 biological 
! repeats (n=3) using 3 technical repeats of each.
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HOXA expression in PaCa-3 cells versus CAM tumours
A1 A2 A3 A4 A5 A6 A7 A9 A10 A11 A13
1
10
100
1000
HOX gene
RQ
 (r
ela
tiv
e t
o β
-a
cti
n)
PaCa-3 cells
PaCa-3-CAM
*
** *
*
*
1 2 3 4 5 6 7 9 10 11 13HOXA
! Figure 4.25: HOX gene expression levels measured by RT-PCR in PaCa-3 cell-line compared 
! with PaCa-3 derived tumours in the HOXA cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (p≤0.05*, p≤0.01**, 
! p≤0.001*** ). Genes represented in green have previously been reported to have a role in 
! pancreas development. Y axis was Log10 scaled. Experiment was performed on 3 biological 
! repeats (n=3) using 3 technical repeats of each.
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HOXA expression in PancTu-1 cells versus CAM tumours
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! Figure 4.26: HOX gene expression levels measured by RT-PCR in PancTu-1 cell-line compared 
! with PancTu-1 derived tumours in the HOXA cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (p≤0.05*, p≤0.01**, 
! p≤0.001*** ). Genes represented in green have previously been reported to have a role in 
! pancreas development. Y axis was Log10 scaled.Experiment was performed on 3 biological 
! repeats (n=3) using 3 technical repeats of each.
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Comparison of HOXB gene expression in CAM tumours is displayed in Figure 4.21-4.24. In 
the HOXB cluster, AsPC-1 and BxPC-3 showed few differences between CAM tumours and 
cell-lines whereas, overall, PaCa-3 tumours showed significantly higher expression in tumours 
compared with PaCa-3 cells and PancTu-1 tumours showed a significantly lower gene 
expression in tumours compared with PancTu-1 cells. 
In AsPC-1 cells, only HOXB9 was differentially expressed and was found to be down-
regulated in AsPC-1 CAM tumours (P≤0.05) (Figure 4.21). Interestingly, this was also 
observed in BxPC-3 tumours (P≤0.01)(Figure 4.22). HOXB4 and HOXB7, on the other hand, 
were significantly up-regulated in BxPC-3 CAM tumours (P≤0.05) and expression was 
completely absent in BxPC-3 cells (Figure 4.22).
In PaCa-3 cells, expression of HOXB2 (p≤0.05), HOXB3, (p≤0.01) HOXB4 (p≤0.05),HOXB5 
(p≤0.01) and HOXB6 (p≤0.001) was significantly higher in PaCa-3 tumours compared with 
PaCa-3 cells. HOXB9 (p≤0.001), however, was found to down-regulated in CAM tumours 
compared with PaCa-3 cells (Figure 4.23).
HOXB5 (p≤0.01), HOXB9 (p≤0.0001) and HOXB13 (p≤0.01) were all down-regulated in 
PanTu-1 CAM tumours compared with PancTu-1 cells (Figure 4.24).
Notably, HOXB9 is the only gene to be universally down regulated in all 4 types of CAM 
derived tumours compared with their cellular predecessors. 
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HOXB expression in AsPC-1 cells versus CAM tumours
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! Figure 4.27: HOX gene expression levels measured by RT-PCR in AsPC-1 cell-line compared 
! with AsPC-1 derived tumours in the HOXB cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (p≤0.05*, p≤0.01**, 
! p≤0.001***). Genes represented in green have been previously described as having a role in 
! pancreas development, genes represented in yellow a role in metastasis suppression and genes 
! represented in red described as over expressed in PDAC. Y axis was Log10 scaled. Experiment 
! was performed on 3 biological repeats (n=3) using 3 technical repeats of each.
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HOXB expression in BxPC-3 cells versus CAM tumours
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! Figure 4.28: HOX gene expression levels measured by RT-PCR in BxPC-3 cell-line compared 
! with BxPC-3 derived tumours in the HOXB cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (p≤0.05*, p≤0.01**, 
! p≤0.001***). Genes represented in green have been previously described as having a role in 
! pancreas development, genes represented in yellow a role in metastasis suppression and genes 
! represented in red described as over expressed in PDAC. Y axis was Log10 scaled. Experiment 
! was performed on 3 biological repeats (n=3) using 3 technical repeats of each.
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HOXB expression in PaCa-3 cells versus CAM tumours
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! Figure 4.29: HOX gene expression levels measured by RT-PCR in PaCa-3 cell-line compared 
! with PaCa-3 derived tumours in the HOXB cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (p≤0.05*, p≤0.01**, 
! p≤0.001***). Genes represented in green have been previously described as having a role in 
! pancreas development, genes represented in yellow a role in metastasis suppression and genes 
! represented in red described as over expressed in PDAC. Y axis was Log10 scaled. Experiment 
! was performed on 3 biological repeats (n=3) using 3 technical repeats of each.
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HOXB expression in PancTu-1 cells versus CAM tumours
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! Figure 4.30: HOX gene expression levels measured by RT-PCR in PancTu-1 cell-line compared 
! with PancTu-1 derived tumours in the HOXB cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (p≤0.05*, p≤0.01**,p≤0.001***). 
! Genes represented in green have been previously described as having a role in pancreas 
! development, genes represented in yellow a role in metastasis suppression and genes 
! represented in red described as over expressed in PDAC. Y axis was Log10 scaled. Experiment 
! was performed on 3 biological repeats (n=3) using 3 technical repeats of each.
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Overall, HOXC expression (Figures 4.25-4.28)) was low compared with the other clusters and 
few differences were observed between CAM tumours and the cell-lines from which they were 
derived. HOXC4 (p≤0.01), HOXC12 (p≤0.001) and HOXC13 (p≤0.01) were significantly down-
regulated in AsPC-1 CAM tumours compared with AsPC-1 cells (Figure 4.25).
No significant differences in gene expression were observed in BxPC-3 tumours compared 
with the BxPC-3 cell line (Figure 4.26. 
Both HOXC6 (p≤0.01)and HOXC9 (p≤0.01) expression was significantly higher in PaCa-3-
CAM tumours compared with PaCa-3 cells. HOXC12 (p≤0.01), on the other hand, was found 
to be down-regulated in PaCa-3 tumours compared with PaCa-3 cells (Figure 4.27) which was 
also observed in BxPC-3 cells. 
PancTu-1-CAM tumours showed a significant down-regulation of HOXC7 (p≤0.01)and 
HOXC13 (p≤0.01) compared with PancTu-1 cells (Figure 4.28).
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HOXC expression in AsPC-1 cells versus CAM tumours
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! Figure 4.31: HOX gene expression levels measured by RT-PCR in AsPC-1 cell-line compared 
! with AsPC-1 derived tumours in the HOXC cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (p≤0.05*, p≤0.01**,p≤0.001***). 
! Y axis was Log10 scaled. Experiment was performed on 3 biological repeats (n=3) using 3 
! technical repeats of each.
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HOXC expression in AsPC-1 cells versus CAM tumours
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! Figure 4.32: HOX gene expression levels measured by RT-PCR in BxPC-3 cell-line compared 
! with BxPC-3 derived tumours in the HOXC cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (no statistical significance 
! achieved)  Y axis was Log10 scaled. Experiment was performed on 3 biological repeats (n=3) 
! using 3 technical repeats of each.
!
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HOXC expression in PaCa-3 cells versus CAM tumours
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! Figure 4.33: HOX gene expression levels measured by RT-PCR in PaCa-3 cell-line compared 
! with PaCa-3 derived tumours in the HOXC cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (p≤0.05*, p≤0.01**,p≤0.001***). 
! Y axis was Log10 scaled. Experiment was performed on 3 biological repeats (n=3) using 3 
! technical repeats of each.
159
HOXC expression in PancTu-1 cells versus CAM tumours
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! Figure 4.34: HOX gene expression levels measured by RT-PCR in PancTu-1 cell-line compared 
! with PancTu-1 derived tumours in the HOXC cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (p≤0.05*, p≤0.01**,p≤0.001***). 
! Y axis was Log10 scaled. Experiment was performed on 3 biological repeats (n=3) using 3 
! technical repeats of each.
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HOXD expression remained very low compared with gene expression in the other HOX gene 
clusters and there were very few differences in HOXD expression overall between CAM 
tumours and the cell-lines from which they were derived (Figures 4.29-4.32). The only 
significant differences observed were that HOXD3 and HOXD4 were up-regulated in BxPC-3 
derived CAM tumours compared with BxPC-3 cells (p≤0.05)(Figure 4.30). Interestingly 
HOXD12 expression was very low (but present) in AsPC-1 and PaCa-3 cell lines but was lost 
in all 4 cell line-derived CAM tumours (Figures 4.29-4.32).  
HOXD expression in AsPC-1 cells versus CAM tumours
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! Figure 4.35: HOX gene expression levels measured by RT-PCR in AsPC-1 cell-line compared 
! with AsPC-1 derived tumours in the HOXD cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (no statistical significance was 
! achieved). Genes represented in green have been previously described as having a role in 
! pancreas development and genes represented in blue previously described as being 
! downregulated in PDAC. Y axis was Log10 scaled. Experiment was performed on 3 biological 
! repeats (n=3) using 3 technical repeats of each.
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HOXD expression in BxPC-3 cells versus CAM tumours
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! Figure 4.36: HOX gene expression levels measured by RT-PCR in BxPC-3 cell-line compared 
! with BxPC-3 derived tumours in the HOXD cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (p≤0.05*, p≤0.01**,p≤0.001***). 
! Genes represented in green have been previously described as having a role in pancreas 
! development and genes represented in blue previously described as being downregulated in 
! PDAC. Y axis was Log10 scaled. Experiment was performed on 3 biological repeats (n=3) using 
! 3 technical repeats of each.
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HOXD expression in PaCa-3 cells versus CAM tumours
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! Figure 4.37: HOX gene expression levels measured by RT-PCR in PaCa-3 cell-line compared 
! with PaCa-3 derived tumours in the HOXD cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (no statistical significance was 
! achieved)). Genes represented in green have been previously described as having a role in 
! pancreas development and genes represented in blue previously described as being 
! downregulated in PDAC. Y axis was Log10 scaled. Experiment was performed on 3 biological 
! repeats (n=3) using 3 technical repeats of each.
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HOXD expression in PancTu-1 cells versus CAM tumours
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! Figure 4.38: HOX gene expression levels measured by RT-PCR in PancTu-1 cell-line compared 
! with PancTu-1 derived tumours in the HOXD cluster. Results were normalised using β-actin. Error 
! bar calculated using SEM and statistical significance using t-test (No statistical significance was 
! achieved). Gees represented in green have been previously described as having a role in 
! pancreas development and genes represented in blue previously described as being 
! downregulated in PDAC. Y axis was Log10 scaled. Experiment was performed on 3 biological 
! repeats (n=3) using 3 technical repeats of each.
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4.5.Discussion
One of the hallmarks of pancreatic cancer is the strong desmoplastic reaction, caused by the 
activation of PSCs and responsible for the production of a dense, cancer-associated stroma, 
a feature crucial to recreate in an in vivo model (Waghray et al., 2013). The ECM (or 
desmoplasia) is an obstacle to therapeutics, due to the distortion of the normal architecture 
and networks formed by lymphatics and blood vessels in turn impeding drug delivery (Feig et 
al., 2012). Tumours grown on the CAM showed remarkable structural similarities to human 
PDAC including glands, stroma and intratumoural blood vessels. At the molecular level, CAM 
tumours also showed significant parallels to human pancreas and particularly PDAC by 
staining positive for SMA, Vimentin, CK19, CK7 and CD5, all of which have been shown to 
have important involvements in PDAC. The experimental design was extended to the MFM 
which showed histological similarities to the CAM model. However, due to interactions with 
the surroundings, cell surface markers were difficult to interpret at the protein level. In 
particular, although positive staining for CK7 was observed on both the CAM model and MFM, 
it must be noted that staining looks different in both models. The mouse model displays a lot 
more background staining compared with the CAM model. The IHC results shown in the 
results sections were performed in an NHS diagnostics lab with staining protocols optimised 
for human samples which could explain the high background in the RFM photomicrographs. 
These findings suggest that the CAM model is a robust and accurate in vivo model for 
recapitulating human PDAC tumour architecture and molecular characteristics in a cost and 
time-efficient manner. 
In this study we aimed to explore gene expression in the CAM model to validate it’s use in 
pancreatic cancer research. Most importantly in PDAC, is the mutational activation of KRAS in 
95% of human cases and its effects on down stream targets. Validation of the CAM model 
required verification that CAM tumours were representative of the cells from which they were 
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derived. Here, we compared levels of protein in downstream effectors of RAS in the MAPK 
pathway in cell lines, CAM tumours and subcutaneous MFM tumours. Our results showed that 
protein levels of downstream effectors of RAS were lower in CAM tumours compared with cell 
lines. However, when comparing a RAS wild type and RAS mutant, CAM tumours appeared to 
conserve RAS activation and subsequent up-regulation of its downstream targets depending 
on the mutational status of RAS in cell lines. We concluded that although downstream effector 
of RAS appeared down-regulated in CAM tumours, the CAM model produced tumours that 
were representative of the cell lines used for challenging. 
Microarray analysis revealed gene expression changes when BxPC-3 and AsPC-1 cells were 
transferred from an in vitro to an in ovo environment. Briefly, in BxPC-3 cells, EGLN3 and 
TFF3 were significantly upregulated when grown on the CAM, whereas CAV1 and PORCN 
were downregulated with EGLN3 and CAV1 both previously reported to be linked to PDAC. In 
AsPC-1 cells, HCP1, DUOX2 and EEF1A2 were significantly upregulated in AsPC-1-CAM 
tumours compared with their  cellular predecessors, whereas, TRAF7, SMURF1, PCSK9 and 
CAPZ2A were significantly downregulated in CAM tumours compared with AsPC-1 cells with 
only DUOX2 and EEF1A2 having previously been linked with pancreatic cancer.
While the purpose of this study was to identify differential gene expression in cell lines 
compared with cell-line derived tumours it is perhaps surprising that there were no 
differentially expressed genes, common to both cells lines. The validated data may provide 
clues as to the genes that may be involved in the process of tumour formation when cells are 
transferred from an in vitro environment to growing in ovo .These genes might therefore 
provide information as to cellular processes that take place when cancer cells become 3-
dimensional, heterogeneous structures fueled by the blood supply of the chick embryo.
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The raw data may also present a valuable data set for future targeted therapy in this model. 
We aim to further this work with an investigation into differentially expressed genes in specific 
cellular pathways that could be of interest for future use of this model.
Previously, we highlighted the dysregulation of HOX genes in several types of cancer and 
more specifically in PDAC based on the literature and also from data generated in chapter III.
Here we showed some differences in HOX genes expression between cell lines and CAM 
tumours although the general pattern of HOX gene expression was very similar. Previously 
published data has used a cell permeable peptide, HXR9 capable of preventing HOX genes 
from binding to their co-factor PBX (also a transcription factor). HOX/PBX dimers have a 
significantly stronger binding affinity with downstream targets than HOX monomers alone. 
HXR9 binds to HOX paralogue groups 1 to 8 (Morgan et al., 2007). In this chapter we have 
not only shown accurate remodeling of PDAC architecture but also conservation of the MAPK 
pathway and maintenance of HOX gene expression in the CAM model and therefore 
demonstrated the suitability of the CAM model for targeting HOX genes in tumours grown in 
the CAM.
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Chapter	  V:	  
5.HOX gene antagonism in vitro and in 
ovo
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5.1.Introduction 
Previous studies have shown that the interaction between HOX genes and one of their co-
factors PBX can be antagonised using a small, cell-permeable peptide, HXR9. HXR9 was 
designed as a competitive inhibitor of the HOX/PBX dimer formation and hence prevents HOX 
genes from fulfilling their role as transcription factors. HXR9 is an 18 amino acid peptide, 
containing a hexapeptide sequence that matches that found on HOX proteins (Morgan et al., 
2007). For effective delivery to the cell, HXR9 includes a polyarginine (R9) sequence, 
previously reported as an effective peptide delivery system(Jiang, Olson et al. 2004). A control 
peptide, CXR9 was designed using the same model as HXR9 but with a single amino acid 
change (W to A (Tryptophan to alanine)). For increased stability, the amino acids located at 
the NH2 and COOH terminals of both HXR9 and CXR9 were synthesised as D-isomers 
(Morgan et al., 2007).
HOX genes have previously been shown to be, to an extent, functionally redundant with 
somewhat overlapping functions. However, although similar, these transcription factors 
appear to have opposing functions in their involvement in cancer. It is thought that this could 
be due, in part, to HOX gene binding to several co-factors such as PBX, MEIS and propyl 
endopeptidase (PREP), or even as monomers subsequently activating or repressing 
transcription of target genes. HXR9 prevents HOX genes 1 to 9 in all 4 HOX gene clusters 
from binding to PBX. In breast cancer, HOXA5 has a known tumour suppressor function, 
partly due to its interaction and activation of the tumour suppressor gene p53. Morgan et al, 
showed that HXR9-induced HOX gene antagonism (HOX1-9) had no effect on levels of p53 
(Morgan et al., 2012). Results in chapter 1 suggest that most HOX genes in clusters A and B 
and some members of HOXC are generally overexpressed in PDAC. 
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HXR9 has previously been shown to induce apoptosis in breast, lung and ovarian cancer cell 
lines and to block cell proliferation in vivo in melanoma and in lung and ovarian cancer 
(Morgan et al., 2007). 
In this work, we used the CAM model to explore the possibilities of HXR9-induced HOX gene 
antagonism. No previous studies have shown HOX gene antagonism with HXR9 in pancreatic 
cancer either in vitro or in vivo.
5.2. Hypothesis
Based on previous studies, summarised in the section above, we suggested that disrupting 
the HOX/PBX dimer in pancreatic cancer derived cell lines would result in induction of 
apoptosis. We also conjectured that apoptosis could be induced in vivo, in the CAM model 
previously shown to recapitulate the tumour architecture and microenvironment of PDAC. 
5.3. Aims of study 
-To target HOX/PBX dimer formation and hence antagonise HOX gene expression in 
pancreatic cancer derived cell lines in order to induce apoptosis.
-To establish an accurate and robust in ovo model, recapitulating tumour architecture and 
molecular signature of PDAC.
-To antagonise HOX genes in ovo using the CAM model to induce apoptosis in vivo.
5.4. Results
5.4.1.Targeting the HOX-PBX dimer: Pancreatic cancer cell line 
sensitivity to HXR9
The half-maximal inhibitory concentrations (IC50) of cell lines AsPC-1, BxPC-3, PaCa-3 and 
PancTu-1 using the HOX antagonist HXR9 and the control peptide CXR9 were determined 
170
using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) (MTS) and lactate dehydrogenase (LDH) assays. The IC50 using the MTS assay 
in AsPC-1 cells was 23 μM (Figure 5.1) compared with 44.33 μM in BxPC-3 (Figure 5.2). 
PaCa-3 cells had an IC50 of 13.25 μM (Figure 5.3) and in the PancTu-1 (Figure 5.4) cell line 
the IC50 was determined at 13.83 μM (results summarised in Figure 5.8). 
AsPC-1 MTS assay
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! Figure 5.1: AsPC-1 cell-line sensitivity to HXR9 shown by MTS assay. Cells were treated with 
! HXR9 or CXR9 (inactive form of the peptide) for 2 hours. No treatment was used as a negative 
! control and Triton was used at a positive control for validity of the experiment (data not shown on 
! the graph). Experiments were performed in triplicate. Error bars were calculated using SEM and 
! statistical significance using T-test (p<0.05*, p<0.01**, p<0.001*** ). Experiment was performed 
! on 3 biological repeats (n=3) using 3 technical repeats of each.
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BxPC-3 MTS assay
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! Figure 5.2: BxPC-3 cell-line sensitivity to HXR9 shown by MTS assay. Cells were treated with 
! HXR9 or CXR9 (inactive form of the peptide)  for 2 hours. No treatment was used as a negative 
! control and Triton was used at a positive control for validity of the experiment (data not shown on 
! the graph). Experiments were performed in triplicate. Error bars were calculated using SEM and 
! statistical significance using T-test (p<0.05*, p<0.01**, p<0.001*** ). Experiment was performed 
! on 3 biological repeats (n=3) using 3 technical repeats of each.
!
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PaCa-3 MTS assay
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! Figure 5.3: PaCa-3 cell-line sensitivity to HXR9 shown by MTS assay. Cells were treated with 
! HXR9 or CXR9 (inactive form of the peptide)  for 2 hours. No treatment was used as a negative 
! control and Triton was used at a positive control for validity of the experiment (data not shown on 
! the graph). Experiments were performed in triplicate. Error bars were calculated using SEM and 
! statistical significance using T-test (p<0.05*, p<0.01**, p<0.001*** ). Experiment was performed 
! on 3 biological repeats (n=3) using 3 technical repeats of each.
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PancTu-1 MTS assay
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! Figure 5.4: PanTu-1 cell-line sensitivity to HXR9 shown by MTS assay. Cells were treated with 
! HXR9 or CXR9 (inactive form of the peptide) for 2 hours. No treatment was used as a negative 
! control and Triton was used at a positive control for validity of the experiment (data not shown on 
! the graph). Experiments were performed in triplicate. Error bars were calculated using SEM and 
! statistical significance using T-test (p<0.05*, p<0.01**, p<0.001*** ). Experiment was performed 
! on 3 biological repeats (n=3) using 3 technical repeats of each.
The calculated IC50s were different when using the LDH assays, although this is to be 
expected as the MTS assay measures mitochondrial respiration while the LDH assay 
measures lactate dehydrogenase that is released when the integrity of the cell membranes is 
lost. The IC50 using the LDH assay in AsPC-1 cells was 15.2 μM, 13.5 μM in PaCa-3 cells and 
35.66 μM in PancTu-1 cells (summary Figure 5.8). Results show CXR9 does not cause cell 
death in pancreatic cancer-derived cell lines using neither LDH nor MTS assays. In BxPC-3 
cells, the IC50 using LDH could not be measured since 50% cell death was not achieved even 
when using a higher dose of HXR9.  Subsequently throughout the project we used the IC50 
values generated using the MTS assay. The rationale behind choosing the MTS values rather 
that the LHD IC50s was to use values for all cell lines generated using the same assay and this 
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would allow to compared sensitivity to HXR9 with previously published results which also 
used MTS assays such as breast cancer cells by Morgan et al (Morgan et al., 2012)
  In this study, MTS assays reported a range of 16 to 51μM in breast cancer cells (Morgan et 
al., 2012), 20 to 200 μM in melanoma (Morgan et al., 2007)  and 32.5 to 69 μM in non-small-
cell lung cancer(Plowright et al., 2009) while ovarian cancer cell line SK-OV3 had an IC50 of 
70 μM and OV-90 was not sensitive to HXR9 (Morgan et al., 2010).  Thus, pancreatic cancer-
derived cell lines are moderately sensitive to HXR9 compared with other solid cancers.
AsPC-1 LDH assay
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! Figure 5.5: AsPC-1 cell-line sensitivity to HXR9 shown by LDH assay. Cells were treated with 
! HXR9 or CXR9 (inactive form of the peptide) for 2 hours. No treatment was used as a negative 
! control and Triton was used at a positive control for validity of the experiment (data not shown on 
! the graph). Experiments were performed in triplicate. Error bars were calculated using SEM and 
! statistical significance using T-test (p<0.05*, p<0.01**, p<0.001*** ). Experiment was performed 
! on 3 biological repeats (n=3) using 3 technical repeats of each.
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PaCa-3 LDH assay
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! Figure 5.6: PaCa-3 cell-line sensitivity to HXR9 shown by LDH assay. Cells were treated with 
! HXR9 or CXR9 (inactive form of the peptide) for 2 hours. No treatment was used as a negative 
! control and Triton was used at a positive control for validity of the experiment (data not shown on 
! the graph). Experiments were performed in triplicate. Error bars were calculated using SEM and 
! statistical significance using T-test (p<0.05*, p<0.01**, p<0.001*** ). Experiment was performed 
! on 3 biological repeats (n=3) using 3 technical repeats of each.
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PancTu-1 LDH assay
0 10 20 30 40 50
0
50
100
150
%
 Li
ve
 ce
lls
Concentration (μM) 
CXR9
HXR9
**
***
***
! Figure 5.7: PancTu-1 cell-line sensitivity to HXR9 shown by LDH assay. Cells were treated with 
! HXR9 or CXR9 (inactive form of the peptide) for 2 hours. No treatment was used as a negative 
! control and Triton was used at a positive control for validity of the experiment (data not shown on 
! the graph). Experiments were performed in triplicate. Error bars were calculated using SEM and 
! statistical significance using T-test (p<0.05*, p<0.01**, p<0.001*** ). Experiment was performed 
! on 3 biological repeats (n=3) using 3 technical repeats of each.
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! Figure 5.8: Summary of pancreatic cell-line sensitivity to HXR9 with IC50 values using MTS and 
! LHD assays.
5.4.2.Mechanisms of cell death caused by HXR9 in vitro measured 
by Annexin V-PE 
Fluorescence-activated cell sorted (FACS) analysis in AsPc-1 cells was repeated 3 times and 
was used to distinguish between apoptotic and necrotic cell death by measuring levels of 
phosphatidylserine detected in early stages of apoptosis by Annexin V-PE. Cells were 
counterstained with the dye 7AAD which can only enter cells whose membrane integrity has 
been compromised. AsPC-1 cells treated with HXR9 were driven into late apoptosis with a 
further increased ratio of late apoptosis to live cells when using double the IC50. Cells treated 
with the control peptide CXR9 show similar levels of apoptosis as do untreated cells 
highlighting the apoptotic effect of HXR9 compared to CXR9 (Figure 5.9).
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AsPC-1 FACS analysis - Annexin-V-PE 
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! Figure 5.9: A: Fluorescence activated cell sorter (FACS) analysis of Annexin V-PE stained 
! AsPc-1 cells and counter-stained with 7-AAD. Cells were treated with 23µM (IC50) CXR9 or 
! HXR9 and 46µM CXR9 or HXR9 (2xIC50) for two hours. The results show a set of 3 independent 
! experiments. B: Raw data (1 repeat). Panel 1 shows FACS analysis in untreated cells, panel 2 in 
! CXR9 (2xIC50) treated cells and panel 3 in HXR9 (2xIC50) treated cells. Error bar calculated 
! using SEM and statistical significance using T-test (p<0.05*, p<0.01**, p<0.001*** ). The lower 
! left quadrant shows the number of live cells, the lower right quadrant the number of cells in early 
! apoptosis, the upper right quadrant the number of cells in late apoptosis and the upper left 
! quadrant the number of necrotic cells. Experiment was performed on 3 biological repeats (n=3) 
! using 3 technical repeats of each.
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Cell death was also measured in BxPC-3 cells (Figure 5.10). After two hours of incubation, 
cells were found to be in both early and late apoptotic stages when treated with the peptide. 
However, when BxPC-3 cells were untreated or treated with CXR9, they also showed low 
levels of apoptosis possibly induced during the course of the assay due to trypsinisation and 
PBS washes. Apoptosis levels are, nonetheless, much higher in HXR9 treated cells stressing 
the apoptotic effect of the peptide. 
Morgan et al. compared HOX gene expression of HOXB1-9 genes with cell line sensitivity to 
HXR9 and found that lower HOXB1-9 expressers were less sensitive to HXR9 (Morgan et al., 
2012). Here, we investigated if a similar correlation could be found in pancreatic cancer cell 
lines. Figure 5.10 shows HXR9 sensitivity and HOXB1-9 and PBX1-4 mean expression. 
Results show no correlation between cell-line sensitivity and HOXB1-9 or PBX1-4 expression.
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! Figure 5.10: Comparison cell line sensitivity to HXR9 with mean expression of HOXB1-9 and 
! PBX1-4. (Data taken form figures 3.2 and 3.17).
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BxPC-3 FACS analysis - Annexin-V-PE 
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! Figure 5.10: A: Fluorescence activated cell sorter (FACS) analysis of Annexin V-PE stained 
! BxPC-3 cells and counter-stained with 7-AAD. Cells were treated with 45µM (IC50) CXR9 or 
! HXR9 and 90µM CXR9 or HXR9 (2xIC50) for two hours. The results show a set of 3 independent 
! experiments. B: Raw data (1 repeat). Panel 1 shows FACS analysis in untreated cells, panel 2 in 
! CXR9 (2xIC50) treated cells and panel 3 in HXR9 (2xIC50) treated cells. Error bar calculated 
! using SEM and statistical significance using T-test (p<0.05*, p<0.01**, p<0.001*** ). The lower 
! left quadrant shows the number of live cells, the lower right quadrant the number of cells in early 
! apoptosis, the upper right quadrant the number of cells in late apoptosis and the upper left 
! quadrant the number of necrotic cells. Experiment was performed on 3 biological repeats (n=3) 
! using 3 technical repeats of each.
The experiment was also performed on PaCa-3 cells. Results shows that all cells treated with 
H2O and CXR9 were essentially viable whereas a proportion of the HXR9 treated cells 
underwent apoptosis. When using the IC50 concentration, approximately 20% of cells were 
181
driven into apoptosis and when using double the IC50 concentration around 40% of cells were 
apoptotic.
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! Figure 5.11: Fluorescence activated cell sorter (FACS) analysis of Annexin V-PE stained PaCa-3 
! cells and counter-stained with 7-AAD. Cells were treated with 13µM (IC50) CXR9 or HXR9 and 
! 26µM CXR9 or HXR9 (2xIC50) for two hours. The results show a set of 3 independent 
! experiments. B: Raw data (1 repeat). Panel 1 shows FACS analysis in untreated cells, panel 2 in 
! CXR9 (2xIC50) treated cells and panel 3 in HXR9 (2xIC50) treated cells. Error bar calculated 
! using SEM and statistical significance using T-test (p<0.05*, p<0.01**, p<0.001*** ). The lower 
! left quadrant shows the number of live cells, the lower right quadrant the number of cells in early 
! apoptosis, the upper right quadrant the number of cells in late apoptosis and the upper left 
! quadrant the number of necrotic cells.Experiment was performed on 3 biological repeats (n=3) 
! using 3 technical repeats of each.
The experiment was repeated for PancTu-1 cells (data not shown). At 1x or 2x the IC50 
concentration, little apoptosis was detected. Consequently, the amount of HXR9 was 
182
increased to 2x and 4x the IC50 concentration. Interestingly, doubling of the IC50 obtained 
using MTS equates approximately to the IC50 measured using the LDH assay. Therefore it is 
perhaps unsurprising that the amount of HXR9 needed to induce apoptosis was around 30uM. 
As a result, higher levels of apoptosis were measured. Results showed that some cell death 
was detectable even with no treatment. For consistency, throughout the project the double 
IC50 concentration was used in subsequent experiments. IC50 data suggests AsPC-1 and 
PaCa-3 are more sensitive to HXR9 compared with BxPC-3 and PacTu-1 cells. Both AsPC-1 
and PaCa-3 display low levels of early apoptosis whereas the less sensitive cell lines BxPC-3 
and PancTu-1 show slightly higher levels of early apoptosis.
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PancTu-1 FACS analysis - Annexin V-PE 
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! Figure 5.12: Fluorescence activated cell sorter (FACS) analysis of Annexin V-PE stained 
! PancTu-1 cells and counter-stained with 7-AAD. Cells were treated with 28µM (2xIC50) CXR9 or 
! HXR9 and 56µM CXR9 or HXR9 (4xIC50) for two hours. The results show a set of 3 independent 
! experiments. B: Raw data (1 repeat). Panel 1 shows FACS analysis in untreated cells, panel 2 in 
! CXR9 (4xIC50) treated cells and panel 3 in HXR9 (4xIC50) treated cells (The experiment was 
! initially performed using 23µM CXR9 and HXR9 and 46µM with little apoptosis observed (data 
! not shown)) Error bar calculated using SEM and statistical significance using T-test (p<0.05*, 
! p<0.01**, p<0.001*** ). The lower left quadrant shows the number of live cells, the lower right 
! quadrant the number of cells in early apoptosis, the upper right quadrant the number of cells in 
! late apoptosis and the upper left quadrant the number of necrotic cells. Experiment was 
! performed on 3 biological repeats (n=3) using 3 technical repeats of each.
5.4.3.  Mechanisms of cell death caused by HXR9 in ovo
In order to determine whether HOX gene antagonism by HXR9 induces apoptosis in vivo. 
Previously, in chapter IV were showed that the CAM model is able to recapitulate the tumour 
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architecture and molecular signature of PDAC. Untreated tumours are photographed in figure 
4.1, the tumour architecture can be visualised in the photographs of H&E stain in figure 4.2 
where blood vessels, stroma and glandular structures can be seen in BxPC-3 cam tumours. 
The molecular signature of PDAC appear to recapitulated including positive staining of SMA 
and CK7 in tumour stroma, CK9 and CD5 (figure 4.4 and table 1.1). BxPC-3 tumours were 
seeded on EDD4 and allowed to grow until EDD17 at which time they were treated with 
HXR9. Caspase-3 is one of the key mediator of the apoptosis pathway during which it is 
cleaved into its active form, cleaved-caspase. IHC was used to detect cytoplasmic localisation 
of the protein in HXR9 CAM treated tumours. Initially, experiments were performed using an 
intratumoural injection. Dosing was calculated using 10x the IC50 of the cell line in question 
(with the assumption that tumours were spherical).
Results (displayed in Appendices 5.1-5.2) showed presence of cytoplasmic cleaved-caspase 
in HXR9 treated tumours in all 4 cell lines. However, lower levels were also observed in CXR9 
treated tumours and the PBS controls showed little, but some positive staining. Results also 
showed that tumour disruption was more substantial in HXR9-treated tumours compared with 
the CXR9 and PBS controls. It was unclear whether the tumour disruption could be attributed 
to the apoptotic properties of HXR9 only, or perhaps by the mechanical disruption created by 
the needle tract during the injection. In order to answer this question further, the method of 
administration was altered and a cap containing the drug was created using the solidifying 
properties of Matrigel at 37°C (Figure 5.13). 
Results showed no caspase activation in PBS-treated tumours and no positive staining in 
tumours treated with CXR9. In tumours treated with HXR9, results showed strong positive 
staining resembling the positive control (tonsil section). In addition, the general architecture of 
the tumour was disrupted leaving hypocellular regions in the tissue which was not observed in 
the CXR9 treated tumours. These results  support the hypothesis that HXR9 is directly 
responsible for cell death by apoptosis leading to tumour disruption. This was a preliminary 
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experiment and these results although promising will have to be verified further using different 
apoptosis stains, experiment will have to be repeat using a higher number of eggs and 
experiments will have to be repeated in the other cell lines AsPC-1, PaCa-3 and PancTu-1 
which were not included due to time constraints. 
PBS CXR9
HXR9 Tonsil/(posi2ve/control)
! Figure 5.13: Cleaved-caspase 3 staining on BxPC-3-derived CAM tumour paraffin sections and 
! on tonsil section (positive control for the antibody). Tumours were treated with a topical 
! application of either PBS, CXR9 or HXR9 (magnification x20). 
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5.5.Discussion
Competitive inhibition of the HOX/PBX dimer has previously been shown to induce apoptosis 
both in vitro and in vivo in several types of solid cancers (Morgan et al., 2012) (Morgan et al., 
2007; Morgan et al., 2010; Plowright et al., 2009).  HOX genes were antagonised in 4 cell 
lines: AsPC-1, BxPC-3, PaCa-3 and Panctu-1 and IC50s  were established. Results showed 
that all cell lines were sensitive to HXR9 and unaffected by the ‘scrambled’ peptide CXR9. 
Pancreatic cell lines are comparatively sensitive to HXR9 compared with other solid cancers 
and show little variability.  In contrast, HXR9 has been shown to have variable results in 
ovarian cancer perhaps due to the numerous subtypes it encompasses, a trait not shared with 
pancreatic cancer (Morgan et al., 2010). Result also showed no correlation between HOXB1-9 
mean expression of HOXB1-9 unlike breast cancer cell-lines whose HOXB-19 expression 
directly correlated with sensitivity to HXR9 (Morgan et al., 2012). Sensitivity the HXR9 was 
also compared with the mean expression of PBX1-4 and no correlation could be determined. 
It is still unclear what determines cell-line sensitivity to HXR9.
In order to investigate whether HXR9 induced apoptosis in vitro, FACS analysis was 
performed on all 4 pancreatic cell lines, previously shown to be sensitive to HXR9. Results 
showed AsPC-1, BxPC-3, PaCa-3 and Panctu-1 cells were driven into apoptosis and are 
consistent with previously published data (Morgan et al., 2007). In order to further confirm that 
HXR9 induces apoptosis in pancreatic cell lines, evaluation of caspase activation and PARP-
cleavage needs to be performed. 
Having established the CAM model as a suitable model of PDAC, the HOX/PBX dimer was 
then antagonised in ovo. Previous findings, along with published data, supported the theory 
that HXR9 would induce apoptosis in CAM-PDAC. In order to test the cell death mechanism in 
ovo, HXR9 treated tumours were stained for cleaved-caspase-3, an important stage in the 
apoptosis pathway. Results showed architectural damage and positive cleaved-caspase 3 
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staining in HXR9 treated tumours, strongly suggesting that cells undergo apoptosis. In order 
to further confirm these findings, Ki-67 (cell proliferation marker) staining needs to be 
performed. In addition, previous findings have suggested that the HOX/PBX dimer activates 
miRs that directly target C-fos and in turn, induce apoptosis. Consequently, C-fos IHC needs 
to be tested (Errico et al., 2013). 
In conclusion, based on these results and previously published data, it has been shown that 
HXR9 induces apoptosis in vitro in pancreatic cancer cell lines. An in vivo model of PDAC was 
also set up, which was markedly similar to its human counterpart and which was used to test 
HOX gene antagonism. In a preliminary experiment, results showed caspase activation in 
HXR9 treated cells in ovo, in a proportion of cells,  suggesting  cell death could be induced 
along the apoptotic pathway. However, the cell population showing expression was not large 
and hence,  further tests will have to be carried out to confirm these findings. 
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In this study we aimed to elucidate the role of HOX genes in PDAC. We, therefore, measured 
HOX gene expression in 4 pancreatic cancer cell lines to determine whether a general HOX 
gene pattern could be determined. While pancreatic cancer derived cell lines provided some 
clues as to which gene might be implicated in the disease, i.e. high expression of genes in 
clusters A and B and little or no expression in clusters C and D, we went on to measure HOX 
gene expression in human RNA, both commercially sourced as well as extracted in-house 
from snap-frozen samples. To date, this is the first study to report expression of all 39 HOX 
genes. Our results showed mainly uniformity with peer-reviewed data though some of our 
findings appear to contradict some published papers. Briefly, we found that HOXA5, HOXA9, 
HOXA10 and HOXA13 expression was significantly higher in tumour tissue compared with 
normal pancreas. In the B cluster, HOXB2, HOXB3, HOXB4, HOXB5 and HOXB9 were also 
significantly more highly expressed in tumour samples compared with RNA from normal 
tissue. However, we were not able to report HOXB7 over-expression (as had been previously 
reported) and while HOXB1 and HOXB2 have been reported to be suppressors of metastasis, 
our HOXB2 data did not support this (no HOXB1 expression was detected in either normal or 
tumour tissue). HOXA10 has been reported as overexpressed in PDAC and has been shown 
to promote invasion. The work of Cui et al. supports the hypothesis that HOXA10 may 
promote invasion through expression of matrix metallopetidase-3 (MMP-3) and subsequent 
TGF-Beta-p38-MAPK pathway mediated invasion (Cui et al., 2014).  HOXA13 has been 
reported as overexpressed in gastric cancer and ovarian cancers (Han et al., 2013). The 
specific function of these genes varies according to which organ is studies. HOXA10 and 
HOXA13 play a key role in the normal maintenance of the female reproductive system and 
sequence alterations in these genes results in congenital absence of the uterus and vagina 
(Ekici et al., 2013). We then tested HOXA13 protein levels by IHC and showed that 45.76% of 
tumours were HOXA13 positive while normal or normal adjacent were negative (100%). We 
aim to take this work further by investigating HOX gene expression in correlation with survival 
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as we were not able do so during this study. We also intend to investigate HOXD gene 
expression further by studying HOXD13 expression and survival in human patients but we 
also aim to investigate the consequences that a suspected loss of function has on tumour 
cells; for example, by knocking out HOXD13 in cell lines and carrying out invasion and 
migration assays. 
In order to determine the usefulness of HOX genes as biomarkers for PDAC it is important to 
discuss the uniqueness of the HOX gene profile discussed in chapter 3 compared with other 
malignancies. The HOX gene profile in malignant B-cells is characterised by high gene 
expression in the HOXA gene cluster. HOXB4, and to a lesser extent HOXB5, are both 
upregulated in cell-lines and in the HOXC cluster only HOXC11 was found to be upregulated 
in these cell lines. Low gene expression in the HOXD cluster was also observed in this 
malignancy (Daniels et al., 2010). In renal cancer, HOX gene expression has been assessed 
in cell lines, human disease and normal kidney tissue. Overexpression in the HOXA gene 
cluster was prominent with HOXA3-5, HOXA6, and HOXA9 overexpression in both cancer 
derived cell-line and renal cancer tissue. HOXB4, HOXB5, HOXB7, HOXC4 and HOXC9 
genes were also found to be overexpressed and overexpression was also observed in the 
HOXD cluster (HOXD8-10). A very similar study design was used to assess HOX gene 
expression in non-small-cell lung cancer. Results showed upregulation of genes in the HOXA 
cluster in normal tissue compared with cell lines and NSCLC biopsies notably in HOXA3 and 
HOXA5. Contrarily, HOXC4, HOXC8, HOXC9, HOXC13, HOXD8 and HOXD10 were 
overexpressed in primary tumours and A549 cells. HOX gene expression in prostate cancer 
cell-lines has shown heterogenous results and other reports have shown overexpression of 
HOXC4, HOXC5, HOXC6 and HOXC8 in prostate cancer cell lines and lymph node 
metastases with high HOXC8 expression associated with a high Gleason score and therefore 
a poorer prognosis (Morgan et al., 2014). HOXB13 on the other hand has been shown to be 
highly expressed in normal prostate tissue and androgen-receptor-positive cell lines and low 
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HOXB13 expression has been reported in androgen-receptor-negative cell lines and, in 
familial prostate cancer, mutations in HOXB13 have been reported (Javed and Langley, 
2014). HOXA9 has also been shown to be overexpressed in and has been implicated in 
prostate carcinogenesis (Bhatlekar et al., 2014). In breast cancer, HOXA5 has a known 
tumour suppressor function resulting from the transcriptional activation of the tumour 
suppressor gene p53. HOXB5 and HOXB7 have been shown to be upregulated in this cancer 
through the activation of FGF2 (Morgan et al., 2012). Overexpression of HOX genes has been 
noted in HOXA6, HOXA13 in the HOXA cluster and in HOXB2, HOXB4, HOXB5, HOXB6, 
HOXB7, HOXB8, HOXB9 in cluster B.  HOXC5, HOXC9, HOXC9, HOXC13, HOXD1 and 
finally HOXD8 have been shown to be overexpressed in breast cancer tissues. Interestingly, 
expression HOXA1, HOXA2, HOXA3, HOXA5, HOXA9, HOXC11, HOXD3, HOXD4, HOXD8, 
HOXD9, and HOXD10 was shown to be lower in breast cancers compared with normal breast 
tissue although this conflicts with other published data. A study also showed overexpression 
of HOXB13 in pre-invasive and invasive primary breast cancers in patients with hormone-
receptor-positive breast cancer (Bhatlekar et al., 2014). HOX gene dysregulation in ovarian 
has also previously been described, mainly in HOX clusters A and B. HOXA9, HOXA10 and 
HOXA11 upregulation have been reported in epithelial ovarian cancers and overexpression of 
HOXA4 an HOXA7 have also been described in ovarian cancer tissue. In the HOXB cluster, 
HOXB7 and HOXB13 have been shown to contribute to invasion while HOXB5 and HOXB8 
overepxression has been linked to serous ovarian cancer and HOXA5, HOXA9, HOXA10 and 
HOXA11 have been described as having prognostic values. DNA methylation of HOXA11 has 
been shown to be associated with poor patient outcome showing potential for methylation as 
a biomarker in ovarian cancer (Kelly et al., 2011).Table 7.1 summarises the current known 
HOX gene dysregulations and highlights the similarities in HOX gene dysregulations across 
gene clusters in these solid cancers. Although some similarities can be observed between 
pancreatic cancer and other tumour types, it is clear that the HOX gene profile of PDAC is 
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unique compared with other cancers. In particular, the expression profile in the HOXA gene 
cluster appears to be relatively specific to PDAC. This profile therefore shows promising 
potential as a biomarker for PDAC diagnostics. It must also be noted that, in particular, 
HOXB13 is dysregulated in 6 types of solid cancers (colon, breast, prostate, thyroid, ovary 
and urinary) but not in PDAC, reinforcing it’s uniqueness (Bhatlekar et al., 2014). This profile 
remains conflicting in parts and requires fine tuning if it is to be used in such a context. 
However, with emerging technologies such as the isolation of circulating tumour cells in 
peripheral blood it seems appropriate to consider HOX gene profiling a reasonable approach 
to diagnosing PDAC in the future.
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HOXA HOXB HOXC HOXD
PDAC
Malignant B-cell
Renal Cancer
NSCLC
Prostate Cancer
Breast Cancer
Ovarian cancer
Significant 
upregulation of 
HOXA5, HOXA9, 
HOXA10, HOXA13 (in 
both commercial RNA 
and Human PDAC). 
In this study, 
upregulation of HOXB4 
and HOXB5 in both 
commercially obtained 
RNA and Human 
PDAC. HOXB7 
overexpression in 
commercial RNA and 
previously published 
data. HOXB2 
previously described is 
overexpressed in 
PDAC
HOXC4 and HOXC9 
overexpressed in both 
commercial RNA and 
human PDAC.
Little or no HOXD gene 
expression in 
pancreatic cancer cell 
lines and human 
PDAC . HOXD10 
upregulation in 
commercial RNA 
(conflicting). Overall 
downregulation of 
HOXD gene cluster in 
human PDAC 
compared with normal 
RNA. HOD13 
previously described 
as downregulated in 
PDAC
High HOXA expression 
in cancer cell-lines
High HOXB4, HOXB5 
in cancer cell lines
High HOXC11 in 
cancer cell lines
Overall low HOXD 
expression in cancer 
cell lines
High HOXA3, HOXA4 
(in cell lines). 
High HOXA5 in tumour 
and cell lines.
High HOXA9 In tumour
High HOXB4, HOXB5, 
HOXB7
High HOXC9 in cell 
lines
High HOXD8, HOXD9, 
HOXD10
Overexpression of 
HOXA3, HOXA5 in 
normal tissue.
HOXB2 overexpression 
(promoter of 
metastasis).
Overexpression 
HOXC4, HOXC8, 
HOXC9 and HOXC13 
in primary tumours and 
A549 cells
HOXD8 and HOXD10 
overexpression in 
primary tumours and 
A549
HOXA9 aberrantly 
expressed in prostate 
cancer
HOXB3 upregulation in 
primary prostate 
cancer. High HOXB13 
expression in normal 
prostate tissue. 
HOXB13 mutations in 
familial prostate 
cancer.
High HOXC4, HOXC5, 
HOXC6 and HOXC8 in 
cell lines and lymph 
node metastases
Overexpression of 
HOXA6, HOXA13 in 
breast cancer. 
Downregulation of 
HOXA1, HOXA2, 
HOXA3, HOXA5, 
HOXA9 in breast 
cancer tissue
HOXB5 overexpression 
in breast cancer tissue. 
HOXB7 overexpression 
(Epithelial to 
mesenchymal 
transition). HOXB13 
upregulation in pre-
invasive and invasive 
primary breast 
cancers.
Upregulation HOXC5, 
HOXC9 and HOXC13 
in breast cancer. 
Downregulation of 
HOXC11 in breast 
cancer
Upregulation of 
HOXD1, HOXD3, 
HOXD8 in breast 
cancer. 
Downregulation of 
HOXD3 (conflicting), 
HOXD4, HOXD8 
(conflicting), HOXD9, 
HOXD10
Overexpression of 
HOXA9, HOXA10 and 
HOXA11 in epithelial 
ovarian cancers. 
Overexpression of 
HOXA4 and HOXA7 
(involved in Müllerian-
like differentiation) in 
ovarian cancer tissue. 
Methylation of HOXA11 
associated with poor 
outcome.
Overexpression of 
HOXB7 and HOXB13 
contributes to invasion. 
HOXB5 and HOXB8 
overexpression linked 
to serous ovarian 
cancer
! Table 6.1: Summary of HOX gene dysregulation in several types of cancers. Boxes 
! represented in purple show the similarities across HOX gene clusters. 
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Although the profile of HOX genes appears to be cancer-specific, several HOX genes are 
commonly dysregulated in several types of cancer. Bhatlekar et al. hypothesised that there 
were similar HOX-related regulatory gene networks that become dysregulated at the onset of 
cancer development by using bioinformatics analysis in colon, breast and lung cancer. Here, 
we ran a similar analysis using dysregulated genes in PDAC from the results of this study as 
well as previously published data namely HOXA5, HOXA9, HOXA10, HOXA13, HOXB2, 
HOXB4, HOXB5, HOXB7, HOXB2, HOXC4, HOXC9, HOXD10 and HOXD13. Rather 
unsurprisingly we found functional coupling with PBX1 and MEIS which was also found in 
colon, breast and lung cancers. We also found coupling with PBX2, PAX6, FOXO1 and FOXI1 
which was also noted in lung cancer (Bhatlekar et al., 2014). These HOX-related regulatory 
pathways may provide a better understanding of mechanisms used by HOX genes but also 
opportunities for future HOX targeting as novel therapies. 
! Figure 6.1: Predicted regulatory gene networks of (available) HOX genes aberrantly expressed 
! in PDAC. Yellow diamonds represent genes that are dysregulated in PDAC. Networks are 
! contracted based on functional associations coupled through metabolic and signalling 
! pathways, protein-protein and physical associations. Grey circles !represent genes that are 
! functionally associated with aberrantly expressed HOX genes (credits http://FunCoup.sbe.su.se)
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Previous studies have antagonised HOX genes in several type of cancer by blocking the 
interaction of HOX genes and their co-factor PBX which had been shown to result in cellular 
death. We therefore disrupted the HOX/PBX dimer using HXR9 and showed that apoptosis 
was induced in cell lines treated with the peptide. Consequently, we aimed to investigate HOX 
gene antagonism in vivo. 
We established thats there was a lack of rapid and cost effective animal models that were 
able to recapitulate tumour architecture and remodel the all important desmoplastic reaction, 
characteristic of PDAC. 
We investigated the accuracy of the CAM model by comparing CAM tumours with human 
disease and we showed that CAM tumours not only expressed pancreas specific cell surface 
markers, but also expressed cancer-associated, stroma-specific proteins. We, therefore, 
showed successful desmoplastic reaction recapitulation in this model. Comparison of CAM 
tumours with human PDAC showed a strong resemblance to human disease. We also 
compared murine flank tumours and although cancer-associated stroma was observed, 
interactions with surrounding tissue made cell surface markers difficult to interpret at the 
protein level. This led us to investigate protein levels of downstream effector of KRAS in the 
MAPK pathway. We compared levels of pMEK and pERK in cell lines and their CAM tumour 
derivatives with subcutaneous murine flank tumours and showed that CAM tumours were 
more representative of the cell-line from which they were derived. In chapter 5, microarray 
analysis was used to determine important gene expression changes between cells grown in 
vitro and in a tumour microenvironment on the CAM. Candidate genes were validated by 
qPCR.
 It is, therefore, not unreasonable to question whether these differentially expressed genes 
may be involved in the formation of the tumour architecture, notably, cancer associated 
stroma, observed in chapter 4, that is unique to this disease. 
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The CAM model is quick, cost effective, robust and incredibly reproducible. We, therefore, 
questioned the current lack of its use as a simple model in pancreatic cancer research. We 
reviewed in chapter I the emerging, sophisticated GEMMs that recapitulate PDAC by 
spontaneous development of the disease in these animals. GEMMs, although accurate and 
useful for targeted drug therapy, involve high cost studies. While we do not propose that the 
CAM assay replaces such models, we question the use of the subcutaneous flank xenografts 
in mice. The CAM model is not only extremely similar to human disease but also offers a new 
dimension for drug delivery whereby the tumour is not only visible but also accessible in living 
embryos. Although topical applications are less likely in humans, the CAM model enables 
testing of less penetrating drugs, in their infancy (e.g. HXR9) without having to resort to intra-
tumoral administration (also less likely in humans). The CAM model used in the context of 
PDAC remodelling offers an interesting insight into HXR9-induced HOX gene targeting by 
showing cleaved-caspase-dependent apoptosis. This provides a platform for testing other 
HOX gene antagonists such as small molecule mimics that would potentially have increased 
cellular delivery.
In Recent years, personalised medicine had become increasingly robust and providespatients 
with more effective treatment options. . The idea of avatar mice, where human tumour cells 
are grafted into a subcutaneous mouse model has recently become a source of interest 
(Malaney et al., 2014). Avatar mice enable drug efficacy studied to be carried out in order to 
find the best treatment for each patient. In the context of PDAC, where the aggressive nature 
of the disease provides patients with little time even in resectable cases, grafting cells into a 
murine flank model, waiting for the tumours to grow, and the subsequent drug efficacy 
studies, takes valuable time. The CAM model requires only a few days from the time the egg 
is ready to receive cells to the time a tumour develops whilst the mouse models takes several 
weeks. CAM-avatars could thus be generated speedily and at a low cost. In order to achieve 
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this, a robust collaboration system between research lab and operating theatres would have 
to be put in place as well as a standard, optimised protocol. 
At the beginning of this work we hypothesised that PDAC could characterised by a unique 
HOX gene profile. We have shown this to be true and have discussed the HOX genes of 
importance in this disease throughout this study. We also hypothesised that HOX genes could 
be antagonised both in vitro and in vivo. We showed that HOX genes could be antagonised in 
vitro and our work suggests that HXR9 drives cells into apoptosis. In order to verify these 
results in vivo, we set up a novel animal to test this and although the in vivo results require 
further studies we showed some evidence of apoptosis-induced cell death in this model.
Finally, this study has provided valuable insight into the levels of HOX gene expression in 
PDAC, although more work is required to correlate expression and survival. This study also 
supports the hypothesis that a number of HOX genes are not only overexpressed but also 
underexpressed. Further work is required to evaluate individual HOX gene function in this 
disease which may lead to the design of specific HOX gene antagonists although overlapping 
functions of HOX gene would have to be investigated further. This study has also shown 
promising results in successfully remodelling PDAC in the CAM model by showing striking 
similarities to human disease and a somewhat higher level of accuracy than conventional 
murine flank models, therefore, deserving its place in routine in vivo studies of pancreatic 
cancer research.
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Appendices 
ID Cancer type Histology [RNA] ng/ul 260/280 260/230 RIN score
3 Duodenal Tumour 252.6 2.06 0.98 8.9
5 Ampulary Tumour 1548.3 2.06 2.19 7.1
7 PDAC Tumour 455.4 2.04 1.97 7.6
10 Collangiocarcinoma Tumour 740.5 2.06 2.17 7.4
11 Collangiocarcinoma Tumour 1037 2.07 2.16 7.5
16 Duodenal Tumour 1688 2.06 2.09 7.3
17 Unknown Tumour 265.9 1.82 1.9 7.9
18 PDAC Tumour 667.1 2.06 2.11 8.4
19 PDAC Tumour 466.1 2.02 2.18 7.3
23 PDAC Tumour 377.8 2.05 2.16 7.2
25 PDAC Tumour 913.9 2.09 2.14 6.7
26 Unknown Tumour 330 2.09 1.45 8.1
27 PDAC Tumour 388.9 2.07 0.94 9
28 Unknown Tumour 470.1 2.06 2.02 8.3
29 PDAC Tumour 938.8 2.09 2.1 7.5
30 Unknown Tumour 1555.3 2.03 1.82 9
31 Unknown Tumour 708.2 2.09 1.03 9.4
! Appendix	  Table	  3.1: Summary of RNA extractions quality control from snap-frozen tissue. Sample 
! in blue were used in HOX gene profiling in Chapter 3. 
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Sample ID FFPE block ID Histology [RNA] ng/ul 260/280 260/230
FFPE 1 12R006810D14 Tumour 13.3 1.77 2.23
FFPE2 12R006810D14 Normal 28.1 1.93 1.97
FFPE 3 12R010768A12 Tumour 48.6 1.89 1.72
FFPE 4 12R010768 A12 Normal 118 1.91 2.11
FFPE 5 11R006565 A8 Tumour 72.4 2.11 1.34
FFPE 6 11R006565 A8 Normal 376.3 2.06 2.23
FFPE 7 12R005319 C14 Tumour 42.8 1.71 1.3
FFPE 8 12R005319 C14 Normal 167.4 1.84 1.89
FFPE 9 11R019038 B9 Tumour 30.1 1.92 1.64
FFPE 10 11R019038 B10 Normal 1435.3 2.02 2.2
FFPE 11 11R019625 A18 Tumour 69.7 1.91 1.55
FFPE 12 11R019625 A19 Normal 880.6 2.05 2.17
FFPE 15 10R001684 A17 Tumour 20.5 1.79 1.44
FFPE 23 10R010229 A7 Tumour 52.2 1.91 1.76
FFPE 23 10R010229 A7 Tumour 52.2 1.91 1.76
Appendix	  Table	  3.2:  Summary  of  RNA  extrac3ons  quality  control  from  FFPE  blocks.  
Pos sex age organ pathology grade tnm type HOXA13 
A1 M 65 Pancreas Duct adenocarcinoma 2 T1aN0M0 Malignant +
A2 M 65 Pancreas Duct adenocarcinoma 2 T1aN0M0 Malignant +
A3 M 70 Pancreas Duct adenocarcinoma 1 TxNxM0 Malignant +
A4 M 70 Pancreas Duct adenocarcinoma 1 TxNxM0 Malignant +
A5 F 54 Pancreas Duct adenocarcinoma 2 T2NxM0 Malignant -Ve
A6 F 54 Pancreas Duct adenocarcinoma 2 T2NxM0 Malignant -Ve
A7 F 58 Pancreas Duct adenocarcinoma 1 TxNxMx Malignant ++
A8 F 58 Pancreas Duct adenocarcinoma 1--2 TxNxMx Malignant ++
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A9 M 49 Pancreas Duct adenocarcinoma 
with necrosis
2 T1aN1M0 Malignant +
A10 M 49 Pancreas Duct adenocarcinoma 
with necrosis
2 T1aN1M0 Malignant +
B1 M 65 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant +
B2 M 65 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant -Ve
B3 F 70 Pancreas Duct adenocarcinoma 
(fibrous tissue and blood 
vessel)
- T1bN0M0 Malignant -Ve
B4 F 70 Pancreas Duct adenocarcinoma 
(fibrous tissue and blood 
vessel)
- T1bN0M0 Malignant -Ve
B5 M 55 Pancreas Duct adenocarcinoma 1 T3N0M1 Malignant -Ve
B6 M 55 Pancreas Duct adenocarcinoma 1 T3N0M1 Malignant -Ve
B7 M 41 Pancreas Duct adenocarcinoma 2 TxNxM0 Malignant +
B8 M 41 Pancreas Duct adenocarcinoma 2 TxNxM0 Malignant +
B9 F 60 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant -Ve
B10 F 60 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant -Ve
C1 M 55 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant -Ve
C2 M 55 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant -Ve
C3 F 54 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant -Ve
C4 F 54 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant -Ve
C5 M 84 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant +
C6 M 84 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant -Ve
C7 M 60 Pancreas Duct adenocarcinoma 2 T1aN0M0 Malignant +
C8 M 60 Pancreas Duct adenocarcinoma 2 T1aN0M0 Malignant +
C9 F 55 Pancreas Duct adenocarcinoma 
(sparse)
2 T2N0M0 Malignant -Ve
C10 F 55 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant -Ve
D1 F 51 Pancreas Duct adenocarcinoma 3 T2N0M0 Malignant +
D2 F 51 Pancreas Duct adenocarcinoma 3 T2N0M0 Malignant -Ve
D3 F 73 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant +
D4 F 73 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant ++
224
D5 F 62 Pancreas Duct adenocarcinoma 2 T2N1M0 Malignant +
D6 F 62 Pancreas Duct adenocarcinoma 2 T2N1M0 Malignant -Ve
D7 M 55 Pancreas Duct adenocarcinoma 3 T1bN0M0 Malignant +
D8 M 55 Pancreas Duct adenocarcinoma 3 T1bN0M0 Malignant +
D9 M 63 Pancreas Duct adenocarcinoma 3 T1bN0M0 Malignant -Ve
D10 M 63 Pancreas Duct adenocarcinoma 3 T1bN0M0 Malignant -Ve
E1 M 50 Pancreas Duct adenocarcinoma 3 T1bN0M0 Malignant -Ve
E2 M 50 Pancreas Duct adenocarcinoma 3 T1bN0M0 Malignant -Ve
E3 M 62 Pancreas Duct adenocarcinoma 
(fibrofatty tissue and 
blood vessel)
- T2N0M0 Malignant -Ve
E4 M 62 Pancreas Duct adenocarcinoma 2 T2N0M0 Malignant -Ve
E5 F 63 Pancreas Duct adenocarcinoma 3 T2N0M0 Malignant +
E6 F 63 Pancreas Duct adenocarcinoma 3 T2N0M0 Malignant +
E7 M 67 Pancreas Duct adenocarcinoma 3 T3N0M0 Malignant +
E8 M 67 Pancreas Duct adenocarcinoma 
(chronic inflammation)
- T3N0M0 Malignant No 
tumour
E9 F 69 Pancreas Carcinoma (sparse) - T2N1M0 Malignant -Ve
E10 F 69 Pancreas Duct adenocarcinoma 
(sparse)
3 T2N1M0 Malignant -Ve
F1 F 62 Pancreas Duct adenocarcinoma 3 T1bN0M0 Malignant +
F2 F 62 Pancreas Duct adenocarcinoma 3 T1bN0M0 Malignant ++
F3 M 65 Pancreas Duct adenocarcinoma 
with necrosis
3 T2N0M0 Malignant -Ve
F4 M 65 Pancreas Duct adenocarcinoma 3 T2N0M0 Malignant -Ve
F5 F 55 Pancreas Duct adenocarcinoma 
with necrosis
3 T1bN0M0 Malignant -Ve
F6 F 55 Pancreas Duct adenocarcinoma 
with necrosis
3 T1bN0M0 Malignant -Ve
F7 F 40 Pancreas Duct adenocarcinoma 3 T1bN0M0 Malignant +
F8 F 40 Pancreas Duct adenocarcinoma 3 T1bN0M0 Malignant +
F9 F 62 Pancreas Duct adenocarcinoma 3 T3N0M0 Malignant -Ve
F10 F 62 Pancreas Duct adenocarcinoma 3 T3N0M0 Malignant -Ve
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G1 M 51 Pancreas Cancer adjacent normal 
pancreatic tissue
- - NAT -Ve
G2 M 51 Pancreas Cancer adjacent normal 
pancreatic tissue
- - NAT -Ve
G3 M 64 Pancreas Cancer adjacent normal 
pancreatic tissue
- - NAT -Ve
G4 M 64 Pancreas Cancer adjacent normal 
pancreatic tissue
- - NAT -Ve
G5 M 49 Pancreas Cancer adjacent normal 
pancreatic tissue
- - NAT -Ve
G6 M 49 Pancreas Cancer adjacent normal 
pancreatic tissue
- - NAT -Ve
G7 F 73 Pancreas Cancer adjacent normal 
pancreatic tissue
- - NAT -Ve
G8 F 73 Pancreas Cancer adjacent normal 
pancreatic tissue
- - NAT -Ve
G9 F 66 Pancreas Cancer adjacent normal 
pancreatic tissue
- - NAT -Ve
G10 F 66 Pancreas Cancer adjacent normal 
pancreatic tissue
- - NAT -Ve
H1 M 35 Pancreas Normal pancreatic tissue - - Normal -Ve
H2 M 35 Pancreas Normal pancreatic tissue - - Normal -Ve
H3 F 21 Pancreas Normal pancreatic tissue - - Normal -Ve
H4 F 21 Pancreas Normal pancreatic tissue - - Normal -Ve
H5 M 19 Pancreas Normal pancreatic tissue - - Normal -Ve
H6 M 19 Pancreas Normal pancreatic tissue - - Normal -Ve
H7 F 40 Pancreas Normal pancreatic tissue - - Normal -Ve
H8 F 40 Pancreas Normal pancreatic tissue - - Normal -Ve
H9 F 21 Pancreas Normal pancreatic tissue - - Normal -Ve
H10 F 21 Pancreas Normal pancreatic tissue - - Normal -Ve
! Appendix Table 3.3: Specification data of pancreatic Tissue Micro Array (TMA) including 
! pancreatic ductal adenocarcinoma, normal adjacent tissue and normal pancreas. (US Biomax 
! Catalogue number: PA803) and the outcome of HOXA13 staining.
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A1 A2
A3 A4
A5 A6
A7 A8
A9 A10
227
B1 B2
B3 B4
B5 B6
B7 B8
B9 B10
228
C1 C2
C3 C4
C5 C6
C7 C8
C9 C10
229
D1 D2
D3 D4
D5 D6
D7 D8
D9 D10
230
E1 E2
E3 E4
E5 E6
E7 E8
E9 E10
231
F1 F2
F3 F4
F5 F6
F7 F8
F9 F10
232
G1 G2
G3 G4
G5 G6
G7 G8
G9 G10
233
H1 H2
H3 H4
H5 H6
H7 H8
H9 H10
Appendix 3.1: HOXA13 TMA. x10 Magnification (pages 203-210)
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PBS CXR9 HXR9
! Appendix 5.1: Cleaved-caspase 3 staining on AsPC-1-derived CAM tumour paraffin sections 
! using intra-tumoral injection (magnification x20).
PBS CXR9 HXR9
! Appendix 5.2: Cleaved-caspase 3 staining on BxPC-3-derived CAM tumour paraffin sections 
! using intra-tumoral injection (magnification PBS: x10; CXR9/HXR9: x20).
PBS CXR9 HXR9
! Appendix 5.3: Cleaved-caspase 3 staining on PaCa-3-derived CAM tumour paraffin sections 
! using intra-tumoral injection (magnification x20).
PBS CXR9 HXR9
! Appendix 5.4: Cleaved-caspase 3 staining on PancTu-1-derived CAM tumour paraffin sections 
! using intra-tumoral injection (magnification x20).
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Presentation 1: Poster presented during the American association of cancer research (AACR) 
conference 2013 in Washington, DC.
236
Targeting HOX genes in 
Pancreatic Cancer!
Sophie Gray!
FHMS Festival of Research 2014!
Pancreatic cancer !
•  Pancreatic ductal adenocarcinoma (PDAC) 
250,000 deaths per year worldwide and on 
average 22 per day in the UK. !
•  5-year survival < 5%. !
•  Late diagnosis, often patients presents with 
metastatic disease!
•  Key characteristic of PDAC is the appearance of 
dense stroma (desmoplastic reaction)!
HOX genes !
•  HOX genes are developmental genes involved 
in pancreatic cancer. !
•  In Human there are 39 HOX genes spread 
across 4 clusters on 4 chromosomes!
•  HOX genes are homeodomain-containing 
transcription factors that determine cellular and 
tissue identity!
•  HOX genes have been found to be re-
expressed in several types of (lung, prostate, 
renal, ovarian and pancreatic cancer) !
HOX genes in PDAC..!
!
1 2 3 4 5 6 7 8 9 10 11 12 13A
3' 5'
1 2* 3 4 5 6 7* 8 9 10 11 12 13
1 2 3 4 5 6 7 8 9 10 11 12 13
1 2 3 4 5 6 7 8 9 10 11 12 13
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D
No HOX gene at this position in the cluster
Possible function in Pancreatic development
Possible suppressor of metastasis
Expression increased in pancreatic cancer
Expression decreased in pancreatic cancer
* High expression associated with poor prognosis
Paralogue
group
HOX genes !
HOX protein PBX
Transcription of targets
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HOX gene targeting !
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Downregulation of targets
BxPC-3 sensitivity to HXR9!
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Cell-death mechanism!
BxPC-3 FACS analysis - Annexin-V-PE 
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The CAM model!
Current in vivo models of PDAC!
Animal model! Advantages! Disadvantages!
Mouse flank model!
!
!
Relatively cheap! Does NOT recapitulate 
tumour architecture,  time 
consuming!
!
GM mouse model: 
“naturally” develops  PDAC 
within 6-8 weeks!
!
Tumour architecture! Pathology doesn’t always 
resemble human PDAC; 
VERY expensive!!
!
Golden Syrian hamster: 
Develops PDAC!
!
Develops PDAC 
histologically similar to 
human cancer!
No acinar cell, time 
consuming.!
Rationale for the CAM model!
•  Cheap and fast (21 days) way of growing 
tumours in vivo!
•  The CAM model has been shown to remodel 
human tumour architecture and pathology in 
vivo!
•  Suitable model for the study of angiogenesis!
•  Tumours are visible and can be observed in real 
time. !
The CAM model!
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
 (EDD)
 Inner shell membrane removal  Challenge with cancer cell line  Tumour grown in the CAM
BxPC-3-CAM tumours!
SMA CK7CK19
BxPC-3-CAM tumours!
BxPC-3-CAM tumours! HXR9 treatment !
Cleaved-caspase 3 IHC !
PBS CXR9
HXR9 Tonsil/(posi2ve/control)
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Summary!
•  PDAC remains an aggressive cancer with few 
treatment options!
•  HOX genes are a potential therapeutic target in 
PDAC!
•  PDAC architecture and molecular signature 
"can be recapitulated in the CAM model!
•  The CAM model is suitable for the evaluation of 
new drugs for the treatment of PDAC!
!
Presentation 2: Power point presentation presented during the Festival of research in July 2014 at 
the University of Surrey.
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